



US009284365B2

(12) **United States Patent**
Xu et al.

(10) **Patent No.:** **US 9,284,365 B2**
(45) **Date of Patent:** **Mar. 15, 2016**

(54) **ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE**

FOREIGN PATENT DOCUMENTS

- (71) Applicant: **Genentech, Inc.**, South San Francisco, CA (US)
- (72) Inventors: **Min Xu**, Millbrae, CA (US); **Mercedesz Balazs**, Seattle, WA (US); **Ning Chai**, Dublin, CA (US); **Nancy Chiang**, San Francisco, CA (US); **Henry Chiu**, San Francisco, CA (US); **Zhonghua Lin**, San Francisco, CA (US); **Patrick Lupardus**, San Francisco, CA (US); **Gerald R. Nakamura**, San Francisco, CA (US); **Hyunjoo Park**, San Leandro, CA (US); **Lee Swem**, Montara, CA (US)

WO	02/46235	A1	6/2002
WO	2008/028946	A2	3/2008
WO	2008/028946	A3	3/2008
WO	2008/110937	A2	9/2008
WO	2008/110937	A3	9/2008
WO	2009/053604	A2	4/2009
WO	2009/053604	A3	4/2009
WO	2009/053604	A9	4/2009
WO	2009/115972	A1	9/2009
WO	2010/010466	A2	1/2010
WO	2010/010466	A3	1/2010
WO	2010/073647	A1	7/2010
WO	2010/130636	A1	11/2010
WO	2011/111966	A2	9/2011
WO	2011/111966	A3	9/2011
WO	2011/117848	A1	9/2011
WO	2011/160083	A1	12/2011
WO	2012/021786	A2	2/2012
WO	2012/021786	A3	2/2012
WO	2013/011347	A1	1/2013

- (73) Assignee: **Genentech, Inc.**, South San Francisco, CA (US)

- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/077,414**

(22) Filed: **Nov. 12, 2013**

(65) Prior Publication Data

US 2014/0161822 A1 Jun. 12, 2014

Related U.S. Application Data

- (60) Provisional application No. 61/725,859, filed on Nov. 13, 2012.

(51) Int. Cl.

C07K 16/10 (2006.01)
A61K 39/42 (2006.01)
A61K 31/215 (2006.01)
A61K 31/235 (2006.01)
A61K 39/00 (2006.01)

(52) U.S. Cl.

CPC **C07K 16/1018** (2013.01); **A61K 31/215** (2013.01); **A61K 31/235** (2013.01); **A61K 39/42** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/507** (2013.01); **A61K 2039/545** (2013.01); **C07K 2317/21** (2013.01); **C07K 2317/33** (2013.01); **C07K 2317/56** (2013.01); **C07K 2317/76** (2013.01); **C07K 2317/94** (2013.01)

(58) Field of Classification Search

None
See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

5,589,174 A 12/1996 Okuno et al.
5,631,350 A 5/1997 Okuno et al.
2011/0274702 A1 11/2011 Lanzavecchia

OTHER PUBLICATIONS

Nakamura et al. Cell Host and Microbes, 2013 in IDS on Mar. 20, 2014.*

Clementi et al., "A Human Monoclonal Antibody with Neutralizing Activity against Highly Divergent Influenza Subtypes" PLoS ONE 6(12) (2011).

PCT International Search Report and Written Opinion for PCT/US2013/069567.

Corti et al., "A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins" Science 333:850-856 (Aug. 2011).

Cui et al., "The Molecular Mechanism of Action of the CR6261-Azithromycin Combination Found through Computational Analysis" PLoS ONE 7(5) (2012).

Dreyfus et al., "Highly Conserved Protective Epitopes on Influenza B Viruses" Science 337:1343-1348 (2012).

Ekiert et al., "A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses" Science 333:843-850 (2011).

Ekiert et al., "Antibody Recognition of a Highly Conserved Influenza Virus Epitope" Science 324:246-251 (2009).

Hu, "Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient" Virology 435:320-328 (2013).

Nakamura et al., "An In Vivo Human-Plasmablast Enrichment Technique Allows Rapid Identification of Therapeutic Influenza A Antibodies" Cell Host & Microbe 14:93-103 (Jul. 2013).

Sui et al., "Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses" Nature Structural & Molecular Biology 16(3):265-273 (2009).

* cited by examiner



Primary Examiner — Agnieszka Boesen


(74) Attorney, Agent, or Firm — James E. Nesbitt

(57) ABSTRACT

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.



12 Claims, 57 Drawing Sheets



**FIG. 1A****FIG. 1B**



**FIG. 2**



Influenza Strain	HA Subtype	37.18		39.29		81.39		36.89		mAb 9		mAb 23	
		IC50 (nM)	95% CI(nM)	IC50 (nM)	95% CI(nM)	IC50 (nM)	95% CI(nM)	IC50 (nM)	95% CI(nM)	IC50 (nM)	95% CI(nM)	IC50 (nM)	95% CI(nM)
A/CA7/2009	H1	1.1	0.75 - 1.6	2.5	2.0 - 3.1	2.1	1.1 - 3.8	NA	NA	NA	NA	NA	NA
A/Brisbane/59/2007	H1	2.3	1.8 - 3.0	1.9	1.2 - 2.9	0.65	0.46 - 0.94	NA	NA	NA	NA	NA	NA
A/Solomon/3/2006	H1	8.0	3.9 - 16.6	25.1	20.1 - 31.4	14.6a	12.3 - 17.4	NA	NA	NA	NA	NA	NA
A/New Caledonia/20/1999	H1	3.1	1.3 - 7.4	9.2	5.7 - 15.0	6.1	4.7 - 7.9	NA	NA	NA	NA	NA	NA
A/PR8/1934	H1	1.2	0.81 - 1.9	2.0	1.3 - 3.3	1.9	1.2 - 3.2	NA	NA	NA	NA	NA	NA
A/Japan/305/1957	H2	2.4	1.4 - 4.1	6.0	4.4 - 8.1	3.7	2.4 - 5.6	NA	NA	NA	NA	NA	NA
A/Victoria/361/2011	H3	NA	NA	3.4	2.4 - 4.8	3.6	2.4 - 5.3	9.7	8.0 - 11.9	41.0	26.3 - 64.1	12.0	7.2 - 20.2
A/Perth/16/2009	H3	NA	NA	3.0	2.4 - 3.8	1.6	1.2 - 2.0	1.1	0.86 - 1.5	13.5	10.4 - 17.5	4.2	3.3 - 5.4
A/Brisbane/10/2007	H3	NA	NA	2.3	2.0 - 2.7	1.9	1.7 - 2.2	1.9	1.5 - 2.4	26.1	18.2 - 37.4	6.3	4.6 - 8.0
A/Wisconsin/67/2005	H3	NA	NA	1.3	0.88 - 1.8	0.81	0.64 - 1.0	1.6	0.81 - 3.3	7.3	4.5 - 11.9	0.85	0.58 - 1.3
A/Victoria/3/1975	H3	NA	NA	2.5	1.9 - 3.4	2.8	2.2 - 3.7	2.2	0.94 - 5.0	17.2	9.3 - 31.9	3.7	2.3 - 6.0
A/Port Chalmers/1/1973	H3	NA	NA	2.2	1.6 - 3.1	1.5	1.1 - 1.9	1.9	0.75 - 4.6	18.4	12.5 - 26.9	2.4	1.5 - 3.8
A/HK/8/1968	H3	NA	NA	45.1	25.7 - 79.2	26.3	14.5 - 47.8	34.7	19.8 - 60.7	843	295 - 2406	336	240 - 470
A/Aichi/2/1968	H3	NA	NA	35.0	21.1 - 58.0	7.3	3.7 - 14.1	13.9	8.2 - 23.4	1172	589 - 2330	271	176 - 419



FIG. 3

**FIG. 4A****FIG. 4B**

**FIG. 5A****FIG. 5B**

**FIG. 6****FIG. 7**

**FIG. 8****FIG. 9**

**FIG. 10****FIG. 11**




FIG. 12B




FIG. 12D




FIG. 12A




FIG. 12C




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19A




FIG. 19B

```

H1N1 -----MKAILVLLYTFATAN---ADTLCIGYHANNSTDVDTVLEKNVTVTHSVNLE 51
H2N2 -----MAIYLILLFTAVR---GDQICIGYHANNSTEMVDTILERNVTVTHAKDILE 49
H3N2 MKTIIALSIVILCLVFAQKLPNDNSTATLCLGHHAVPNGTIVKTTNDQIEVINA TELVQ 60
H5N1 -----MEKIVLLFAIVSLVK---SDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILE 50
H7N4 MN-----TRILILTAVIHTN---ADKICLGHHAVSNGTKVNTLTERGVEVVNATETVE 52

H1N1 DKHNGKLCNLRGVAPHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGD 111
H2N2 KTHNGKLCNLRGIPPLELGDCSIAGWLLGNPECDRLLSVPEWSYIMEKENPRDGLCYPGS 109
H3N2 SSSTGEICDS-PHQILDGKNCTLIDALLGDPQCDGFQNK-KWDLFVERSKA-YSNCYPYD 117
H5N1 KKHNGKLCNLDGVKPLILRDCSVAGWLLGNPMCEDEFINPEWSYIVEKANPVNDLCYPGD 110
H7N4 QMNIPRICTK-GKKAIDLGCGLLGIVTGPPQCDQFLEF-TADLIIRERREG-NDVCYPGK 109

H1N1 FIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAAACPHAGAKSFYKNLIWLVK- 170
H2N2 FNDYEELKHLSSVKHFEKVILPK-DRWTQHTTTGG-SRACAVSGNPSFFRNMVWLTK- 166
H3N2 VPDYASLRSLVASSGTLEFNNESEFNWTGVTQN-----GTSSACIRRSKNSFFSRLNWLTH- 172
H5N1 FNDYEELKHLSSRINHFEKIQTIPK-SSWSSHEASLGVSSACPYQCKSSFFRNVLWLIK- 168
H7N4 FVNEEARQLRSGSGGINKETTGTGTYSGIRTN-----GVTSACRR-SESSFYAEMKWLLSN 164

H1N1 -KGSYPKLSKSYINDKGKEVLVLWGIIHPSTADQQSLYQNADAYVFGSSRYSKFKFP 229
H2N2 -KGSYPAKAGSYNNTSGEQMLIIGVHHPNDETEQRTLYQNVGTYSVGTSTLNKRSTP 225
H3N2 -LNFKYPALNVTMPNNEQFDKLYIWGVHHPGTDKDKQIFLYAQASGRITVSTKRSQQTVP 231
H5N1 -KNSTYPTIKRSYNNNTQEDLLVLWGIIHPNDAAEQTKLYQNPTTYISVGTSTLNQLRVP 227
H7N4 TDNAAFPQMTKSYKNTRNEPALIVWGIIHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVP 224

H1N1 EIAIRPKVRXXEGRMNYYWTLVEPGDKITFEATGNLVVPRIYAFAMERNAGSGIIISDTPV 289
H2N2 EIAIRLVNGQGGRMEFSWTLDMWDTINFESTGNLIAPEYGFKISKRGSSGIMKTEGTL 285
H3N2 NIGSRPRVRNIPSRISYWTIVKPGDILLINSTGNLIAPRGYFKIRS-GKSSIMRSDAPI 290
H5N1 RIATRSKVNQSGRMEFFWTILKPNDAINFESNGNFIAPYAYKIVKKGSTIMKSELEY 287
H7N4 SPGARPOVNGQSGRIDFHWLILNPNDTVTFSPNGAFVAP-DRVSFFK-GESTGIQSEVPV 282

H1N1 H-DNMTTCQTPKGAINITSLPFONIHPTIGKCPKYVKSTKLRLATGLRNIPSIO-----SR 344
H2N2 E-NDETTCQTPKGAINITSLPFHNVHPLTIGECPKYVKSEKLVLATGLRNVPQIE-----SR 340
H3N2 G-KNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLKLATGMNRNVE-----KQTR 345
H5N1 G-NDETTCQTPMGAINITSLPFHNIHPLTIGECPKYVKSNRLVLATGLRNSPQORRRRKR 346
H7N4 DANDEGECYHSGGTITSLNLPFQNVNSRAVGKCPKYVKQKSLLLATGMKNVPEIPR-KRRR 341

H1N1 GLFGAIAAGFIEGGWTCMVDGWYGYHHQNEQSGYAADLRSTQNAIDETNKVNSVIEKMN 404
H2N2 GLFGAIAAGFIEGGWQGMVDGWYGYHHSNDQSGYAADKESTQKAFDQITNKVNSVIEKMN 400
H3N2 GIFGAIAAGFIENGWEGMVDGWYGFRRHNSQEGRCQADLRSTQNAIDQINGKLNRLITKTN 405
H5N1 GLFGAIAAGFIEGGWQGMVDGWYGYHHSNEQSGYAADKESTQKATIDGVTKVNSVIEKMN 406
H7N4 GLFGAIAAGFIENGWEGMVDGWYGFRRHNSQEGTAADYKSTQSAIDQITGKLNRLITKTN 401



H1N1 TQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLENERTLDYHDSNVKNLYE 464
H2N2 TQFEAVGKEFSNLERRLENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYD 460
H3N2 EKPHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLE 465
H5N1 TQFEAVGREFNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYD 466
H7N4 QQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMKNLYE 461

H1N1 KVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVIRNGTYDYPKYSEEAKLNREEIDGVKLES 524
H2N2 KVRMQLRDNVKELGNGCFEFYHKCDDCMNSVKIRNGTYDYPKYEEESKLNREIKGVKLSS 520
H3N2 KTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKS 525
H5N1 KVRQLRDNNAKELGNGCFEFYHKCDNECMESVIRNGTYDYPKYSEEARLKREEISGVKLES 526
H7N4 RVRRQLRENAEEDGTGCFEIPHKDDDCMASIRNNNTYDHSYREEAMQNRLKIDPVKLSS 521

H1N1 TRIYQILAIYSTVASSLVVSLGAISFWMCSNGSLQCRICI 566 (SEQ ID NO: 224)
H2N2 MGVEYQILAIYATVAGSLSLAIMMAGISFWMCSNGSLQCRICI 562 (SEQ ID NO: 225)
H3N2 -GYKDWLWISFAISCFLLCVALLGFIMWACQGNIRCNICI 566 (SEQ ID NO: 226)
H5N1 IGIYQILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI 568 (SEQ ID NO: 227)
H7N4 -GYKDVLWFSFGSCFLLLAIAMGLGFCVKNGNMRCITICI 562 (SEQ ID NO: 228)

```

FIG. 20

**FIG. 21A****FIG. 21B**

Light Chain, Kappa

Light Chain, Kappa																																									
Kabat - CDR L1																																									
Chothia - CDR L1																																									
Contact - CDR L1																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
[IGKV3-15*01	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y
81.39B1C1	E	I	V	[L]	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	[D]	S	N	L	A	W	Y

Kabat - CDR L2											
Chothia - CDR L2											
Contact - CDR L2											

37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71
IGKV3-15*01	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F
81.39 B1C1	Q	Q	K	P	G	Q	A	P	R	L	L	[Y]	[S]	[S]	A	S	T	R	A	T	C	I	P	A	R	F	S	G	S	G	S	G	T	E	F

Kabat - CDR L3											
Chothia - CDR L3											
Contact - CDR L3											

72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107
IGKV3-15*01	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	V	C	Q	Q	Y	N	N	W	P	L	T	F	G	G	G	T	K	V	E	I	K
81.39B1C1	T	L	[A]	I	S	S	L	Q	S	E	D	F	A	V	Y	V	C	Q	[H]	[Y]	[T]	[N]	[P..R]	L	T	F	G	G	G	[S]	K	V	E	I	K	

FIG. 22A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M E . . W V R Q A P G K
81.39B1C1 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F [A] F [H N R] A M E . . W V R Q A P G K

Kabat - CDR H1
Chothia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Chothia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
81.39B1C1 G L E W V A [L] I [Y F] . . D G S [K Q] Y Y A D S V K G R F T I S R D N S K N T [V F] L Q M N S L

Kabat - CDR H3
Chothia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ1*01
81.39B1C1 R [E] E D T A V Y Y C A [V P G P I F G I F P P W S Y F] . . D H W G Q G I L . . V T V S S

FIG. 22B

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
81.39 SVSH-NYP[E] V Q L V E S G G G V V Q P G R S L R L S C A A S G F[A] F[H] N[R] A M H . . W V R Q A P G K

Kabat - CDR H2
Choithia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
81.39 SVSH-NYP G L E W V A[L] I[Y..E] . . D G S[X..Q] Y Y A D S V K G R F T I S R D N S K N T[V..F] L Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ1*01
81.39 SVSH-NYP R[P] E D T A V Y Y C A[V] P G P I F G I F P P W S Y . . . F[D] H W G Q G[I] L V T V S S

FIG. 23B

Light Chain, Kappa

Light Chain, Kappa																																									
Kabat - CDR L1																																									
Choithia - CDR L1																																									
Contact - CDR L1																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGKV3-15*01	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y
81.39B1F1	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	[D]	S	N	L	A	W	Y

Kabat - CDR L2											
Choithia - CDR L2											
Contact - CDR L2											

37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71
IGKV3-15*01	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	T	R	.	.	.	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F	
81.39B1F1	Q	Q	K	P	G	Q	A	P	R	L	L	[V]	Y	[S]	A	S	T	R	.	.	.	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F	

Kabat - CDR L3											
Choithia - CDR L3											
Contact - CDR L3											

72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107
IGKV3-15*01	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	Q	Y	N	N	W	P	L	T	F	G	G	G	T	K	V	E	I	K	IGKJ4
81.39B1F1	T	L	[A]	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	[H]	Y	[T]	N	W	P	[P]	R	.	.	L	T	F	G	G	G	[S]	K	V	E	I	K	

FIG. 24A

Kabat number	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	A	B	C	D	E	F	G	H	I	J	K	101	102	103	104	105	106	107	108	109	110	111	112	113	
IGHV3-30*01	R	A	E	D	T	A	V	Y	C	A	R	F	Q	H	N	G	Q	G	T	L	V	T	V	S	S	IGHJ*01
8139B1F1	R	F	E	D	T	A	V	Y	C	A	V	P	G	P	I	F	G	I	F	P	P	W	S	Y	.	.	.	F	D	H	N	G	Q	G	T	L	V	T	V	S	S		

FIG. 24B

Light Chain, Kappa

Light Chain, Kappa

Kabat - CDR L1																																									
Choithia - CDR L1																																									
Contact - CDR L1																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGKV3-15*01	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y
81.39 SVDS	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	[D]	S	N	L	A	W	Y

Kabat - CDR L2																																							
Choithia - CDR L2																																							
Contact - CDR L2																																							
37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71
IGKV3-15*01	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F
81.39 SVDS	Q	Q	K	P	G	Q	A	P	R	L	L	[V]	Y	[S]	A	S	T	R	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F

Kabat - CDR L3																																										
Choithia - CDR L3																																										
Contact - CDR L3																																										
72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107	
IGKV3-15*01	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	Q	Y	N	N	N	P	L	T	F	G	G	G	T	K	V	E	I	K	IGKJ4
81.39 SVDS	T	L	[A]	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	[H]	Y	[T]	N	N	P	[P	R]	.	.	.	L	T	F	G	G	G	[S]	K	V	E	I	K	

FIG. 25A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S C F T F S S Y A M H . . W V R Q A P G K
81.39 SVDS [E] V Q L V E S G G G V V Q P G R S L R L S C A A S C F [A] F [H] N R [A] M H . . W V R Q A P G K

Kabat - CDR H1
Choithia - CDR H1
Kabat - CDR H1
Choithia - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Kabat - CDR H2
Choithia - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
81.39 SVDS G L E W V A [L] I [Y] F [X] Q [Y] Y A D S V K G R F T I S R D N S K N T [V] F [L] Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Kabat - CDR H3
Choithia - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ*01
81.39 SVDS R [E] E D T A V Y Y C A [V] P [G] P [Y] F [G] I [F] P [W] S [Y] . . . F [D] R W G Q G [I] L V T V S S

Kabat - CDR H3
Choithia - CDR H3
Kabat - CDR H3
Choithia - CDR H3

FIG. 25B

Light Chain, Kappa

Light Chain, Kappa

Kabat - CDR L1																																									
Chothia - CDR L1																																									
Contact - CDR L1																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGKV3-15*01 E I V M T Q S P A T L S V S P G E R A T L S C R A S Q S V S S N L A W Y																																									
81.39 SVSS E I V [L] T Q S P A T L S V S P G E R A T L S C R A S Q S V S S N L A W Y																																									

Kabat - CDR L2																																									
Chothia - CDR L2																																									
Contact - CDR L2																																									
37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71		
IGKV3-15*01 Q Q K P G Q A P R L L I Y G A S T R A T G I P A R F S G S G S G T E F																																									
81.39 SVSS Q Q K P G Q A P R L L [V] Y [S] A S T R A T G I P A R F S G S G S G T E F																																									

Kabat - CDR L3																																										
Chothia - CDR L3																																										
Contact - CDR L3																																										
72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107	
IGKV3-15*01 T L T I S S L Q S E D F A V Y Y C Q Q Y N N W P L T F G G G T K V E I K IGKJ4																																										
81.39 SVSS T L [A] I S S L Q S E D F A V Y Y C Q [H] Y [E] N W P [P.R] L T F G G G [S] K V E I K																																										

FIG. 26A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
81.39 SVSS [E] V Q L V E S G G G V V Q P G R S L R L S C A A S G F [A] F [H N R] A M H . . W V R Q A P G K

Kabat - CDR H1
Choithia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
81.39 SVSS G L E W V A [E] I [Y F] . . D G S [K Q] Y Y A D S V K G R F T I S R D N S K N T [V F] L Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ*01
81.39 SVSS R [E] E D T A V Y Y C A [V] P G P I F G I F P P W S Y . . . F [D] H W G Q G [I] L V T V S S

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

FIG. 26B

Light Chain, Kappa

Kabat - CDR L1

Chothia - CDR L1

Contact - CDR L1

123456789101112131415161718192021222324252627ABCE282930313233343536

IGKV3-15*01EIVMTQSPATLSVSPGERATLSCRASQ...SVSSNLAWY

81.39 SVDHEIV[LE]TQSPA TL SVSPGERATLS CRASQ...SV[D][H]NLAWY

Kabat - CDR L2

Chothia - CDR L2

Contact - CDR L2

373839404142434445464748495051525354ABCDE5556575859606162636465666768697071

IGKV3-15*01Q Q K P G Q A P R L L I Y G A S T R...ATG I P A R F S G S G S G T E F

81.39 SVDH Q Q K P G Q A P R L L [V] Y [S] A S T R...ATG I P A R F S G S G S G T E F

Kabat - CDR L3

Chothia - CDR L3

Contact - CDR L3

727374757677787980818283848586878889909192939495ABCDE F[96]979899100101102103104105106107

IGKV3-15*01T L T I S S L Q S E D F A V Y Y C Q Q Y N N W P...L T F G G G T X V E I K I G K J 4

81.39 SVDH T L [A] I S S L Q S E D F A V Y Y C Q [H] Y [T] N N W P [P] R...L T F G G G [S] K V E I K

FIG. 27A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
81.39 SVDH [E] V Q L V E S G G G V V Q P G R S L R L S C A A S G F [A] F [H N R] A M H . . W V R Q A P G K

Kabat - CDR H2

Choithia - CDR H2

Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
81.39 SVDH G L E W V A [L] I [Y F] . . D G S [Y Q] Y Y A D S V K G R F T I S R D N S K N T [Y F] L Q M N S L

Kabat - CDR H3

Choithia - CDR H3

Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ*01
81.39 SVDH R [E] E D T A V Y Y C A [V P G P I F G I F P P W S Y] . . . F [D] H W G Q G [I] L V T V S S

FIG. 27B

Light Chain, Kappa

Light Chain, Kappa																																									
Kabat - CDR L1																																									
Chothia - CDR L1																																									
Contact - CDR L1																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGKV3-15*01	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y
81.39SVSH	E	I	V	[L]	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	[E]	N	L	A	W	Y

Kabat - CDR L2											
Chothia - CDR L2											
Contact - CDR L2											

37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71
IGKV3-15*01	Q	Q	X	P	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	T	G	I	P	A	R	R	F	S	G	S	G	S	G	T	E	F
81.39SVSH	Q	Q	X	P	Q	A	P	R	L	L	[V]	Y	[S]	A	S	T	R	A	T	G	I	P	A	R	R	F	S	G	S	G	S	G	T	E	F

Kabat - CDR L3											
Chothia - CDR L3											
Contact - CDR L3											

72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107
IGKV3-15*01	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	Q	Y	N	N	W	P	L	T	F	G	G	G	T	K	V	E	I	K	IGKJ4
81.39SVSH	T	L	[A]	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	[H]	Y	[T]	N	N	P	[P	R]	.	.	L	T	F	F	G	G	G	[S]	K	V	E	I	K

FIG. 28A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
81.39 SVSH [E] V Q L V E S G G G V V Q P G R S L R L S C A A S C F [A] F [H N R] A M H . . W V R Q A P G K

Kabat - CDR H1
Choithia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
81.39 SVSH G L E W V A [I] I [Y F] . . D G S [K Q] Y Y A D S V K G R F T I S R D N S K N T [V F] L Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ*01
81.39 SVSH R [F] E D T A V Y Y C A [V R G P I F G I F P P W S Y] . . . F [D] H W G Q G [I] L V T V S S

FIG. 28B

Light Chain, Kappa

Light Chain, Kappa																																		
Kabat - CDR L1																																		
Chothia - CDR L1																																		
Contact - CDR L1																																		
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 A B C D E F 28 29 30 31 32 33 34 35 36																																		
IGKV3-15*01 E I V M T Q S P A T L S V S P G E R A T L S C R A S Q S V S S N L A W Y																																		
81.39 SVSH.NFP E I V [I] T Q S P A T L S V S P G E R A T L S C R A S Q S V S [H] N L A W Y																																		

Kabat - CDR L2																																			
Chothia - CDR L2																																			
Contact - CDR L2																																			

37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71		
IGKV3-15*01 Q Q K P G Q A P R L L I Y G A S T R A T G I P A R F S G S G S G T E F																																									
81.39 SVSH.NFP Q Q K P G Q A P R L L [V] Y [S] A S T R A T G I P A R F S G S G S G T E F																																									

Kabat - CDR L3																																			
Chothia - CDR L3																																			
Contact - CDR L3																																			

72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107	
IGKV3-15*01 T L T I S S L Q S E D F A V Y Y C Q Q Y N N W P L T F G G G T K V E I K IGKJ4																																										
81.39 SVSH.NFP T L [A] I S S L Q S E D F A V Y Y C Q [H] Y [T] N [E] F [P.R] L T F F G G G [S] K V E I K																																										

FIG. 29A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
81.39 SVSH.NFP [E] V Q L V E S G G G V V Q P G R S L R L S C A A S G F [A] F [H N R] A M H . . W V R Q A P G K

Kabat - CDR H1
Choithia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
81.39 SVSH.NFP G L E W V A [E] I [Y F] . . D G S [K Q] Y Y A D S V K G R F T I S R D N S K N T [V F] L Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ1*01
81.39 SVSH.NFP R [F] E D T A V Y Y C A [V L P G P I F G I F P P W S Y] . . . F [D] H W G Q G [I] L V T V S S

FIG. 29B

Light Chain, Kappa

Light Chain, Kappa

Kabat - CDR L1																																			
Choithia - CDR L1																																			
Contact - CDR L1																																			

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGKV3-15*01	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y
81.39 SVDS.F	E	I	V	[L]	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	[D]	S	N	L	A	W	Y

Kabat - CDR L2																																			
Choithia - CDR L2																																			
Contact - CDR L2																																			

37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71
IGKV3-15*01	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	T	R	.	.	.	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F	
81.39 SVDS.F	Q	Q	K	P	G	Q	A	P	R	L	L	[V]	Y	[S]	A	S	T	R	.	.	.	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F	

Kabat - CDR L3																																			
Choithia - CDR L3																																			
Contact - CDR L3																																			

72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107
IGKV3-15*01	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	Q	Y	N	N	W	P	L	T	F	G	G	G	T	K	V	E	I	K
81.39 SVDS.F	T	L	[A]	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	[H]	Y	[T]	N	[F]	P	[P]	R	.	.	L	T	F	G	G	G	[S]	K	V	E	I	K	

FIG. 30A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M E . . W V R Q A P G K
81.39 SVDS.F [E] V Q L V E S G G G V V Q P G R S L R L S C A A S G F [A] F [H N R] A M E . . W V R Q A P G K

Kabat - CDR H1
Choithia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
81.39 SVDS.F G L E W V A [L] I [Y F] . . D G S [K Q] Y Y A D S V K G R F T I S R D N S K N T [V F] L Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ1*01
81.39 SVDS.F R [E] E D T A V Y Y C A [V P G P I F G I F P P W S Y] . . . F [D] H W G Q G [I] L V T V S S

FIG. 30B

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
81.39 SVDS.Y [E] V Q L V E S G G G V V Q P G R S L R L S C A A S G F [A] F [H N R] A M H . . W V R Q A P G K

Kabat - CDR H1
Choithia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
81.39 SVDS.Y G L E W V A [L] I [Y F] . . D G S [K Q] Y Y A D S V K G R F T I S R D N S K N T [V F] L Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ1*01
81.39 SVDS.Y R [P] E D T A V Y Y C A [V P G P I F G I F P P W S Y] . . . F [D] E W G Q G [I] L V T V S S

FIG. 31B

Light Chain, Kappa

Light Chain, Kappa																																									
Kabat - CDR L1																																									
Chothia - CDR L1																																									
Contact - CDR L1																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGKV3-15*01	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y	
39.29D2C4	E	T	T	L	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	I	S	H	N	L	A	W	Y

Kabat - CDR L2																																									
Chothia - CDR L2																																									
Contact - CDR L2																																									
37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71		
IGKV3-15*01	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F		
39.29D2C4	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	S	G	I	P	A	R	F	S	G	S	G	S	G	T	D	Y		

Kabat - CDR L3																																										
Chothia - CDR L3																																										
Contact - CDR L3																																										
72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107	
IGKV3-15*01	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	Q	Y	N	N	W	P	L	T	F	G	G	G	T	K	V	E	I	K	IGKJ4
39.29D2C4	T	L	T	I	T	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	H	Y	S	N	W	P	P	P	R	.	.	L	T	F	G	G	G	T	K	V	E	I	K	

FIG. 32A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
39.29D2C4 [E] V Q L V [Q] S G G G V V Q P G [K] S L R L S C A A S G [L] T F S S Y A [V] H . . W V R Q A P G K

Kabat - CDR H1
Choithia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
39.29D2C4 G L E W V [T] I S Y . . D G [A] N [Q] Y Y A D S V K G R R F T I S R D N S K N T [V] Y L Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F D Y W G Q G T L V T V S S IGHJ4
39.29D2C4 R [E] E D T A V Y Y C A [V] P G P V F G I F P P W S Y . . . F D [N] W G Q G [I] L V T V S S

FIG. 32B

Light Chain, Kappa

Light Chain, Kappa																																									
Kabat - CDR L1																																									
Chothia - CDR L1																																									
Contact - CDR L1																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGKV3-15*01	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y
39.29D8C2	E	I	V	[L]	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	[V]	[I]	S	[H]	N	L	A	W	Y

Kabat - CDR L2											
Chothia - CDR L2											
Contact - CDR L2											

37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71
IGKV3-15*01	Q	Q	K	P	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F	
39.29D8C2	Q	Q	K	P	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	[S]	G	I	P	A	R	F	S	G	S	G	S	G	T	[D]	Y	


Kabat - CDR L3											
Chothia - CDR L3											
Contact - CDR L3											

72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107	
IGKV3-15*01	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	Q	Y	N	N	W	P	L	T	F	G	G	G	T	X	V	E	I	X	IGKJ4
39.29D8C2	T	L	T	I	[T]	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	[H]	Y	[S]	N	W	[P]	[R]	.	.	.	L	T	F	G	G	G	T	K	V	E	I	K		


FIG. 33A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
39.29D8C2 Q V Q L V Q S G G G V V Q P G [K] S L R L S C A A S G [L] T F S S Y A [V] H . . W V R Q A P G K



Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
39.29D8C2 G L E W V [T] [L] I S Y . . D G [A] N [Q] Y Y A D S V K G R F T I S R D N S K N T [V] Y L Q M N S L



Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F D Y W G Q G T L V T V S S IGHJ4
39.29D8C2 R [E] E D T A V Y Y C A [V] [P] G [P] V [F] G [I] F [P] W [S] Y . . . F D [N] W G Q G [L] L V T V S S

FIG. 33B

Light Chain, Kappa

Light Chain, Kappa

Kabat - CDR L1

Choithia - CDR L1

Contact - CDR L1

123456789101112131415161718192021222324252627ABCE

282930313233343536

IGKV3-15*01EIVMTQSPATLSVSPGERATLS

39.29NCv1EIV[L]TQSPA TL SVSPGERATLS

CRASQ.....S V S S N L A W Y

CRASQ.....[V-I]S[E]N L A W Y

Kabat - CDR L2

Choithia - CDR L2

Contact - CDR L2

373839404142434445464748495051525354ABCE

5556575859606162636465666768697071

IGKV3-15*01Q Q K P G Q A P R L L I Y G A S T R.....A T G I P A R F S G S G S G T E F

39.29NCv1Q Q K P G Q A P R L L I Y G A S T R.....A[S]G I P A R F S G S G S G T [D-Y]

Kabat - CDR L3

Choithia - CDR L3

Contact - CDR L3

727374757677787980818283848586878889909192939495ABCDE

96979899100101102103104105106107

IGKV3-15*01T L T I S S L Q S E D F A V Y Y C Q Q Y N N W P.....L T F F G G G T K V E I K IGKJ4

39.29NCv1T L T I [E]S L Q [D]E D F A V Y Y C Q [H]Y[S]N W P[P-R].....L T F F G G G T K V E I K

FIG. 34A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
39.29NCv1 Q V Q L V Q S G G G V V Q P G [K] S [P] R L S C A A S G [P] T F S S Y A [V] H . . W V R Q A P G K

Kabat - CDR H1
Choithia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
39.29NCv1 G L E W V [T] L [I] I S Y . . D G [A] N [Q] Y Y A D S V K G R F T I S R D N S K N T [V] Y L Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F D Y W G Q G T L V T V S S IGHJ4
39.29NCv1 R [F] E D T A V Y Y C A [V] P G P V F G I F P P W S Y . . . F D [N] W G Q G [I] L V T V S S

FIG. 34B

Light Chain, Kappa

Light Chain, Kappa																																									
Kabat - CDR L1																																									
Chothia - CDR L1																																									
Contact - CDR L1																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGKV3-15*01	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	N	Y
39.29D8E7	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	[V]	[I]	S	[H]	N	L	A	N	Y

Kabat - CDR L2											
Chothia - CDR L2											
Contact - CDR L2											

37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71
IGKV3-15*01	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F
39.29D8E7	Q	Q	K	P	G	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	[S]	G	I	P	A	R	F	S	G	S	G	S	G	T	[D]	[Y]


Kabat - CDR L3											
Chothia - CDR L3											
Contact - CDR L3											

72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107	
IGKV3-15*01	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	Q	Y	N	N	W	P	L	T	F	G	G	G	T	K	V	E	I	K	
39.29D8E7	T	L	T	I	[T]	S	L	Q	S	E	D	F	A	V	Y	Y	C	Q	[H]	Y	[S]	N	N	W	[P]	[R]	.	.	.	L	T	F	F	G	G	G	T	K	V	E	I	K


FIG. 35A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
39.29D8E7 Q V Q L V Q S G G G V V Q P G [K] S L R L S C A A S G [L] T F S S Y A [V] H . . W V R Q A P G K



Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
39.29D8E7 G L E W V [T][L] I S Y . . D G [A] N [Q] Y Y A D S V K G R F T I S R D N S K N T [V] Y L Q M N S L



Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F D Y W G Q G T L V T V S S IGHJ4
39.29D8E7 R [E] E D T A V Y Y C A [V][P][G][P][Y][F][G][L][P][M][S][Y] . . . F D [N] W G Q G [I] L V T V S S






FIG. 35B

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
39.29.NFPP [E] V Q L V Q S G G G V V Q P G [K] S L R L S C A A S G [L] T F S S Y A [V] H . . W V R Q A P G K



Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
39.29.NFPP [T] [L] I S Y . . D G [A] N [Q] Y Y A D S V K G R F T I S R D N S K N T [V] Y L Q M N S L



Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F D Y W G Q G T L V T V S S IGHJ4
39.29.NFPP R [P] E D T A V Y Y C A [V] P G P V F G I F P P W S V . . . F D [N] W G Q G [I] L V T V S S




FIG. 36B

FIG. 37A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M H . . W V R Q A P G K
39.29.NYPP [E] V Q L V Q S G G G V V Q P G [K] S L R L S C A A S G [L] T F S S Y A [V] H . . W V R Q A P G K

Kabat - CDR H1
Chothia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Chothia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L
39.29.NYPP G L E W V [H] I S Y . . D G [A] N [Q] Y Y A D S V K G R F T I S R D N S K N T [V] Y L Q M N S L

Kabat - CDR H3
Chothia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV3-30*01 R A E D T A V Y Y C A R F D Y W G Q G T L V T V S S IGHJ4
39.29.NYPP R [E] E D T A V Y Y C A [V] P G P V F G I F P P W S Y . . . F D [N] W G Q G [I] L V T V S S

FIG. 37B

Light Chain, Kappa

Kabat - CDR L1																																									
Chothia - CDR L1																																									
Contact - CDR L1																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGKV3-15*01	E	I	V	M	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y
39.29.NWPP	E	I	V	[L]	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	[V]	[I]	S	[H]	N	L	A	W	Y

Kabat - CDR L2																																							
Chothia - CDR L2																																							
Contact - CDR L2																																							
37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71
IGKV3-15*01	Q	Q	K	P	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F	
39.29.NWPP	Q	Q	K	P	Q	A	P	R	L	L	I	Y	G	A	S	T	R	A	[S]	G	I	P	A	R	F	S	G	S	G	S	G	T	[D]	[Y]	

Kabat - CDR L3																																									
Chothia - CDR L3																																									
Contact - CDR L3																																									
72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107
IGKV3-15*01	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	V	C	Q	Q	Y	N	N	W	P	[L]	T	F	G	G	G	T	K	V	E	I	X	IGKJ4
39.29.NWPP	T	L	T	I	[E]	S	L	Q	S	E	D	F	A	V	Y	V	C	Q	[H]	Y	[S]	N	W	P	[P	R]	.	.	[L]	T	F	G	G	G	T	K	V	E	I	X	

FIG. 38A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43

IGHV3-30*01 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y A M E . . W V R Q A P G K

39.29.NWPP [E] V Q L V Q S G G G V V Q P G [K] S L R L S C A A S G [L] T F S S Y A [V] H . . W V R Q A P G K

Kabat - CDR H1
Choithia - CDR H1
Kabat - CDR H1
Choithia - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Kabat - CDR H2
Choithia - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C

IGHV3-30*01 G L E W V A V I S Y . . D G S N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L

39.29.NWPP G L E W V [E] I S Y . . D G [A] N [Q] Y Y A D S V K G R F T I S R D N S K N T [V] Y L Q M N S L

Kabat - CDR H3
Choithia - CDR H3
Kabat - CDR H3
Choithia - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113

IGHV3-30*01 R A E D T A V Y Y C A R F D Y W G Q G T L V T V S S IGHJ4

39.29.NWPP R [E] E D T A V Y Y C A V P G P V F G I F P P W S Y . . . F D [N] W G Q G [I] L V T V S S

FIG. 38B

Heavy Chain

Kabat number	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	A	B	36	37	38	39	40	41	42	43
IGHV1-69*01	Q	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	V	K	V	S	C	K	A	S	G	G	T	F	S	S	Y	A	I	S	.	.	W	V	R	Q	A	P	G	Q
39*18B11	E	V	Q	L	V	Q	S	G	A	E	V	K	K	P	G	S	S	K	V	S	C	K	A	S	G	S	T	F	S	N	Y	G	I	S	.	.	W	V	R	Q	A	P	G	Q	

Kabat - CDR H1	
Choithia - CDR H1	
Contact - CDR H1	

Kabat - CDR H2	
Chothia - CDR H2	
Contact - CDR H2	

Kabat number	44	45	46	47	48	49	50	51	52	A	B	C	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	A	B	C
IGHV1-69*01	G	L	E	W	M	G	C	I	I	P	.	.	I	F	G	T	A	N	Y	A	Q	K	F	Q	C	R	V	T	I	T	A	D	E	S	T	S	T	A	Y	M	E	L	S	S	L
39*18B11	G	L	E	W	M	G	C	I	I	P	.	.	I	F	G	[A]	A	N	Y	A	Q	K	F	Q	C	R	V	T	I	T	A	D	E	S	T	S	T	V	Y	M	E	V	R	:S	L

Kabat - CDR H3
Chothia - CDR H3
Contact - CDR H3

[illegible]

FIG. 39B

Light Chain, Kappa

Light Chain, Kappa																																											
Kabat - CDR L1																																											
Chothia - CDR L1																																											
Contact - CDR L1																																											
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36		
IGKV3-15*01 E I V M T Q S P A T L S V S P G E R A T L S C R A S Q S V S S N L A W Y																																											
39.18E12	E	I	V	I	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y		
39.18E12	E	I	V	I	T	Q	S	P	A	T	L	S	V	S	P	G	E	R	A	T	L	S	C	R	A	S	Q	S	V	S	S	N	L	A	W	Y		

Kabat - CDR L2																																	
Chothia - CDR L2																																	
Contact - CDR L2																																	

37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71		
IGKV3-15*01 Q Q K P G Q A P R L L I Y G A S T R A T G I P A R F S G S G S G T E F																																									
39.18E12	Q	Q	K	P	G	Q	[5]	P	R	L	L	I	Y	G	A	S	T	R	[5]	T	G	I	P	A	R	F	S	G	S	G	S	G	T	E	F	

Kabat - CDR L3																																	
Chothia - CDR L3																																	
Contact - CDR L3																																	

72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107			
IGKV3-15*01 T L T I S S L Q S E D F A V Y V C Q Q Y N N N P Y T F G Q G T K V E I K I G K J 2																																												
39.18E12	T	L	T	I	S	S	L	Q	S	E	D	F	A	V	Y	V	C	Q	Q	Y	N	N	N	P	[P.M]	Y	T	F	G	Q	G	T	K	V	E	I	K	I		

FIG. 40A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV1-69*01 Q V Q L V Q S G A E V K K P G S S V K V S C K A S G G T F S S Y A I S . . W V R Q A P G Q
39.18.E12 Q V Q L V Q S G A [G] V K K P G S S [M] K V S C K A S G [S] [T] F S [N] Y [G] I S . . W V R Q A P G Q

Kabat - CDR H1
Choithia - CDR H1
Kabat - CDR H1
Contact - CDR H1

Kabat - CDR H2
Choithia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV1-69*01 G L E W M G G I I P . . I F G T A N Y A Q K F Q G R V T I T A D E S T S T A Y M E L S S L
39.18.E12 G L E W M G G I I P . . I F G [A] A N Y A Q K F Q G R V T I T A D E S T S T [V] Y M E [V] R S L

Kabat - CDR H3
Choithia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV1-69*01 R S E D T A V Y Y C A R F Q H W G Q G T L V T V S S IGHJ1*01
39.18.E12 R S E D T A V Y Y C A R [H] Q I V K [Q] Y Y H H W G Q G T L V T V S S

FIG. 40B

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV1-18*01 Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T S Y G I S . . W V R Q A P G Q
36.89 Q V Q L V Q S G A E [L] K [R] P G A S V K V S C K [T] S G Y [S] F [N] Y G I [N] . . W V R Q A P G Q

Kabat - CDR H1
Chothia - CDR H1
Contact - CDR H1

Kabat - CDR H2
Chothia - CDR H2
Contact - CDR H2

Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV1-18*01 G L E W M G W I S A . . Y N G N T N Y A Q K L Q G R V T M T T D T S T S T A Y M E L R S L
36.89 G L E W M G W I S A . . Y [T] G N T [H] Y A [K] N F [E] G R V T [I] T T D T S T S T A Y M E [V] R S L

Kabat - CDR H3
Chothia - CDR H3
Contact - CDR H3

Kabat number 83 84 85 86 87 88 89 90 91 92 93 94*95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV1-18*01 R S D D T A V Y C A R F Q H W G Q G T L V T V S S IGHJ1*01
36.89 R S D D [S] A V Y [F] C A R A W I Q G V V T L Y I R P G . . D Y W G Q G T I V T V S S

FIG. 41B

Light Chain, Lambda

Light Chain, Lambda																																										
Kabat - CDR L1																																										
Chothia - CDR L1																																										
Contact - CDR L1																																										
Kabat number	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	A	B	C	D	E	F	28	29	30	31	32	33	34	35	36
IGLV1-44*01	Q	S	V	L	T	Q	P	P	S	.	A	S	G	T	P	G	Q	R	V	T	I	S	C	S	G	S	S	S	N	.	.	.	I	G	S	N	T	V	N	W	Y	
901F3	[S]	[S]	[E]	[L]	T	Q	P	P	S	.	A	S	G	T	P	G	Q	R	V	T	I	S	C	S	G	S	[T]	S	N	.	.	.	I	G	[Y]	N	[F]	V	[S]	W	Y	

Kabat - CDR L2											
Chothia - CDR L2											
Contact - CDR L2											

Kabat number	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	A	B	C	D	E	55	56	57	58	59	60	61	62	63	64	65	66	A	B	67	68	69	70	71
IGLV1-44*01	Q	Q	L	P	G	T	A	P	K	L	L	I	Y	S	N	N	Q	R	P	S	G	V	P	D	R	F	S	G	S	K	.	.	S	G	T	S	A	
901F3	Q	Q	[V]	P	G	T	A	P	K	L	L	I	Y	S	N	[E]	R	P	S	G	V	P	D	R	F	S	G	S	K	.	.	S	G	T	S	A		



Kabat - CDR L3											
Chothia - CDR L3											
Contact - CDR L3											

Kabat number	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	A	B	C	D	E	F	96	97	98	99	100	101	102	103	104	105	106	107
IGLV1-44*01	S	L	A	I	S	G	L	Q	S	E	D	E	A	D	Y	Y	C	A	A	W	D	D	S	L	N	G	.	.	.	Y	V	F	G	T	G	T	K	V	T	V	L	IGLJ1
901F3	S	L	A	I	S	G	L	Q	S	E	D	E	A	D	Y	Y	C	A	A	W	D	D	T	L	N	G	.	.	.	P	V	P	G	G	T	K	V	T	V	L		

FIG. 42A

Heavy Chain


Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV1-2*02 Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T G Y Y M E . . W V R Q A P G Q
9.01F3 Q V Q L V Q S G A E V K [Q] P G A S V K V S C K A S G Y T F [N A] Y Y [I] E . . W V R Q A P G Q



Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV1-2*02 G L E W M G W I N P . . N S G G T N Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L
9.01F3 G L E W M G W I N P . . N [F] G G T [H] Y A [E] K F Q G R V T M T R R D [A] S I [N] T A Y M E L [D] R L



Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV1-2*02 R S D D T A V Y Y C A R M D V W G Q G T T V T V S S IGHJ6*
9.01F3 [I] S D D T A V Y Y C [V] R W R A A A V I N D Q F Y K . . . M D V W G Q G T [I] V T V S S 01/02/04



Human Germlines

FIG. 42B

Light Chain, Kappa

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 A B C D E F 28 29 30 31 32 33 34 35 36

IGKV2-30*01 D V V M T Q S P L S L P V T L G Q P A S I S C R S S Q S L V Y S . D G N T Y L N W F
 23.06C2 D [H-Q-H] T Q S P L S [P] P V T L G Q P A S I S C R S S Q S L [L] Y [T] . D G [F] T Y L [S] W [Y]

Kabat - CDR L1
Chothia - CDR L1
Contact - CDR L1

Kabat - CDR L2
Chothia - CDR L2
Contact - CDR L2

Kabat number 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 A B C D E 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71

IGKV2-30*01 Q Q R P G Q S P R R L I Y K V S N R D S G V P D R F S G S G S G T D F
 23.06C2 [E] Q R P G Q S P R R L I Y K [I] S N R D S G V P D R F S G S G S G T D F

Kabat - CDR L3
Chothia - CDR L3
Contact - CDR L3



Kabat number 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 97 98 99 100 101 102 103 104 105 106 107

IGKV2-30*01 T L K I S R V E A E D V G V Y Y C M Q G T H W P L T F G G G T K V E I K IGKJ4
 23.06C2 T L K I S R V E A E D V G V Y Y C M Q [A] T H W P L T F G [E] G T K V E I K

FIG. 43A

Heavy Chain

Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 A B 36 37 38 39 40 41 42 43
IGHV4-39*01 Q L Q L Q E S G P G L V K P S E T L S L T C T V S G G S I S S S S Y Y W G W I R Q P P G K
23.06C2 Q [V] Q L Q E S G P G L V K P S E T L S L T C T V S G G [L] I [G T G] S Y Y W G W I R Q [E] P G K



Kabat number 44 45 46 47 48 49 50 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B C
IGHV4-39*01 G L E W I G S I Y . . . Y S G S T Y Y N P S L K S R V T I S V D T S X N Q F S L K L S S V
23.06C2 G [K] E W I G S I [S] . . . Y S G S T Y Y [E] P S L K S R V T I S [D] D T S X N Q [L F] L K I [R] S V



Kabat number 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113
IGHV4-39*01 T A A D T A V Y Y C A R F D L W G R G T L V T V S S IGHJ2*01
23.06C2 T A A D T A [Q] Y Y C A R Y N W G I R Y F D [E] W G R G T L V T V S S

Human Germlines

FIG. 43B

1

ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 61/725,859, filed on 13 Nov. 2012, which is incorporated by reference herein in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 22, 2013, is named P4982R1_US_SL.txt and is 222,627 bytes in size.

FIELD OF THE INVENTION

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

BACKGROUND

Influenza virus infection causes between three and five million cases of severe illness and between 250,000 and 500,000 deaths every year around the world. In the United States alone, 5% to 20% of the population becomes infected with influenza virus each year, with the majority of these infections caused by the influenza A virus. (See, e.g., Dushoff et al., (2006) *Am J Epidemiology* 163:181-187; Thompson et al., (2004) *JAMA* 292:1333-1340; Thompson et al., (2003) *JAMA* 289:179-186.) Approximately 200,000 people in the United States become hospitalized with influenza-related complications every year, resulting in 7,000 to 30,000 deaths annually. The burden associated with influenza virus infection on health care costs and lost productivity is extensive. Hospitalization and deaths mainly occur in high-risk groups, such as the elderly, children, and chronically ill.

Influenza viruses are segmented membrane-enveloped negative-strand RNA viruses belonging to the Orthomyxoviridae family. Influenza A virus consists of 9 structural proteins and 1 non-structural protein, which include three virus surface proteins: hemagglutinin (HA or H), neuraminidase (NA or N), and matrix protein 2 (M2). The segmented nature of the influenza viral genome allows the mechanism of genetic reassortment (i.e., exchange of genome segments) to take place during mixed infection of a cell with different influenza viral strains. Annual epidemics of influenza occur when the antigenic properties of the viral surface proteins hemagglutinin and neuraminidase are altered. The mechanism of altered antigenicity is twofold: antigenic shift, caused by genetic rearrangement between human and animal viruses after co-infection of host cells with at least two viral subtypes, which can cause a pandemic; and antigenic drift, caused by small changes in the hemagglutinin and neuraminidase proteins on the virus surface, which can cause influenza epidemics.

Influenza A viruses may be further classified into various subtypes depending on the different hemagglutinin and neuraminidase viral proteins displayed on their surface. Each influenza A virus subtype is identified by the combination of its hemagglutinin and neuraminidase proteins. There are 16 known HA subtypes (H1-H16) and 9 known NA subtypes (N1-N9). The 16 hemagglutinin subtypes are further classified into two phylogenetic groups: Group1 includes hemag-

2

glutinin H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16 subtypes; Group2 includes hemagglutinin H3, H4, H7, H10, H14, and H15 subtypes.

Hemagglutinin promotes viral attachment and entry into the host cell; neuraminidase is required for viral budding from the infected cell. The hemagglutinin of influenza A virus comprises two structurally distinct regions—a globular head region and a stalk or stem region. The globular head region contains a receptor binding site which is responsible for virus attachment to a target cell. The stalk (or stem) region of hemagglutinin contains a fusion peptide which is necessary for membrane fusion between the viral envelope and an endosomal membrane of the infected cell. (See, e.g., Bouvier and Palese (2008) *Vaccine* 26 Suppl 4: D49-53; Wiley et al., (1987) *Ann Rev Biochem* 56:365-394.)

Current treatment for influenza virus infection includes neuraminidase inhibitors, such as oseltamivir and zanamivir. Oseltamivir is a widely used prophylactic and early therapeutic treatment option for influenza A virus infection. (See, e.g., Kandel and Hartshorn (2001) *BioDrugs: Clinical Immunotherapy, Biopharmaceuticals and Gene Therapy* 15:303-323; Nicholson et al., (2000) *Lancet* 355:1845-1850; Treanor et al., (2000) *JAMA* 283:1016-1024; and Welliver et al., (2001) *JAMA* 285:748-754.) However, oseltamivir treatment must begin within 48 hours of symptom onset to provide a significant clinical benefit. (See, e.g., Aoki et al (2003) *J Antimicrobial Chemotherapy* 51:123-129.) This liability compromises oseltamivir's ability to treat severely ill patients, who are typically beyond the optimal 48-hour treatment window at the time of seeking treatment. Therefore, significant focus has recently been placed on identifying influenza virus therapeutics to treat hospitalized influenza virus infected patients. One strategy has focused on development of human monoclonal antibodies (mAbs) that target a highly conserved epitope on the stalk of influenza A virus hemagglutinin. (See, e.g., Corti et al., (2011) *Science* 333:850-856; Ekiert et al., (2009) *Science* 324:246-251; Ekiert et al., (2011) *Science* 333:843-850; Sui et al., (2009) *Nature Structural & Molecular Biology* 16:265-273; Dreyfus et al., (2012) *Science* 337:1343-1348; Wu et al., (2012) *J Virology* 2012.09.034; Clementi et al., (2011) *PLoS One* 6:1-10. See also International Patent Application Publication Nos: WO2009/115972, WO2011/117848, WO2008/110937, WO2010/010466, WO2008/028946, WO2010/130636, WO2012/021786, WO2010/073647, WO2011/160083, WO2011/111966, WO2002/46235, and WO2009/053604; U.S. Pat. Nos. 5,631,350 and 5,589,174.)

Several reports have described monoclonal antibodies (mAb) that bind hemagglutinin and broadly neutralize influenza A virus. For example, Corti et al. (supra) described antibody FI6v3, which was cloned from a human plasma cell and shown to neutralize human influenza A viruses belonging to both Group1 and Group2 hemagglutinin subtypes. The FI6v3 mAb was discovered as a result of a heroic effort of analyzing approximately 104,000 human plasma cells. Additionally, Dreyfus et al. (supra) recently described the identification of antibody CR9114 by phage display panning; antibody CR9114 was shown to bind to a highly conserved stalk epitope shared between influenza A virus and influenza B virus hemagglutinin.

Despite these reports, a need still exists in the art for novel influenza A virus therapies effective against Group1 and Group2 influenza A virus subtypes. The present invention meets this need and provides other benefits for the treatment of influenza A virus infection.

SUMMARY OF THE INVENTION

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3) and three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:178;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:179;
- (c) HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:180 and 181;
- (d) HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:182, 183, 184, 185, and 186;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:187; and
- (f) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:188, 189, and 190.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, three, four, five and/or six hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:178;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:179;
- (c) HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:180 and 181;
- (d) HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:182, 183, 184, 185, and 186;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:187; and
- (f) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:188, 189, and 190.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:182, 183, 184, 185, and 186;
- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:187; and
- (c) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:188, 189, and 190.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:178;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:179; and
- (c) HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:180 and 181.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three light chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:182, 183, 184, 185, and 186;

(b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:187; and

(c) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:188, 189, and 190.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three heavy chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:178;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:179; and
- (c) HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:180 and 181.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:111 and 115, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:113, 117, 119, 122, 124, 126, 128, 130, and 132.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:113, 117, 119, 122, 124, 126, 128, 130, and 132.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:111 and 115.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:110, 114, and 120, and the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:112, 116, 118, 121, 123, 125, 127, 129, and 131.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:112, 116, 118, 121, 123, 125, 127, 129, and 131.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:110, 114, and 120.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3) and three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:191 and 192;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:193;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:194;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:195;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:196; and
- (f) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:197, 198, and 199.

5

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, three, four, five and/or six hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:191 and 192;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:193;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:194;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:195;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:196; and
- (f) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:197, 198, and 199.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three light chain hypervariable regions (HVR-L1, HVR-L2, and LVR-L3), wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:195;
- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:196; and
- (c) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:197, 198, and 199.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3), wherein:

- (a) HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:191 and 192;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:193; and
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:194.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three light chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:195;
- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:196; and
- (c) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:197, 198, and 199.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three heavy chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:191 and 192;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:193; and
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:194.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 134, 138, 142, 148, and 234, and the light chain variable

6

region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:136, 140, 144, 146, 150, 152, and 235.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 136, 140, 144, 146, 150, 152, and 235.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 134, 138, 142, 148, and 234.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 133, 137, 141, and 147, and the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:135, 139, 143, 145, 149, and 151.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 135, 139, 143, 145, 149, and 151.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 133, 137, 141, and 147.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3) and three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:200;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:201;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:202;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:203;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:204; and
- (f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:205.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, three, four, five and/or six hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:200;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:201;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:202;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:203;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:204; and
- (f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:205.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three light chain hypervariable regions (HVR-L1, HVR-L2, and LVR-L3), wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:203;

- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:204; and
- (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:205.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:200;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:201; and
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:202.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three light chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:203;
- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:204; and
- (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:205.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three heavy chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:200;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:201; and
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:202.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 154 and 158, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:156.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:156.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 154 and 158.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 153 and 157, and the light chain comprises the amino acid sequence of SEQ ID NO:155.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain comprising the amino acid sequence of SEQ ID NO:155.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:153 and 157.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3) and three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:206;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:207;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:208;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:209;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:210; and
- (f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:211.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, three, four, five and/or six hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:206;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:207;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:208;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:209;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:210; and
- (f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:211.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:209;
- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:210; and
- (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:211.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:206;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:207; and
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:208.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three light chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:209;
- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:210; and
- (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:211.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three heavy chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:206;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:207; and

(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:208.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:160, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:162.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:162.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:160.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:159, and the light chain comprises the amino acid sequence of SEQ ID NO:161.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain comprising the amino acid sequence of SEQ ID NO:161.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:159.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3) and three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:212;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:213;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:214;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:215;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:216; and
- (f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:217.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, three, four, five and/or six hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:212;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:213;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:214;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:215;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:216; and
- (f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:217.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:215;

(b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:216; and

(c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:217.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:212;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:213; and
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:214.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three light chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:215;
- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:216; and
- (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:217.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three heavy chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:212;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:213; and
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:214.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:164, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:166.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:166.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:164.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:163, and the light chain comprises the amino acid sequence of SEQ ID NO:165.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain comprising the amino acid sequence of SEQ ID NO:165.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:163.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3) and three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:218;

11

- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:219;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:220;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:221;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:222; and
- (f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:223.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, three, four, five and/or six hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:218;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:219;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:220;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:221;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:222; and
- (f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:223.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three light chain hypervariable regions (HVR-L1, HVR-L2, and LVR-L3), wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:221;
- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:222; and
- (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:223.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:218;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:219; and
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:220.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three light chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:221;
- (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO:222; and
- (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:223.

In some embodiments, the invention provides an isolated anti-hemagglutinin antibody comprising: at least one, two, and/or three heavy chain hypervariable region (HVR) sequences, wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:218;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:219; and
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:220.

12

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:168, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:170.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:170.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 168.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:167, and the light chain comprises the amino acid sequence of SEQ ID NO:169.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a light chain comprising the amino acid sequence of SEQ ID NO:169.

In some embodiments, an isolated anti-hemagglutinin antibody of the present invention comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:167.

The invention also provides isolated nucleic acids encoding an anti-hemagglutinin antibody of the present invention. The invention also provides vectors comprising a nucleic acid encoding an anti-hemagglutinin antibody of the present invention. The invention also provides host cells comprising a nucleic acid or a vector of the present invention. A vector can be of any type, for example, a recombinant vector such as an expression vector. Any of a variety of host cells can be used. In one embodiment, a host cell is a prokaryotic cell, for example, *E. coli*. In another embodiment, a host cell is a eukaryotic cell, for example, a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell.

The invention further provides a method of producing an anti-hemagglutinin antibody of the present invention. For example, the invention provides methods for making an anti-hemagglutinin antibody (which, as defined herein, includes full length antibody and fragments thereof), the method comprising expressing in a suitable host cell a recombinant vector of the invention encoding the anti-hemagglutinin antibody or fragments thereof so that the antibody or fragments thereof are produced. In some embodiments, the method comprises culturing a host cell comprising nucleic acid encoding an anti-hemagglutinin antibody of the present invention (or fragments thereof) so that the nucleic acid is expressed. The method may further comprise recovering the anti-hemagglutinin antibody or fragments thereof from the host cell culture or the host cell culture medium.

The invention also provides a pharmaceutical formulation comprising an anti-hemagglutinin antibody of the present invention and a pharmaceutically acceptable carrier. The pharmaceutical formulation may further comprise an additional therapeutic agent (e.g., a neuraminidase inhibitor, such as oseltamivir or zanamivir; another antibody, such as another anti-hemagglutinin antibody or an anti-M2 antibody; etc).

The invention also provides compositions comprising an anti-hemagglutinin antibody of the present invention. The composition may further comprise an additional therapeutic agent (e.g., a neuraminidase inhibitor, such as oseltamivir or zanamivir; another antibody, such as another anti-hemagglutinin antibody or an anti-M2 antibody; etc).

The invention also provides a composition comprising an anti-hemagglutinin antibody of the present invention for use in preventing influenza A virus infection. In some embodiments, the invention provides a pharmaceutical composition comprising an anti-hemagglutinin antibody of the present invention for use in preventing influenza A virus infection. The invention further provides a composition comprising an anti-hemagglutinin antibody of the present invention for use in treating influenza A virus infection. In some embodiments, the invention provides a pharmaceutical composition comprising an anti-hemagglutinin antibody of the present invention for use in treating influenza A virus infection. The invention further provides a composition comprising an anti-hemagglutinin antibody of the present invention for use in inhibiting influenza A virus infection. In some embodiments, the invention provides a pharmaceutical composition comprising an anti-hemagglutinin antibody of the present invention for use in inhibiting influenza A virus infection.

Compositions comprising an anti-hemagglutinin antibody of the present invention may also be used in the manufacture of a medicament. The medicament may be for use in the inhibition, treatment, or prevention of influenza A virus infection. In certain embodiments, the medicament may further comprise an additional therapeutic agent (e.g., a neuraminidase inhibitor, such as oseltamivir or zanamivir; another antibody, such as another anti-hemagglutinin antibody or an anti-M2 antibody; etc).

The invention also provides a method for inhibiting influenza A virus infection, the method comprising administering to a patient in need thereof an effective amount of a composition comprising an anti-hemagglutinin antibody of the present invention, thereby inhibiting influenza A virus infection. The invention also provides a method for treating influenza A virus infection, the method comprising administering to a patient in need thereof an effective amount of a composition comprising an anti-hemagglutinin antibody of the present invention, thereby treating influenza A virus infection. The invention also provides a method for preventing influenza A virus infection, the method comprising administering to a patient in need thereof an effective amount of a composition comprising an anti-hemagglutinin antibody of the present invention, thereby preventing influenza A virus infection.

The invention also provides a method for inhibiting, treating, or preventing influenza A virus infection, the method comprising administering to a patient in need thereof an effective amount of a composition comprising an anti-hemagglutinin antibody of the present invention, and administering to the patient an effective amount of an additional therapeutic agent, thereby inhibiting, treating, or preventing influenza A virus infection. In some embodiments, the additional therapeutic agent is a neuraminidase inhibitor, such as oseltamivir or zanamivir.

In other embodiments, the additional therapeutic agent is another anti-hemagglutinin antibody. In yet other embodiments, the additional therapeutic agent is an anti-M2 antibody. In various aspects of such combination treatments, the therapeutic agents are administered at about the same time, are administered together, or are administered sequentially or consecutively. In particular embodiments, an anti-neuraminidase inhibitor is administered prior to the administration of an anti-hemagglutinin antibody of the present invention.

In another aspect, the invention provides use of an anti-hemagglutinin antibody of the present invention in the manufacture of a medicament. The medicament may be for use in the inhibition, treatment, or prevention of influenza A virus infection. In certain embodiments, the medicament may fur-

ther comprise an additional therapeutic agent (e.g., a neuraminidase inhibitor, such as oseltamivir or zanamivir; another antibody, such as another anti-hemagglutinin antibody or an anti-M2 antibody; etc).

In another aspect, the invention provides use of a nucleic acid of the invention in the manufacture of a medicament. The medicament may be for use in the inhibition, treatment, or prevention of influenza A virus infection. In certain embodiments, the medicament may further comprise an additional therapeutic agent (e.g., a neuraminidase inhibitor, such as oseltamivir or zanamivir; another antibody, such as another anti-hemagglutinin antibody or an anti-M2 antibody; etc).

In another aspect, the invention provides use of an expression vector of the invention in the manufacture of a medicament. The medicament may be for use in the inhibition, treatment, or prevention of influenza A virus infection. In certain embodiments, the medicament may further comprise an additional therapeutic agent (e.g., a neuraminidase inhibitor, such as oseltamivir or zanamivir; another antibody, such as another anti-hemagglutinin antibody or an anti-M2 antibody; etc).

In another aspect, the invention provides use of a host cell of the invention in the manufacture of a medicament. The medicament may be for use in the inhibition, treatment, or prevention of influenza A virus infection. In certain embodiments, the medicament may further comprise an additional therapeutic agent (e.g., a neuraminidase inhibitor, such as oseltamivir or zanamivir; another antibody, such as another anti-hemagglutinin antibody or an anti-M2 antibody; etc).

In another aspect, the invention provides use of an article of manufacture of the invention in the manufacture of a medicament. The medicament may be for use in the inhibition, treatment, or prevention of influenza A virus infection. In certain embodiments, the medicament may further comprise an additional therapeutic agent (e.g., a neuraminidase inhibitor, such as oseltamivir or zanamivir; another antibody, such as another anti-hemagglutinin antibody or an anti-M2 antibody; etc).

In another aspect, the invention provides use of a kit of the invention in the manufacture of a medicament. The medicament may be for use in the inhibition, treatment, or prevention of influenza A virus infection. In certain embodiments, the medicament may further comprise an additional therapeutic agent (e.g., a neuraminidase inhibitor, such as oseltamivir or zanamivir; another antibody, such as another anti-hemagglutinin antibody or an anti-M2 antibody; etc).

In various aspects, an anti-hemagglutinin antibody of the present invention binds hemagglutinin. In some aspects, an anti-hemagglutinin antibody of the present invention binds Group1 hemagglutinin, binds Group2 hemagglutinin, or binds Group1 and Group2 hemagglutinin. In other aspects, an anti-hemagglutinin antibody of the present invention binds hemagglutinin and neutralizes influenza A virus. In some embodiments, an anti-hemagglutinin antibody of the present invention neutralizes influenza A virus in vitro, in vivo, or in vitro and in vivo.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B sets forth data showing FACS analysis of anti-hemagglutinin-positive (hemagglutinin H3+ and hemagglutinin H1+) plasmablasts from day 7 post-vaccinated human peripheral blood mononuclear cells (PBMCs) prior to SCID/beige mouse enrichment (FIG. 1A) and day 8 post-intrasplenic implantation after SCID/beige mouse enrichment with and without antigen premix (FIG. 1B) in the upper and lower panels, respectively.

15

FIG. 2 sets forth data showing analysis of splenocytes obtained from day 8 post-intrasplenic implantation of PBMCs from individual SCID/beige mice with no PBMC/antigen premix (circles) and with PBMC/antigen premix (squares), as percent hemagglutinin (H1)⁺/CD38^{high} plasmablasts. The rectangle indicates mice that presented hemagglutinin H1⁺ plasmablasts.

FIG. 3 sets forth data showing in vitro neutralization of various influenza A Group1 and Group2 virus strains by anti-hemagglutinin antibodies of the present invention.

FIGS. 4A and 4B set forth data showing in vitro neutralization of various influenza A Group1 (FIG. 4A) and Group2 (FIG. 4B) virus strains by monoclonal antibody 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177).

FIGS. 5A and 5B set forth data showing in vitro neutralization of various influenza A Group1 (FIG. 5A) and Group2 (FIG. 5B) virus strains by monoclonal antibody 81.39 SVSH-NYP ("SVSH" disclosed as SEQ ID NO: 171).

FIG. 6 sets forth data showing in vitro neutralization of various influenza A Group1 virus strains by monoclonal antibody 39.18 B11.

FIG. 7 sets forth data showing in vitro neutralization of various influenza A Group1 and Group2 virus strains by monoclonal antibody 36.89.

FIG. 8 sets forth data showing in vitro neutralization of various influenza A Group1 and Group2 virus strains by monoclonal antibody mAb9 01F3.

FIG. 9 sets forth data showing in vitro neutralization of various influenza A Group 1 and Group2 virus strains by monoclonal antibody mAb23 06C2.

FIG. 10 sets forth data showing in vitro neutralization of an hemagglutinin H5-expressing pseudovirus by monoclonal antibody 39.29 NCv1.

FIG. 11 sets forth data showing in vitro neutralization of an H7N7 equine influenza virus by monoclonal antibody 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177).

FIGS. 12A, 12B, 12C, and 12D set forth data showing percent survival of mice infected with various influenza A virus strains (A/PR/8/1934 (PR8), FIG. 12A; A/Port Chalmers/1/1973 (PC73), FIG. 12B; A/Hong Kong/1/1968 (HK68), FIG. 12C); and A/Aichi/2/1968 (Aichi68), FIG. 12D) and administered various amounts of monoclonal antibody 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177).

FIG. 13 sets forth data showing percent survival of mice infected with A/PR/8/1934 influenza A virus and administered various amounts of monoclonal antibody 39.29 NCv1.

FIG. 14 sets forth data showing percent survival of mice infected with A/Hong Kong/1/1968 influenza A virus (an influenza A virus having a high IC₅₀) and administered various amounts of monoclonal antibody 39.29 NCv1.

FIG. 15 sets forth data showing percent survival of mice infected with A/Port Chalmers/1/1973 influenza A virus and administered various amounts of monoclonal antibody 39.29 NCv1.

FIG. 16 sets forth data showing percent survival of mice infected with A/Aichi/2/1968 influenza A virus and administered various amounts of monoclonal antibody 39.29 NCv1.

FIG. 17 sets forth data comparing percent survival of mice infected with influenza A virus strain A/PR/8/1934 and administered a 50:50 mixture of monoclonal antibody 39.29 D8C2 and monoclonal antibody 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) or oseltamivir (Tamiflu®).

FIG. 18 sets forth data showing comparing percent survival of mice infected with influenza A virus strain A/PR/8/1934 and administered monoclonal antibody 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177), oseltamivir (Tami-

16

flu®), or a combination of monoclonal antibody 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) and oseltamivir.

FIGS. 19A and 19B set forth data comparing percent survival of ferrets infected with influenza A virus strain A/Vietnam/1203/04 (H5N1) and administered monoclonal antibody 39.29 D8C2 (FIG. 19A), monoclonal antibody 81.39 B1C1 (FIG. 19B), or oseltamivir (Tamiflu®) at 48 hours or 72 hours post-infection.

FIG. 20 shows an amino acid sequence alignment of hemagglutinin amino acid sequences from hemagglutinin H1, H2, H3, H5 and H7, showing hemagglutinin contact residues (shaded) of monoclonal antibody 39.29NCv1 and the hemagglutinin binding epitope.

FIGS. 21A and 21B set forth data from competition ELISA experiments of various monoclonal antibodies of the present invention competing with binding of biotin-labeled monoclonal antibody 39.29 to hemagglutinin H1 from A/NWS/1933 (FIG. 21A) and hemagglutinin H3 from A/HK/8/1968 (FIG. 21B).

FIGS. 22A and 22B show an amino acid sequence alignment of the light chain variable region and the heavy chain variable region of monoclonal antibody 81.39 B1C1 (SEQ ID NOs:113 and 111, respectively) with the immunoglobulin kappa variable 3-15*01 germ-line (IGKV3-15*01) and the immunoglobulin heavy chain variable 3-30*01 germ-line (IGHV3-30*01) (SEQ ID NOs:236 and 237, respectively). The amino acids are numbers according to Kabat numbering. The Kabat, Chothia, and Contact CDRs are indicated.

FIGS. 23A and 23B show an amino acid sequence alignment of the light chain variable region and the heavy chain variable region of monoclonal antibody 81.39 SVSH-NYP ("SVSH" disclosed as SEQ ID NO: 171) (SEQ ID NOs:117 and 115, respectively) with immunoglobulin kappa variable 3-15*01 germ-line (IGKV3-15*01) and the immunoglobulin heavy chain variable 3-30*01 germ-line (IGHV3-30*01) (SEQ ID NOs:236 and 237, respectively). The amino acids are numbers according to Kabat numbering. The Kabat, Chothia, and Contact CDRs are indicated.

FIGS. 24A and 24B show an amino acid sequence alignment of the light chain variable region and the heavy chain variable region of monoclonal antibody 81.39 B1F1 (SEQ ID NOs:119 and 111, respectively) with the immunoglobulin kappa variable 3-15*01 germ-line (IGKV3-15*01) and the immunoglobulin heavy chain variable 3-30*01 germ-line (IGHV3-30*01) (SEQ ID NOs:236 and 237, respectively). The amino acids are numbers according to Kabat numbering. The Kabat, Chothia, and Contact CDRs are indicated.

FIGS. 25A and 25B show an amino acid sequence alignment of the light chain variable region and the heavy chain variable region of monoclonal antibody 81.39 SVDS ("SVDS" disclosed as SEQ ID NO: 172) (SEQ ID NOs:113 and 115, respectively) with the immunoglobulin kappa variable 3-15*01 germ-line (IGKV3-15*01) and the immunoglobulin heavy chain variable 3-30*01 germ-line (IGHV3-30*01) (SEQ ID NOs:236 and 237, respectively). The amino acids are numbers according to Kabat numbering. The Kabat, Chothia, and Contact CDRs are indicated.

FIGS. 26A and 26B show an amino acid sequence alignment of the light chain variable region and the heavy chain variable region of monoclonal antibody 81.39 SVSS ("SVSS" disclosed as SEQ ID NO: 173) (SEQ ID NOs:122 and 115, respectively) with the immunoglobulin kappa variable 3-15*01 germ-line (IGKV3-15*01) and the immunoglobulin heavy chain variable 3-30*01 germ-line (IGHV3-30*01) (SEQ ID NOs:236 and 237, respectively). The amino acids are numbers according to Kabat numbering. The Kabat, Chothia, and Contact CDRs are indicated.

The amino acids are numbers according to Kabat numbering. The Kabat, Chothia, and Contact CDRs are indicated.

FIGS. 41A and 41B show an amino acid sequence alignment of the light chain variable region and the heavy chain variable region of monoclonal antibody 36.89 (SEQ ID NOs: 162 and 160, respectively) with the immunoglobulin kappa variable 1-5*03 germ-line (IGKV1-5*03) and the immunoglobulin heavy chain variable 1-18*01 germ-line (IGHV1-18*01) (SEQ ID NOs: 239 and 240, respectively). The amino acids are numbers according to Kabat numbering. The Kabat, Chothia, and Contact CDRs are indicated.

FIGS. 42A and 42B show an amino acid sequence alignment of the light chain variable region and the heavy chain variable region of monoclonal antibody 9.01F3 (SEQ ID NOs: 166 and 164, respectively) with the immunoglobulin light variable 1-44*01 germ-line (IGKV1-44*01) and the immunoglobulin heavy chain variable 1-2*02*01 germ-line (IGHV1-2*02) (SEQ ID NOs: 241 and 242, respectively). The amino acids are numbers according to Kabat numbering. The Kabat, Chothia, and Contact CDRs are indicated.

FIGS. 43A and 43B show an amino acid sequence alignment of the light chain variable region and the heavy chain variable region of monoclonal antibody 23.06C2 (SEQ ID NOs: 170 and 168, respectively) with the immunoglobulin kappa variable 2-30*01 germ-line (IGKV2-30*01) and the immunoglobulin heavy chain variable 4-39*01 germ-line (IGHV4-39*01) (SEQ ID NOs: 243 and 244, respectively). The amino acids are numbers according to Kabat numbering. The Kabat, Chothia, and Contact CDRs are indicated.

DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

I. Definitions

An “acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.

“Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.

An “affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.

The terms “anti-hemagglutinin antibody” and “an antibody that binds to hemagglutinin” refer to an antibody that binds hemagglutinin with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting hemagglutinin, including targeting hemagglutinin of influenza virus. In one embodiment, the extent of binding of an anti-hemagglutinin antibody to an unrelated, non-hemagglutinin protein is less than about 10% of the binding of the antibody to hemagglutinin as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to hemagglutinin has a dissociation constant (Kd) of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, or $\leq 0.001 \text{ nM}$ (e.g., 10^{-8} M or less, e.g., from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M). In certain embodiments, an anti-hemagglutinin antibody binds to an epitope of hemagglutinin that is conserved among hemagglutinin from different strains, subtypes, and isolates of influenza A viruses.

The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. An antibody fragment also refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds hemagglutinin and neutralizes influenza A virus. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')₂; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.

An “antibody that binds to the same epitope” as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more. An exemplary competition assay is provided herein.

The term “chimeric” antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively.

The term “cytotoxic agent” as used herein refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial,

fungal, plant or animal origin, including fragments and/or variants thereof; and the various antitumor or anticancer agents disclosed below.

"Effector functions" refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation.

An "effective amount" of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

The term "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.

"Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

The terms "full length antibody," "intact antibody," and "whole antibody" are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

A "human antibody" is an antibody which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.

A "human consensus framework" is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., *Sequences of Proteins of Immunological Interest*, Fifth Edition, NIH Publication 91-3242, Bethesda Md. (1991), vols. 1-3. In one embodiment, for the

VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., supra.

A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

The term "hypervariable region" or "HVR" as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence ("complementarity determining regions" or "CDRs") and/or form structurally defined loops ("hypervariable loops") and/or contain the antigen-contacting residues ("antigen contacts"). Generally, antibodies comprise six HVRs: three in the VH(H1, H2, H3), and three in the VL (L1, L2, L3). Exemplary HVRs herein include:

- (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, *J. Mol. Biol.* 196:901-917 (1987));
- (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991));
- (c) antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. *J. Mol. Biol.* 262: 732-745 (1996)); and
- (d) combinations of (a), (b), and/or (c), including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).

Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.

An "immunoconjugate" is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.

An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

An "isolated" antibody is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For review of methods for assessment of antibody purity, see, e.g., Flatman et al., *J. Chromatogr. B* 848:79-87 (2007).

An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extra-

chromosomally or at a chromosomal location that is different from its natural chromosomal location.

"Isolated nucleic acid encoding an anti-hemagglutinin antibody" refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

A "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.

"Native antibodies" refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.

"Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance,

using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

The term "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

The term "hemagglutinin," as used herein, refers to any native hemagglutinin from any influenza virus source, unless otherwise indicated. The term encompasses "full-length," unprocessed hemagglutinin as well as any form of hemagglutinin that results from processing in an influenza virus or an influenza virus-infected cell. The term also encompasses naturally occurring variants of hemagglutinin, e.g., splice variants or allelic variants. The amino acid sequences of exemplary hemagglutinin proteins from various influenza A virus strains are shown in SEQ ID NOs:225 (H2 from A/Japan/305/1957), 226 (H3 from A/Perth/16/2009), 227 (H5 from A/Vietnam/1203/2004), 228 (H7 from A/chicken/NSW/1/1997), 229 (H1 from A/California/07/2009), 230 (H1 from A/NSW/1933), 231 (H3 from A/Hong Kong/8/1968), 232 (H7 from A/Netherlands/219/2003), and 233 (A/South Carolina/1918).

As used herein, "treatment" (and grammatical variations thereof such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease (e.g., preventing occurrence or recurrence of influenza A virus infection), reduction (e.g., reducing) or alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.

The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al. *Kuby Immunology*, 6th ed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., *J. Immunol.* 150:880-887 (1993); Clarkson et al., *Nature* 352:624-628 (1991).

The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."

II. Compositions and Methods

In one aspect, the invention is based, in part, on anti-hemagglutinin antibodies and uses thereof. In certain embodiments, antibodies that bind to hemagglutinin are provided. Antibodies of the invention are useful, e.g., for the diagnosis, treatment, or prevention of influenza A virus infection.

A. Exemplary Anti-Hemagglutinin Antibodies

In one aspect, the invention provides isolated antibodies that bind to hemagglutinin. In certain embodiments, an anti-hemagglutinin antibody of the present invention binds hemagglutinin, binds Group1 hemagglutinins, binds Group2 hemagglutinins, or binds Group1 and Group2 hemagglutinins. In other embodiments, an anti-hemagglutinin antibody of the present invention neutralizes influenza A virus in vitro. In other embodiments, an anti-hemagglutinin antibody of the present invention neutralizes influenza A virus in vivo. In yet other embodiments, an anti-hemagglutinin antibody of the present invention reduces influenza A virus infection, prevents influenza A virus infection, inhibits influenza A virus infection, or treats influenza A virus infection. In some embodiments, an anti-hemagglutinin antibody of the present invention prevents, inhibits, or reduces hemagglutinin-mediated fusion between influenza virus membrane and infected cell endosomal membranes (thus preventing, inhibiting, or

reducing viral RNA entry into the infected cell cytoplasm, thus preventing, inhibiting, or reducing further propagation of influenza virus infection.)

In one aspect, the invention provides an anti-hemagglutinin antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:178; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:179; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:180; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:182; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:187; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:188.

In one aspect, the invention provides an anti-hemagglutinin antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:178; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:179; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:181; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:183; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:187; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:189.

In one aspect, the invention provides an anti-hemagglutinin antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:178; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:179; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:181; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:182; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:187; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:188.

In one aspect, the invention provides an anti-hemagglutinin antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:178; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:179; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:181; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:184; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:187; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:188.

In one aspect, the invention provides an anti-hemagglutinin antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:178; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:179; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:181; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:185; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:187; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:188.

In one aspect, the invention provides an anti-hemagglutinin antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:178; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:179; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:181; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:183; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:187; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:188.

In one aspect, the invention provides an anti-hemagglutinin antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:178; (b) HVR-H2 comprising the

In one aspect, the invention provides an anti-hemagglutinin antibody comprising at least one, two, three, four, five, or six HVRs selected from (a) HVR-H1 comprising the amino acid

In another aspect, the invention provides an antibody comprising (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:191; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:193; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:194; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:195; (e) HVR-L2 comprising the amino acid sequence of SEQ ID

In one embodiment, the invention provides an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:234 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:235.

In another aspect, the invention provides an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:164.

In another aspect, the invention provides an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:169.

In another aspect, the invention provides an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:167, and a light chain comprising the amino acid sequence of SEQ ID NO:169.

In any of the above embodiments, an anti-hemagglutinin antibody of the present invention is humanized. In one embodiment, an anti-hemagglutinin antibody comprises HVRs as in any of the above embodiments, and further comprises an acceptor human framework, e.g., a human immunoglobulin framework or a human consensus framework.

In another aspect, an anti-hemagglutinin antibody of the present invention comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:111, 115, 134, 138, 142, 148, 154, 158, 160, 164, 168, and 234. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-hemagglutinin antibody comprising that sequence retains the ability to bind to hemagglutinin. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NOs: 111, 115, 134, 138, 142, 148, 154, 158, 160, 164, 168, or 234. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti hemagglutinin antibody comprises the VH sequence in SEQ ID NO: 111, 115, 134, 138, 142, 148, 154, 158, 160, 164, 168, or 234, including post-translational modifications of that sequence.

In another aspect, an anti-hemagglutinin antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:113, 117, 119, 122, 124, 126, 128, 130, 132, 136, 140, 144, 146, 150, 152, 156, 162, 166, 170, and 235. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-hemagglutinin antibody comprising that sequence retains the ability to bind to hemagglutinin. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NOs: 113, 117, 119, 122, 124, 126, 128, 130, 132, 136, 140, 144, 146, 150, 152, 156, 162, 166, 170, or 235. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-hemagglutinin antibody comprises the VL sequence in SEQ ID NOs: 113, 117, 119, 122, 124, 126, 128, 130, 132, 136, 140, 144, 146, 150, 152, 156, 162, 166, 170, or 235, including post-translational modifications of that sequence.

In another aspect, an anti-hemagglutinin antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NOs: 111, 115, 134, 138, 142, 148, 154, 158, 160, 164, 168, or 234, and SEQ ID NOs: 113, 117, 119, 122, 124, 126, 128, 130, 132, 136, 140, 144, 146, 150, 152, 156, 162, 166, 170, or 235, respectively, including post-translational modifications of those sequences.

In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-hemagglutinin antibody provided herein. For example, in certain embodiments, an

antibody is provided that binds to the same epitope as an anti-hemagglutinin antibody comprising a VH sequence of SEQ ID NO:111 and a VL sequence of SEQ ID NO:113; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:117; a VH sequence of SEQ ID NO:111 and a VL sequence of SEQ ID NO:119; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:113; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:122; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:124; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:126; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:128; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:130; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:132; a VH sequence of SEQ ID NO:134 and a VL sequence of SEQ ID NO:136; a VH sequence of SEQ ID NO:138 and a VL sequence of SEQ ID NO:140; a VH sequence of SEQ ID NO:142 and a VL sequence of SEQ ID NO:144; a VH sequence of SEQ ID NO:138 and a VL sequence of SEQ ID NO:146; a VH sequence of SEQ ID NO:148 and a VL sequence of SEQ ID NO:150; a VH sequence of SEQ ID NO:148 and a VL sequence of SEQ ID NO:152; a VH sequence of SEQ ID NO:148 and a VL sequence of SEQ ID NO:140; a VH sequence of SEQ ID NO:234 and a VL sequence of SEQ ID NO:235; a VH sequence of SEQ ID NO:154 and a VL sequence of SEQ ID NO:156; a VH sequence of SEQ ID NO:158 and a VL sequence of SEQ ID NO:156; a VH sequence of SEQ ID NO:160 and a VL sequence of SEQ ID NO:162; a VH sequence of SEQ ID NO:164 and a VL sequence of SEQ ID NO:166; or a VH sequence of SEQ ID NO:168 and a VL sequence of SEQ ID NO:170.

In a further aspect of the invention, an anti-hemagglutinin antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized, or human antibody. In one embodiment, an anti-hemagglutinin antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')₂ fragment. In another embodiment, the antibody is a full length antibody, e.g., an intact, e.g., IgG1 antibody or other antibody class or isotype as defined herein.

In a further aspect, an anti-hemagglutinin antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below:

1. Antibody Affinity

In certain embodiments, an antibody provided herein has a dissociation constant (K_d) of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, $\leq 0.01 \text{ nM}$, or $\leq 0.001 \text{ nM}$ (e.g., 10^{-8} M or less, e.g., from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M).

In one embodiment, K_d is measured by a radiolabeled antigen binding assay (RIA). In one embodiment, an RIA is performed with the Fab version of an antibody of interest and its antigen. For example, solution binding affinity of Fabs for antigen is measured by equilibrating Fab with a minimal concentration of (¹²⁵I)-labeled antigen in the presence of a titration series of unlabeled antigen, then capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen et al., *J. Mol. Biol.* 293:865-881 (1999)). To establish conditions for the assay, MICROTITER® multi-well plates (Thermo Scientific) are coated overnight with 5 $\mu\text{g/ml}$ of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23° C.). In a non-adsorbent plate (Nunc #269620), 100 pM or 26 pM [¹²⁵I]-antigen antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent

with assessment of the anti-VEGF antibody, Fab-12, in Presta et al., *Cancer Res.* 57:4593-4599 (1997)). The Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room temperature (e.g., for one hour). The solution is then removed and the plate washed eight times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. When the plates have dried, 150 µl/well of scintillant (MICROSCINT-20™; Packard) is added, and the plates are counted on a TOPCOUNT™ gamma counter (Packard) for ten minutes. Concentrations of each Fab that give less than or equal to 20% of maximal binding are chosen for use in competitive binding assays.

According to another embodiment, K_d is measured using a BIACORE® surface plasmon resonance assay. For example, an assay using a BIACORE®-2000 or a BIACORE®-3000 (BIAcore, Inc., Piscataway, N.J.) is performed at 25° C. with immobilized antigen CM5 chips at ~10 response units (RU). In one embodiment, carboxymethylated dextran biosensor chips (CM5, BIAcore, Inc.) are activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 µg/ml (~0.2 µM) before injection at a flow rate of 5 µl/minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-20™) surfactant (PBST) at 25° C. at a flow rate of approximately 25 µl/min. Association rates (k_{on}) and dissociation rates (k_{off}) are calculated using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (K_d) is calculated as the ratio k_{off}/k_{on}. See, e.g., Chen et al., *J. Mol. Biol.* 293:865-881 (1999). If the on-rate exceeds 10⁶ M⁻¹s⁻¹ by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation=295 nm; emission=340 nm, 16 nm band-pass) at 25° C. of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophotometer (Aviv Instruments) or a 8000-series SLM-AMINCO™ spectrophotometer (ThermoSpectronic) with a stirred cuvette.

2. Antibody Fragments

In certain embodiments, an antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')₂, Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, see Hudson et al., *Nat. Med.* 9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthün, in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab')₂ fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046.

Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al., *Nat. Med.* 9:129-134 (2003); and Hollinger et al., *Proc. Natl. Acad. Sci.*

USA 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., *Nat. Med.* 9:129-134 (2003).

Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516 B1).

Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g., *E. coli* or phage), as described herein.

3. Chimeric and Humanized Antibodies

In certain embodiments, an antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, e.g., in U.S. Pat. No. 4,816,567; and Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1984)). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a "class switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008), and are further described, e.g., in Riechmann et al., *Nature* 332:323-329 (1988); Queen et al., *Proc. Natl. Acad. Sci. USA* 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., *Methods* 36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan, *Mol. Immunol.* 28:489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., *Methods* 36:43-60 (2005) (describing "FR shuffling"); and Osbourn et al., *Methods* 36:61-68 (2005) and Klimka et al., *Br. J. Cancer*, 83:252-260 (2000) (describing the "guided selection" approach to FR shuffling).

Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the "best-fit" method (see, e.g., Sims et al. *J. Immunol.* 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. *Proc. Natl. Acad. Sci. USA*, 89:4285 (1992); and Presta et al. *J. Immunol.*, 151:2623 (1993)); human mature (somatic mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., *J. Biol. Chem.* 272:10678-10684 (1997) and Rosok et al., *J. Biol. Chem.* 271:22611-22618 (1996)).

4. Human Antibodies

In certain embodiments, an antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art or using techniques described herein. Human antibodies are described generally in van Dijk and van de Winkel, *Curr. Opin. Pharmacol.* 5: 368-74 (2001) and Lonberg, *Curr. Opin. Immunol.* 20:450-459 (2008).

Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg, *Nat. Biotech.* 23:1117-1125 (2005). See also, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Pat. No. 5,770,429 describing HuMAB® technology; U.S. Pat. No. 7,041,870 describing K-M MOUSE® technology, and U.S. Patent Application Publication No. US 2007/0061900, describing VELOCIMOUSE® technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.

Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor *J. Immunol.*, 133: 3001 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., *J. Immunol.*, 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., *Proc. Natl. Acad. Sci. USA*, 103:3557-3562 (2006). Additional methods include those described, for example, in U.S. Pat. No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, *Xiandai Mianyixue*, 26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, *Histology and Histopathology*, 20(3):927-937 (2005) and Vollmers and Brandlein, *Methods and Findings in Experimental and Clinical Pharmacology*, 27(3):185-91 (2005).

Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.

5. Library-Derived Antibodies

Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al. in *Methods in Molecular Biology* 178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., 2001) and further described, e.g., in the McCafferty et al., *Nature* 348: 552-554; Clackson et al., *Nature* 352: 624-628 (1991); Marks et al., *J. Mol. Biol.* 222: 581-597 (1992); Marks and Bradbury, in *Methods in Molecular Biology* 248:161-175 (Lo, ed.,

Human Press, Totowa, N.J., 2003); Sidhu et al., *J. Mol. Biol.* 338(2): 299-310 (2004); Lee et al., *J. Mol. Biol.* 340(5): 1073-1093 (2004); Fellouse, *Proc. Natl. Acad. Sci. USA* 101 (34): 12467-12472 (2004); and Lee et al., *J. Immunol. Methods* 284(1-2): 119-132 (2004).

In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al., *Ann. Rev. Immunol.*, 12: 433-455 (1994). Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths et al., *EMBO J.* 12: 725-734 (1993). Finally, naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter, *J. Mol. Biol.*, 227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.

Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.

6. Multispecific Antibodies

In certain embodiments, an antibody provided herein is a multispecific antibody, e.g., a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for hemagglutinin and the other is for any other antigen. In certain embodiments, bispecific antibodies may bind to two different epitopes of hemagglutinin. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express hemagglutinin. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.

Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, *Nature* 305: 537 (1983)), WO 93/08829, and Traunecker et al., *EMBO J.* 10: 3655 (1991)), and "knob-in-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al., *Science*, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny et al., *J. Immunol.*, 148(5):1547-1553 (1992)); using "diabody" technology for making bispecific antibody fragments (see, e.g., Hollinger et al., *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (see, e.g. Gruber et al., *J. Immunol.*, 152:5368 (1994)); and preparing trispecific antibodies as described, e.g., in Tutt et al. *J. Immunol.* 147: 60 (1991).

Engineered antibodies with three or more functional antigen binding sites, including "Octopus antibodies," are also included herein (see, e.g., US 2006/0025576A1).

The antibody or fragment herein also includes a "Dual Acting Fab" or "DAF" comprising an antigen binding site that binds to hemagglutinin as well as another, different antigen (see, US 2008/0069820, for example).

7. Antibody Variants

In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.

a) Substitution, Insertion, and Deletion Variants

In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions." More substantial changes are provided in Table 1 under the heading of "exemplary substitutions," and as further described below in reference to amino acid side chain classes. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.

TABLE 1

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	Val; Leu; Ile	Val
Arg (R)	Lys; Gln; Asn	Lys
Asn (N)	Gln; His; Asp, Lys; Arg	Gln
Asp (D)	Glu; Asn	Glu
Cys (C)	Ser; Ala	Ser
Gln (Q)	Asn; Glu	Asn
Glu (E)	Asp; Gln	Asp
Gly (G)	Ala	Ala
His (H)	Asn; Gln; Lys; Arg	Arg
Ile (I)	Leu; Val; Met; Ala; Phe; Norleucine	Leu
Leu (L)	Norleucine; Ile; Val; Met; Ala; Phe	Ile
Lys (K)	Arg; Gln; Asn	Arg
Met (M)	Leu; Phe; Ile	Leu
Phe (F)	Trp; Leu; Val; Ile; Ala; Tyr	Tyr
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Val; Ser	Ser
Trp (W)	Trp; Phe	Tyr
Tyr (Y)	Trp; Phe; Thr; Ser	Phe
Val (V)	Ile; Leu; Met; Phe; Ala; Norleucine	Leu

Amino acids may be grouped according to common side-chain properties:

- (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
- (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- (3) acidic: Asp, Glu;
- (4) basic: His, Lys, Arg;
- (5) residues that influence chain orientation: Gly, Pro;
- (6) aromatic: Trp, Tyr, Phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the result-

ing variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g., binding affinity).

Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR "hotspots," i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, *Methods Mol. Biol.* 207:179-196 (2008)), and/or residues that contact antigen, with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom et al., in *Methods in Molecular Biology* 178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.

In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may, for example, be outside of antigen contacting residues in the HVRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.

A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) *Science*, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino

acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

b) Glycosylation Variants

In certain embodiments, an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.

Where the antibody comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al., *TIBTECH* 15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.

In one embodiment, antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e.g., complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example. Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ± 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to "defucosylated" or "fucose-deficient" antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al., *J. Mol. Biol.* 336:1239-1249 (2004); Yamane-Ohnuki et al., *Biotech. Bioeng.* 87: 614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al., *Arch. Biochem. Biophys.* 249:533-545 (1986); US Pat Appl No US 2003/0157108 A1, Presta, L.; and WO 2004/056312 A1, Adams et al., especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al., *Biotech. Bioeng.* 87: 614 (2004); Kanda, Y. et al., *Biotechnol. Bioeng.*, 94(4):680-688 (2006); and WO2003/085107).

Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosy-

lation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean-Mairet et al.); U.S. Pat. No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al.). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).

c) Fc Region Variants

In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.

In certain embodiments, the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcγR binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, *Annu. Rev. Immunol.* 9:457-492 (1991). Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (see, e.g. Hellstrom, I. et al. *Proc. Nat'l Acad. Sci. USA* 83:7059-7063 (1986)) and Hellstrom, I et al., *Proc. Nat'l Acad. Sci. USA* 82:1499-1502 (1985); U.S. Pat. No. 5,821,337 (see Bruggemann, M. et al., *J. Exp. Med.* 166:1351-1361 (1987)). Alternatively, non-radioactive assays methods may be employed (see, for example, ACTITM non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, Wis.). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al. *Proc. Nat'l Acad. Sci. USA* 95:652-656 (1998). C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al., *J. Immunol. Methods* 202:163 (1996); Cragg, M. S. et al., *Blood* 101:1045-1052 (2003); and Cragg, M. S. and M. J. Glennie, *Blood* 103:2738-2743 (2004)). FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S. B. et al., *Int'l Immunol.* 18(12):1759-1769 (2006)).

Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).

Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Pat. No. 6,737,056; WO 2004/056312, and Shields et al., *J. Biol. Chem.* 9(2): 6591-6604 (2001).)

In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).

In some embodiments, alterations are made in the Fc region that result in altered (i.e., either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et al. *J. Immunol.* 164: 4178-4184 (2000).

Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., *J. Immunol.* 117:587 (1976) and Kim et al., *J. Immunol.* 24:249 (1994)), are described in US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (U.S. Pat. No. 7,371,826).

See also Duncan & Winter, *Nature* 322:738-40 (1988); U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.

d) Cysteine Engineered Antibody Variants

In certain embodiments, it may be desirable to create cysteine engineered antibodies, e.g., "thioMAbs," in which one or more residues of an antibody are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated as described, e.g., in U.S. Pat. No. 7,521,541.

e) Antibody Derivatives

In certain embodiments, an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer are

attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.

In another embodiment, conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam et al., *Proc. Natl. Acad. Sci. USA* 102: 11600-11605 (2005)). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody-nonproteinaceous moiety are killed.

B. Recombinant Methods and Compositions

Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one embodiment, isolated nucleic acid encoding an anti-hemagglutinin antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an anti-hemagglutinin antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

For recombinant production of an anti-hemagglutinin antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, *Methods in Molecular Biology*, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254, describing expression of antibody fragments in *E. coli*.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and

yeast strains whose glycosylation pathways have been "humanized," resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, *Nat. Biotech.* 22:1409-1414 (2004), and Li et al., *Nat. Biotech.* 24:210-215 (2006).

Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants).

Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., *J. Gen. Virol.* 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, *Biol. Reprod.* 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., *Annals N.Y. Acad. Sci.* 383: 44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR⁻ CHO cells (Urlaub et al., *Proc. Natl. Acad. Sci. USA* 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, *Methods in Molecular Biology*, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).

C. Assays

Anti-hemagglutinin antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.

1. Binding Assays and Other Assays

In one aspect, an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, Western blot, etc.

In another aspect, competition assays may be used to identify an antibody that competes for binding of hemagglutinin with any anti-hemagglutinin antibody described herein. In certain embodiments, such a competing antibody binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by an anti-hemagglutinin antibody described here (e.g., an anti-hemagglutinin antibody comprising a VH sequence of SEQ ID NO:111 and a VL sequence of SEQ ID NO:113; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:117; a VH sequence of SEQ ID NO:111 and a VL sequence of SEQ ID NO:119; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:113; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:122; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:124; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:126; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:128; a VH sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:130; a VH

sequence of SEQ ID NO:115 and a VL sequence of SEQ ID NO:132; a VH sequence of SEQ ID NO:134 and a VL sequence of SEQ ID NO:136; a VH sequence of SEQ ID NO:138 and a VL sequence of SEQ ID NO:140; a VH sequence of SEQ ID NO:142 and a VL sequence of SEQ ID NO:144; a VH sequence of SEQ ID NO:138 and a VL sequence of SEQ ID NO:146; a VH sequence of SEQ ID NO:148 and a VL sequence of SEQ ID NO:150; a VH sequence of SEQ ID NO:148 and a VL sequence of SEQ ID NO:152; a VH sequence of SEQ ID NO:148 and a VL sequence of SEQ ID NO:140; a VH sequence of SEQ ID NO:234 and a VL sequence of SEQ ID NO:235; a VH sequence of SEQ ID NO:154 and a VL sequence of SEQ ID NO:156; a VH sequence of SEQ ID NO:158 and a VL sequence of SEQ ID NO:156; a VH sequence of SEQ ID NO:160 and a VL sequence of SEQ ID NO:162; a VH sequence of SEQ ID NO:164 and a VL sequence of SEQ ID NO:166; or a VH sequence of SEQ ID NO:168 and a VL sequence of SEQ ID NO:170. Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris (1996) "Epitope Mapping Protocols," in *Methods in Molecular Biology* vol. 66 (Humana Press, Totowa, N.J.).

In an exemplary competition assay, immobilized hemagglutinin is incubated in a solution comprising a first labeled antibody that binds to hemagglutinin and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to hemagglutinin. The second antibody may be present in a hybridoma supernatant. As a control, immobilized hemagglutinin is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to hemagglutinin, excess unbound antibody is removed, and the amount of label associated with immobilized hemagglutinin is measured. If the amount of label associated with immobilized hemagglutinin is substantially reduced in the test sample relative to the control sample, then that indicates that the second antibody is competing with the first antibody for binding to hemagglutinin. See Harlow and Lane (1988) *Antibodies: A Laboratory Manual* ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

2. Activity Assays

In one aspect, assays are provided for identifying anti-hemagglutinin antibodies and fragments thereof having biological activity. Biological activity may include, e.g., specifically binding to influenza A virus hemagglutinin, neutralizing influenza A virus, etc. Antibodies and compositions comprising antibodies or fragments thereof having such biological activity in vivo and/or in vitro are also provided.

In certain embodiments, an antibody of the invention is tested for such biological activity. See Examples 4, 5, 6, 7, 8, 9, 10, and 13 for exemplary descriptions of such assays.

D. Immunoconjugates

The invention also provides immunoconjugates comprising an anti-hemagglutinin antibody herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes.

In one embodiment, an immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody is conjugated to one or more drugs, including but not limited to a maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1); an auristatin such as monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483 and 5,780,588, and 7,498,298);

a dolastatin; a calicheamicin or derivative thereof (see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al., *Cancer Res.* 53:3336-3342 (1993); and Lode et al., *Cancer Res.* 58:2925-2928 (1998)); an anthracycline such as daunomycin or doxorubicin (see Kratz et al., *Current Med. Chem.* 13:477-523 (2006); Jeffrey et al., *Bioorganic & Med. Chem. Letters* 16:358-362 (2006); Torgov et al., *Bioconj. Chem.* 16:717-721 (2005); Nagy et al., *Proc. Natl. Acad. Sci. USA* 97:829-834 (2000); Dubowchik et al., *Bioorg. & Med. Chem. Letters* 12:1529-1532 (2002); King et al., *J. Med. Chem.* 45:4336-4343 (2002); and U.S. Pat. No. 6,630,579); methotrexate; vindesine; a taxane such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; a trichothecene; and CC 1065.

In another embodiment, an immunoconjugate comprises an antibody as described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolacca americana* proteins (PAPI, PAPII, and PAP-S), *momordica charantia* inhibitor, curcin, crotin, *sapaonaria officinalis* inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.

In another embodiment, an immunoconjugate comprises an antibody as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioactive isotopes are available for the production of radioconjugates. Examples include At^{211} , I^{131} , I^{125} , Y^{90} , Re^{186} , Re^{188} , Sm^{153} , Bi^{212} , P^{32} , Pb^{212} and radioactive isotopes of Lu. When the radioconjugate is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example $\text{tc}^{99\text{m}}$ or I^{123} , or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

Conjugates of an antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., *Science* 238:1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026. The linker may be a "cleavable linker" facilitating release of a cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., *Cancer Res.* 52:127-131 (1992); U.S. Pat. No. 5,208,020) may be used.

The immunoconjugates or ADCs herein expressly contemplate, but are not limited to such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SLAB, SMCC, SMPB, SMPI, sulfo-EMCS, sulfo-

GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinyl-sulfone)benzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Ill., U.S.A.).

E. Methods and Compositions for Diagnostics and Detection

In certain embodiments, any of the anti-hemagglutinin antibodies provided herein is useful for detecting the presence of hemagglutinin or influenza A virus in a biological sample. The term "detecting" as used herein encompasses quantitative or qualitative detection. In certain embodiments, a biological sample comprises a cell or tissue, such as, for example, lung, upper respiratory tract, nasal canal, blood, sputum, or comprises a biological sample obtained by nasal or throat swab.

In one embodiment, an anti-hemagglutinin antibody for use in a method of diagnosis or detection is provided. In a further aspect, a method of detecting the presence of hemagglutinin or influenza A virus in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with an anti-hemagglutinin antibody as described herein under conditions permissive for binding of the anti-hemagglutinin antibody to hemagglutinin, and detecting whether a complex is formed between the anti-hemagglutinin antibody and hemagglutinin. Such method may be an in vitro or in vivo method. In one embodiment, an anti-hemagglutinin antibody is used to select subjects eligible for therapy with an anti-hemagglutinin antibody, e.g., where hemagglutinin is a biomarker for selection of patients.

Exemplary disorders that may be diagnosed using an antibody of the invention include influenza A virus infection, including influenza A virus infection in children, infants, adults, and the elderly.

In certain embodiments, labeled anti-hemagglutinin antibodies are provided. Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, the radioisotopes ^{32}P , ^{14}C , ^{125}I , ^3H , and ^{131}I , fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like.

F. Pharmaceutical Formulations

Pharmaceutical formulations of an anti-hemagglutinin antibody as described herein are prepared by mixing such antibody having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (*Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium

chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Application Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.

Exemplary lyophilized antibody formulations are described in U.S. Pat. No. 6,267,958. Aqueous antibody formulations include those described in U.S. Pat. No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.

The formulation herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide a neuraminidase inhibitor, an anti-hemagglutinin antibody, an anti-M2 antibody, etc. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.

Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.

G. Therapeutic Methods and Compositions

Any of the anti-hemagglutinin antibodies provided herein may be used in therapeutic methods.

In one aspect, an anti-hemagglutinin antibody for use as a medicament is provided. In further aspects, an anti-hemagglutinin antibody for use in treating, preventing, or inhibiting influenza A virus infection is provided. In certain embodiments, an anti-hemagglutinin antibody for use in a method of treatment is provided. In certain embodiments, the invention provides an anti-hemagglutinin antibody for use in a method of treating an individual having influenza A virus infection comprising administering to the individual an effective amount of the anti-hemagglutinin antibody. In one such

embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below. In further embodiments, the invention provides an anti-hemagglutinin antibody for use in preventing, inhibiting, or reducing hemagglutinin-mediated fusion between influenza A virus viral membrane and infected cell endosomal membranes, thus preventing viral RNA entry into the infected cell cytoplasm and preventing further propagation of infection. In certain embodiments, the invention provides an anti-hemagglutinin antibody for use in a method of preventing, inhibiting, or treating influenza A virus infection in an individual comprising administering to the individual an effective amount of the anti-hemagglutinin antibody to prevent, inhibit, or treat influenza A virus infection. An "individual" according to any of the above embodiments is preferably a human.

In a further aspect, the invention provides for the use of an anti-hemagglutinin antibody in the manufacture or preparation of a medicament. In one embodiment, the medicament is for treatment of influenza A virus infection. In a further embodiment, the medicament is for use in a method of treating influenza A virus infection comprising administering to an individual having influenza A virus infection an effective amount of the medicament. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below. In a further embodiment, the medicament is for preventing, inhibiting, or reducing hemagglutinin-mediated fusion between influenza A virus viral membrane and infected cell endosomal membranes, thus preventing viral RNA entry into the infected cell cytoplasm and preventing further propagation of infection. In a further embodiment, the medicament is for use in a method of preventing, inhibiting, or treating influenza A virus infection in an individual comprising administering to the individual an amount effective of the medicament to prevent, inhibit, or reduce, influenza A virus infection. An "individual" according to any of the above embodiments may be a human.

In a further aspect, the invention provides a method for treating influenza A virus infection. In one embodiment, the method comprises administering to an individual having such influenza A virus infection an effective amount of an anti-hemagglutinin antibody. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described herein. An "individual" according to any of the above embodiments may be a human.

The present invention provides anti-hemagglutinin antibodies effective at inhibiting, preventing, or treating influenza A virus infection in an individual (e.g., a subject or a patient). In some aspects, an anti-hemagglutinin antibody of the present invention is effective at prophylactically treating an individual in order to prevent influenza A virus infection of the individual.

In some aspects, an individual suitable for treatment with an anti-hemagglutinin antibody of the present invention is an individual having or suspected having influenza A virus infection. In some embodiments, such individuals include infants, children, adults, and the elderly. In some embodiments, the individual is hospitalized with influenza A virus infection. In other embodiments, the individual having influenza A virus infection has one or more co-morbidities, such as, for example, immunodeficiency, pregnancy, lung disease, heart disease, renal disease, or co-infection (e.g., a bacterial infection or a viral infection, such as bacterial or viral pneumonia).

In some aspects, treatment of an individual with an anti-hemagglutinin antibody of the present invention reduces influenza A virus infection severity, reduces the length of influenza A virus infection, or reduces influenza A virus infectivity. In other aspects, treatment of influenza A virus infection with an anti-hemagglutinin antibody of the present invention provides additional benefit, including a reduction in the length of hospital stay, reduction or prevention of the need for intensive care unit (ICU) use, reduction or prevention of the need for assisted or mechanical ventilation, reduction or prevention of the need for supplemental oxygen use, and reduction of mortality. In some aspects, the reduction in the length of hospital stay is 1 day, 2 days, 3 days, 4 days, 5 days, or longer than 5 days. In some aspects, the reduction in the need for intensive care unit use is 1 day, 2 days, 3 days, 4 days, 5 days, or longer than 5 days. In some aspects, the reduction in need for assisted or mechanical ventilation is 1 day, 2 days, 3 days, 4 days, 5 days, or longer than 5 days. In some aspects, the reduction in the need for supplemental oxygen is 1 day, 2 days, 3 days, 4 days, 5 days, or longer than 5 days. In some aspects, treatment of an individual with an anti-hemagglutinin antibody of the present invention reduces influenza A virus infection disease symptoms, such as, for example, fever, coryza, chills, sore throat, muscle pain, body aches, headache, cough, nasal congestion, weakness or fatigue, irritated or watering eyes, and general discomfort.

In some aspects, treatment of an individual with an anti-hemagglutinin antibody of the present invention reduces the time to normalization of respiratory function, such as a reduction of time to normalization of respiratory rate, or a reduction of time to normalization of oxygen saturation. In some aspects, treatment of an individual with an anti-hemagglutinin antibody of the present invention reduces the time to return to normal oxygen saturation, e.g., to an oxygen saturation of about 92% or greater, as measured over a 24 hour period without supplemental oxygen administration. In other aspects, treatment of an individual with an anti-hemagglutinin antibody of the present invention reduces the time to normalization of vital signs, such as heart rate, blood pressure, respiratory rate, and temperature.

In some aspects, treatment of an individual with an anti-hemagglutinin antibody of the present invention improves virologic endpoints, such as, for example, influenza virus titer. Virus titer can be measured by various ways known to one of skill in the art, such as, for example, viral area under the curve (AUC), as measured by, for example, qPCR or tissue culture infective dose (TCID₅₀). In some aspects, the treatment results in greater than or equal to 50% reduction in viral AUC as measured by qPCR or TCID₅₀.

In various aspects of the present invention, an anti-hemagglutinin antibody provided herein is effective at treating influenza A virus infection when administered at about 12 hours, at about 24 hours, at about 36 hours, at about 48 hours, at about 60 hours, at about 72 hours, at about 84 hours, and at about 96 hours after onset of symptoms (e.g., onset of illness). In other aspects, an anti-hemagglutinin antibody provided herein is effective at treating influenza A virus infection when administered between about 24 hours and 48 hours after onset of symptoms (e.g., the individual has been symptomatic for between 24 and 48 hours), when administered between about 48 hours and 72 hours after onset of symptoms, or when administered between about 72 hours and 96 hours after onset of symptoms. In certain embodiments of the present invention, an anti-hemagglutinin antibody of the present invention is effective at treating or reducing influenza A virus infection and extends the treatment window of current standard of care (e.g., oseltamivir) beyond 48 hours after onset of symptoms.

In a further aspect, the invention provides pharmaceutical formulations comprising any of the anti-hemagglutinin antibodies provided herein, e.g., for use in any of the above therapeutic methods. In one embodiment, a pharmaceutical formulation comprises any of the anti-hemagglutinin antibodies provided herein and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutical formulation comprises any of the anti-hemagglutinin antibodies provided herein and at least one additional therapeutic agent, e.g., as described below.

Antibodies of the invention can be used either alone or in combination with other agents in a therapy. For instance, an antibody of the invention may be co-administered with at least one additional therapeutic agent. In certain embodiments, an additional therapeutic agent is a neuraminidase inhibitor (e.g., zanamivir, oseltamivir phosphate, amantadine, rimantadine), an anti-M2 antibody, an anti-hemagglutinin antibody, etc. In some aspects, treatment of an individual having influenza A virus infection with an anti-hemagglutinin antibody of the present invention co-administered with a neuraminidase inhibitor provides a synergistic therapeutic effect compared to treatment with either agent alone.

Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent or agents. In one embodiment, administration of the anti-hemagglutinin antibody and administration of an additional therapeutic agent occur within about one month, or within about one, two, or three weeks, within about one, two, three, four, five, or six days, or within about one, two, three, four, five, six, eight, ten, twelve, sixteen, twenty, or twenty-four hours of each other.

An antibody of the invention (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.

Antibodies of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.

For the prevention or treatment of disease, the appropriate dosage of an antibody of the invention (when used alone or in

57

combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 µg/kg to about 45 mg/kg (e.g., about 1.0 mg/kg to about 15 mg/kg) of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 µg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. Exemplary dosages of the antibody would be in the range from about 1.0 mg/kg to about 45 mg/kg, from about 1.0 mg/kg to about 30 mg/kg, from about 1.0 mg/kg to about 15 mg/kg, from about 1.0 mg/kg to about 10 mg/kg, or from about 1.0 mg/kg to about 5 mg/kg. Thus, one or more doses of about 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10 mg/kg, 15 mg/kg, 30 mg/kg, or 45 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g., every day, every two days, every three days, etc. An initial higher loading dose, followed by one or more lower doses may be administered. Dosing can also be at a fixed dose, such as, for example, 200 mg, 400 mg, 600 mg, 800 mg, 1000 mg, 1200 mg, 1400 mg, 1500 mg, 1600 mg, 1800 mg, 2000 mg, 2200 mg, 2400 mg, 2500 mg, 2600 mg, 2800 mg, 3000 mg, 3200 mg, 3400 mg, 3600 mg, etc. The progress of this therapy is easily monitored by conventional techniques and assays.

It is understood that any of the above formulations or therapeutic methods may be carried out using an immunoconjugate of the invention in place of or in addition to an anti-hemagglutinin antibody.

H. Articles of Manufacture

In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody of the invention. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-

58

acceptable buffer, such as bacteriostatic water for injection (BWI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

It is understood that any of the above articles of manufacture may include an immunoconjugate of the invention in place of or in addition to an anti-hemagglutinin antibody.

III. Examples

The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.

Example 1

Identification of Anti-Hemagglutinin Antibodies by Phage Display

Construction of Phage Libraries from Influenza Virus Vaccinated Human Donors

Antibodies directed against influenza A virus hemagglutinin were identified using a phage display library constructed from peripheral blood mononuclear cells (PBMCs) isolated from human donors vaccinated with the seasonal influenza virus vaccine as follows.

Leukopacs from normal human donors that received the seasonal influenza Fluvirin® vaccine (Novartis Lot #111796P1) 7 days prior to their blood donation were obtained from Blood Centers of the Pacific (San Francisco, Calif.). PBMCs were isolated from the leukopacs using standard methodologies. The PBMCs were sorted for CD19⁺/CD20⁻ plasmablast cells by FACS. RNA from the CD19⁺/CD20⁻ sorted plasmablasts was extracted using RNeasy purification kit (Qiagen, USA) and cDNA was generated from the isolated RNA by reverse transcription using SuperScript® III Reverse Transcriptase (Invitrogen, USA). Human variable heavy (VH), variable kappa (VK), and variable light (VL) genes were PCR amplified from the cDNA using the following back and forward DNA primer mixtures.

```
VH Back
BssHII .HuVH1 : (SEQ ID NO: 1)
ATCGTTTCATAAGCGCGCCAGGTGCAGCTGGTGAGTC

BssHII .HuVH2 : (SEQ ID NO: 2)
ATCGTTTCATAAGCGCGCCAGRTACCTTGAAGGAGTC

BssHII .HuVH3 .1 : (SEQ ID NO: 3)
ATCGTTTCATAAGCGCGCGAGGTGCAGCTGGTGAGTC

BssHII .HuVH3 .2 : (SEQ ID NO: 4)
ATCGTTTCATAAGCGCGCCAGGTGCAGCTGGTGAGTC

BssHII .HuVH3 .3 : (SEQ ID NO: 5)
ATCGTTTCATAAGCGCGCAAGTGCAGCTGGTGAGTC

BssHII .HuVH4 .1 : (SEQ ID NO: 6)
ATCGTTTCATAAGCGCGCCAGGTGCAGCTGCAGGAGTC
```

59

-continued

BssHII.HuVH4.2: (SEQ ID NO: 7)
ATCGTTTCATAAGCGCGCCAGGTGCAGCTGCAGGAGTC
5
BssHII.HuVH5: (SEQ ID NO: 8)
ATCGTTTCATAAGCGCGCARGTGCAGCTGGTGCAGTC
BssHII.HuVH6: (SEQ ID NO: 9) 10
ATCGTTTCATAAGCGCGCCAGGTACAGCTGCAGCAGTC
BssHII.HuVH7: (SEQ ID NO: 10)
ATCGTTTCATAAGCGCGCCAGGTGCAGCTGGTGCAATC
15
BssHII.HuVH1.A: (SEQ ID NO: 11)
ATCGTTTCATAAGCGCGCCAGGTCCAGCTTGTGCAGTC
BssHII.HuVH1.B: (SEQ ID NO: 12) 20
ATCGTTTCATAAGCGCGCCAGGTTCAGCTGGTGCAGTC
BssHII.HuVH1.C: (SEQ ID NO: 13)
ATCGTTTCATAAGCGCGCCAGGTCCAGCTGGTACAGTC
25
BssHII.HuVH1.D: (SEQ ID NO: 14)
ATCGTTTCATAAGCGCGCCAGATGCAGCTGGTGCAGTC
BssHII.HuVH1.E: (SEQ ID NO: 15) 30
ATCGTTTCATAAGCGCGCCAAATCCAGCTGGTGCAGTC
BssHII.HuVH1.F: (SEQ ID NO: 16)
ATCGTTTCATAAGCGCGCGAGGTCCAGCTGGTGCAGTC
35
BssHII.HuVH3.A: (SEQ ID NO: 17)
ATCGTTTCATAAGCGCGCGAGGTGCAGCTGTTGGAGTC
BssHII.HuVH3.B: (SEQ ID NO: 18) 40
ATCGTTTCATAAGCGCGCGAGGTGCAGCTGGTGGAGAC
BssHII.HuVH4.A: (SEQ ID NO: 19)
ATCGTTTCATAAGCGCGCCAGGTGCAGCTACAGCAGTG
45
VH Forward
NheI.JH 2: (SEQ ID NO: 20)
GACATTCTACGAGCTAGCTGAGGAGACAGTGACCAGGGT
NheI.JH1/4/5: (SEQ ID NO: 21)
GACATTCTACGAGCTAGCTGAGGAGACGGTGACCAGGGT
NheI.JH3: (SEQ ID NO: 22) 55
GACATTCTACGAGCTAGCTGAAGAGACGGTGACCATTGTC
NheI.JH6: (SEQ ID NO: 23)
GACATTCTACGAGCTAGCTGAGGAGACGGTGACCGTGG
VK Back
NheI.OL.HuVK1: (SEQ ID NO: 24)
TCTCCTCACTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGTG
GTGGCAGCGACATCCAGWTGACCCAGTC

60

-continued

NheI.OL.HuVK2: (SEQ ID NO: 25)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
5
GGTGGCAGCGATGTTGTGATGACTCAGTC
NheI.OL.HuVK3: (SEQ ID NO: 26)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
10
GGTGGCAGCGAAATTGTGWTGACRCAGTC
NheI.OL.HuVK4: (SEQ ID NO: 27)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
15
GGTGGCAGCGATATTGTGATGACCCACAC
NheI.OL.HuVK5: (SEQ ID NO: 28)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
20
GGTGGCAGCGAAACGACACTCAGCAGTC
NheI.OL.HuVK6: (SEQ ID NO: 29)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
25
GGTGGCAGCGAAATTGTGCTGACTCAGTC
VK Forward
NcoI.JK1-: (SEQ ID NO: 30)
AGTTCATGCCATGGTTTTGATTTCCACCTTGGTCCCTT
30
NcoI.JK2-: (SEQ ID NO: 31)
AGTTCATGCCATGGTTTTGATCTCCACCTTGGTCCC
35
NcoI.JK3-: (SEQ ID NO: 32)
AGTTCATGCCATGGTTTTGATATCCACTTTGGTCCCAG
NcoI.JK4-: (SEQ ID NO: 33)
AGTTCATGCCATGGTTTTGATCTCCAGCTTGGTCCCT
40
NcoI.JK5-: (SEQ ID NO: 34)
AGTTCATGCCATGGTTTTAATCTCCAGTCGTGTCCCTT
45
VL Back
NheI.OL.HuVL1.1: (SEQ ID NO: 35)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
50
GGTGGCAGCCAGTCTGTG CTGACTCAGCC
NheI.OL.HuVL1.2: (SEQ ID NO: 36)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
55
GGTGGCAGCCAGTCTGTG YTGACGCAGCC
NheI.OL.HuVL1.3: (SEQ ID NO: 37)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
60
GGTGGCAGCCAGTCTGTG GTGACGCAGCC
NheI.OL.HuVL2: (SEQ ID NO: 38)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
65
GGTGGCAGCCARTCTGCC CTGACTCAGCC

61

-continued

NheI .OL .HuVL3 .1 :
(SEQ ID NO: 39)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
GGTGGCAGCTCCTATGWG CTGACTCAGCC

NheI .OL .HuVL3 .2 :
(SEQ ID NO: 40)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
GGTGGCAGCTCTTCTGAG CTGACTCAGGA

NheI .OL .HuVL4 :
(SEQ ID NO: 41)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
GGTGGCAGCCACGTTATA CTGACTCAACC

NheI .OL .HuVL5 :
(SEQ ID NO: 42)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
GGTGGCAGCCAGGCTGTG CTGACTCAGCC

NheI .OL .HuVL6 :
(SEQ ID NO: 43)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
GGTGGCAGCAATTTTATG CTGACTCAGCC

NheI .OL .HuVL7/8 :
(SEQ ID NO: 44)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
GGTGGCAGCCAGRCTGTG GTGACYCAGGA

NheI .OL .HuVL9 :
(SEQ ID NO: 45)
TCTCCTCAGCTAGCGGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGT
GGTGGCAGCCWGCCTGTG CTGACTCAGCC

VL Forward
NcoI .JL1- :
(SEQ ID NO: 46)
AGTTCATGCCATGGTTAGGACGGTGACCTTGGTCC

NcoI .JL2/3- :
(SEQ ID NO: 47)
AGTTCATGCCATGGTTAGGACGGTCAGCTTGGTCC

NcoI .JL7- :
(SEQ ID NO: 48)
AGTTCATGCCATGGTGAGGACGGTCAGCTGGGTG

(SEQ ID NO: 49)
BssHII .VH .OL+ : ATCGTTTCATAAGCGCGCSA

(SEQ ID NO: 50)
NotI .JK .OL- : AGTTCATGCCATGGTTTGGAT

(SEQ ID NO: 51)
NotI .JL .OL- : AGTTCATGCCATGGTKAGGAC

The resulting amplified cDNA products were assembled to scFv using overlap PCR with the following overlap primers.

Purified scFv cDNA fragments (1 µg) and phagemid vector p2056BNN (2 µg) were digested with BssHII and NcoI restriction endonuclease (New England Biolabs, USA). Phagemid vector p2056BNN is a modified version of pS2025e (Sidhu et al., (2004) J Mol Biol 338:299-310), engineered to contain BssHII, NheI, and NcoI restriction sites. The scFv cDNA fragments were then ligated into the p2056BNN vector (6:1 M ratio) using T4 DNA ligase enzyme (New England Biolabs). The resulting cDNA/phage ligation products were purified using a PCR purification kit (Qiagen,

62

USA) and transformed into electro-competent SS320 *E. coli* cells. The size of the phage library was estimated by plating 10 µl of 1:10 diluted library culture onto LB/Carbenicillin plates. The library culture was then further amplified and propagated in a total volume of 60 ml 2YT medium, and phage-scFv expression was induced by co-infection with M13KO7 helper phage. Kanamycin was later added to the library culture, and incubated with shaking for 30 hours at 30° C. The library culture was then centrifuged to pellet the cells. The phage-scFv-containing supernatant was precipitated with 5xPEG/2.5 M NaCl and resuspended in PBS. Phage Library Sorting and Screening to Identify Anti-Hemagglutinin Antibodies

Influenza A virus hemagglutinin H1 and H3 proteins (produced as described below in Example 2) were used as antigens for phage library sorting. Hemagglutinin H1 and H3 antigens were coated onto a high-binding 96-well maxisorp plate. The plates and phage libraries were pre-blocked with phage blocking buffer (phosphate-buffered saline (PBS), 1% (w/v) bovine serum albumin (BSA), and 0.05% (v/v) tween-20 (PBS-T)) and incubated for 2 hours at room temperature. The blocked phage library (100 µl) was added to the hemagglutinin-coated wells and incubated for 3 hours. The unbound phage were washed off the plates using 0.05% PBS-Tween, and bound phage were eluted with 100 µl 50 mM HCl and 500 mM NaCl for 30 minutes followed by neutralization with 100 µl of 1 M Tris base (pH 7.5). Recovered phage were amplified in *E. coli* XL-1 Blue cells. The resulting phage were precipitated and subjected another round of panning/selection against the hemagglutinin proteins. During subsequent panning/selection rounds, antibody phages were incubated with same or different hemagglutinin antigens. The stringency of plate washing was gradually increased from washing 15x to washing 40x.

After 2-3 rounds of panning and selection, significant enrichment of hemagglutinin-specific phage was observed. 96 phage clones were picked from the library sorting to determine whether they specifically bound to hemagglutinin H1 and/or H3. The variable regions of the phage clones displaying specific binding to the hemagglutinin proteins were sequenced to identify phage clones containing unique immunoglobulin nucleic acid sequences. Unique phage antibodies that bound hemagglutinin H1 and/or H3 with at least 5x above background were further characterized. Phage-derived clones of interest were reformatted into IgGs by cloning V_L and V_H regions of individual clones into the LPG3 and LPG4 expression vectors, respectively, transiently expressed in mammalian 293 cells, and purified using a protein A column. Two antibodies (mAb9 and mAb23) were identified for further analysis. (See Example 5 below.)

Example 2

Plasmablast Enrichment and Expansion

To discover and identify rare antibodies against influenza A virus hemagglutinin, the following plasmablast enrichment and expansion technique was developed. (See co-pending patent application U.S. patent application Ser. No. 61/725,764, which is incorporated by reference herein in its entirety.)

Leukopacs from normal human donors that received the seasonal influenza Fluvirin® vaccine (Novartis Lot #111796P1) 7 days prior to their blood donation were obtained from Blood Centers of the Pacific (San Francisco, Calif.). Peripheral blood mononuclear cells (PBMCs) were isolated from the leukopacs using standard methodologies. Six- to eight-week old female SCID/beige mice were pur-

chased from Charles River Laboratories (Hollister, Calif.) and housed and maintained at Genentech in accordance with American Association of Laboratory Animal Care guidelines. All experimental studies were conducted under the approval of the Institutional Animal Care and Use Committees of Genentech Lab Animal Research in an AAALACi-accredited facility in accordance with the Guide for the Care and Use of Laboratory Animals and applicable laws and regulations. Leukopak or blood from healthy human donors was obtained after written informed consent was provided and ethical approval granted from the Western Institutional Review Board.

In vivo antigen-driven plasmablast enrichment and expansion was performed using intrasplenic transplantation of PBMCs as follows. Isolated PBMCs were resuspended with hemagglutinin antigens (0.1-2 μ g for each one million B cells) and incubated for 30 minutes at 37° C. (PBMC/antigen pre-mix). Following this incubation, the PBMCs were washed to remove unbound antigens. To enrich for plasmablasts that produced cross-reactive hemagglutinin antibodies, the hemagglutinin antigen variants used for PBMC/antigen pre-mix and single cell sorting were specifically chosen to differ from the hemagglutinin antigen variants contained within the influenza Fluvirin® vaccine. Hemagglutinin antigens used in this study, therefore, included H1 hemagglutinin from influenza A virus isolate A/NWS/1933 (a Group1 influenza A virus hemagglutinin), H3 hemagglutinin from influenza A virus isolate A/Hong Kong/8/1968 (a Group2 influenza A virus hemagglutinin), and H7 hemagglutinin from influenza A virus isolate A/Netherlands/219/2003 (a Group2 influenza A virus hemagglutinin). The hemagglutinin antigens were produced at Genentech using standard molecular biology techniques.

6-8 week old female SCID/beige mice (Charles River Laboratories, Hollister, Calif.) were sub-lethally irradiated with 350 rads using a Cesium-137 source. Polymyxin B (110 mg/L) and neomycin (1.1 g/L) were added to the drinking water for 7 days following irradiation. Four hours after irradiation, the left flank of each mouse was shaved and prepped with Betadine® (Purdue Pharma, Stamford, Conn.) and 70% alcohol. Surgical procedures were performed under anesthesia using aseptic surgical procedures. A 1-cm skin incision was made just below the costal border of each mouse, followed by an incision of the abdominal wall and the peritoneum. The spleen of each mouse was carefully exposed and injected with 50×10^6 human PBMCs resuspended in 30 μ L PBS. The incisions were closed in the muscular layer and in the skin using 5-0 Vicryl® sutures (Ethicon, Somerville, N.J.) and surgical staples, respectively. For antigen-specific cell sorting experiments, mice were sacrificed at 8 days post-transplantation, and their spleens harvested. Single cell suspensions of spleen cells obtained from the mice were stained with a cocktail of anti-human monoclonal antibodies CD38 PEcy7 (BD Biosciences, San Jose, Calif.) and IgG Dylight (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.) which define human IgG+ plasmablasts as CD38^{high}/IgG+ expression. To identify hemagglutinin cross-reactive plasmablasts within the suspension of isolated spleen cells, the cells were stained with hemagglutinin H1 from influenza virus A isolate A/NWS/1933 and hemagglutinin H3 from influenza virus A isolate A/Hong Kong/8/1968, which were previously conjugated with FITC or PE, respectively, using Lightning-Link® labeling kits (Innova Biosciences, Cambridge, UK).

FIG. 1A shows representative FACS data analysis of anti-hemagglutinin-positive plasmablasts from day 7 post-vaccinated PBMCs prior to SCID/beige mice enrichment (i.e.,

prior to PBMC/antigen pre-mix). FIG. 1B shows representative FACS data analysis of hemagglutinin-positive plasmablasts from day 8 post-transplant after SCID/beige mice enrichment, comparing no pre-mix and antigen pre-mix in the upper and lower panels, respectively. As shown in FIGS. 1A and 1B, PBMC/antigen pre-mix prior to intrasplenic injection resulted in higher frequency of H3⁺/H1⁺ anti-hemagglutinin plasmablasts.

Table 2 below shows a comparison of anti-H1⁺/anti-H3⁺ plasmablast frequencies before and after SCID enrichment as described herein. As shown in Table 2, the frequency of anti-H1⁺/anti-H3⁺ plasmablasts was greatly increased using the SCID/beige mouse enrichment methods of the present invention compared to that observed without SCID/beige mouse enrichment.

TABLE 2

Condition	Anti-H1 ⁺ /Anti-H3 ⁺ Plasmablast Frequency (%)
Vaccinated PBMC	0.00028 \pm 0.00008
SCID + Antigen Premix	0.011 \pm 0.007

Samples were then analyzed in the presence of propidium iodide dead cell exclusion on Aria high-speed cell sorter (BD Biosciences, San Jose, Calif.) and anti-hemagglutinin-specific plasmablasts were sorted in a single cell manner into 96-well tissue culture plates containing 50 μ L RPMI cell culture media supplemented with 5% Low IgG fetal bovine serum. (Gibco, Grand Island, N.Y.). Five million live cells were recorded for all analysis profiles. Profiles were analyzed by Flowjo version 9.4.11 software.

FIG. 2 shows analysis of splenocytes obtained from day-8 post-transplant from individual SCID/beige mice showing stochastic response, comparing no pre-mix (circles) and antigen-pre-mix (squares). Data is presented as percent anti-H1⁺/CD38^{high} plasmablasts. The rectangle indicates mice that presented anti-H1⁺ plasmablasts.

These results showed that broad hemagglutinin cross-reactive plasmablasts were detected if influenza virus A Group1 (e.g., hemagglutinin H1) and Group2 (e.g., hemagglutinin H3, hemagglutinin H7) hemagglutinin antigens were incubated with PBMCs prior to intrasplenic transplant. These results further indicated that in vitro stimulation of hemagglutinin antigen-primed PBMCs from influenza-vaccinated donors promoted hemagglutinin antigen-specific enrichment of plasmablasts within the SCID/beige mouse recipients.

Example 3

IgG Cloning from Single Plasmablasts

Hemagglutinin H1 and H3 cross-reactive human plasmablasts (described above) were single-cell sorted, resulting in approximately 950 plasmablasts. Single plasmablasts were sorted directly into U-bottom 96-well micro-well plates containing 50 μ L RPMI containing 5% Low IgG fetal bovine serum. The plates were centrifuged for 5 minutes at 600 \times g (Beckman Coulter, Brea, Calif.) and the media was carefully removed by aspiration. The cells were re-suspended and washed twice in 90 μ L of PBS following the same procedure.

To generate cDNA encoding the variable heavy chains and light chains, each cell was re-suspended in 6 μ L of Reverse Transcriptase (RT) reaction mixture containing 2 units RNaseout (Invitrogen, Grand Island, N.Y.), 0.5 mM 4dNTP (Perkin Elmer, Waltham, Mass.), 1.5 mM MgCl₂, 37.5 mM

65

KCl, 10 mM DTT (dithiothreitol), 0.25% Nonidet P40 (US Biological, Marblehead, Mass.), 0.1 mg/ml bovine serum albumin (Sigma-Aldrich), 25 mM Tris pH 8.3, 0.25 pmol of IgG₁₋₄ constant, kappa chain constant, and lambda chain constant region specific oligonucleotides (shown below) and 40 U Superscript III (Invitrogen, Grand Island, N.Y.).

(SEQ ID NO: 52)
IgG₁₋₄ constant: GAAGTAGTCCTTGACCAGGCAG

(SEQ ID NO: 53)
Kappa constant: CTCAGCGTCAGGCTGCTGCTGAG

(SEQ ID NO: 54)
Lambda constant: GGGTKTGGTSGTCTCCAC

The reaction was incubated for 3×30-minute intervals at 45° C., 50° C., and 55° C. each. Following the incubation, the reaction mixture was diluted to 15 µl with TE buffer (10 mM Tris HCl, 1 mM EDTA). Initial polymerase chain reactions (PCR) were performed to amplify IgG heavy chains, kappa chains, and lambda chains using 2 µl of the diluted RT cocktail from above and Advantage-GC 2 Polymerase Mix (Clontech, Mountain View, Calif.), following protocols provided by the manufacturers. The PCR amplifications were performed using degenerate oligonucleotides based on variable heavy chain and light chain germline and constant region sequences shown below.

(SEQ ID NO: 55)
IGVH1a CAGGTGCAGCTGGTGCAGTCTGGGGC

(SEQ ID NO: 56)
IGVH1b CAGGTCCAGCTGGTGCAGTCTGGGGC

(SEQ ID NO: 57)
IGVH2 CAGGTCACCTTGAAGGAGTCTGGTCC

(SEQ ID NO: 58)
IGVH3 GAGGTGCAGCTGGTGGAGTCTGGGGG

(SEQ ID NO: 59)
IGVH4 CAGGTGCAGCTGCAGGAGTCGGGCCC

(SEQ ID NO: 60)
IGVH5 GAGGTGCAGCTGGTGCAGTCTGG

(SEQ ID NO: 61)
IGVH6 CAGGTACAGCTGCAGCAGTCAGGTCC

(SEQ ID NO: 62)
IGVH7 CAGGTGCAGCTGGTGCAATCTGG

(SEQ ID NO: 63)
IGKV1 GHCATCCRGWTGACCCAGTCTC

(SEQ ID NO: 64)
IGKV2 GATRTTGTGATGACYCAGWCTC

(SEQ ID NO: 65)
IGKV3 GAAATWGTWGTGACRCAGTCTC

(SEQ ID NO: 66)
IGKV4 GACATCGTGATGACCCAGTCTCC

(SEQ ID NO: 67)
IGKV5 GAAACGACACTCACGCAGTCTC

(SEQ ID NO: 68)
IGKV6 GAWRTTGTGMTGACWCAGTCTC

(SEQ ID NO: 69)
IGLV1 CAGTCTGTGTYGACKCAGCCRCCTC

66

-continued

(SEQ ID NO: 70)
CAGTCTGCCCTGACTCAGCCT

(SEQ ID NO: 71)
TCCTATGAGCTGACWCAGSHVCCCKC

(SEQ ID NO: 72)
CAGCCTGTGCTGACTCARTCVCCCTC

(SEQ ID NO: 73)
CAGCCTGTGCTGACTCAGCCAACTTC

(SEQ ID NO: 74)
AATTTTATGCTGACTCAGCCCCAC

(SEQ ID NO: 75)
CAGGCTGTGGTGAATCAGGAGCCC

(SEQ ID NO: 76)
CAGACTGTGGTGAATCAGGAGCC

(SEQ ID NO: 77)
CAGCCTGTGCTGACTCAGCCACC

(SEQ ID NO: 78)
GCAGCCCAGGGCAGTGTGC

(SEQ ID NO: 79)
GCACACAACAGAGGAGTTCAG

(SEQ ID NO: 80)
CTTGRAGCTCCTCAGAGGAG

Heavy chain and light chain PCR amplification reactions were each divided into two reactions as follows: heavy chain families VH.1,2,3 (primers IGVH1a, IGVH1b, IGVH2, IGVH3) and VH.4,5,6,7 (primers IGVH4, IGVH5, IGVH6, and IGVH7); kappa chain families VK.1,2,3 (primers IGKV1, IGKV2, and IGKV3) and VK.4,5,6 (primers IGKV4, IGKV5, and IGKV6); and lambda chain families VL.1,2,3,4,5 (IGLV1, IGLV2, IGLV3, IGLV4, and IGLV5) and VL.6,7,8,9 (primers IGLV6, IGLV7, IGLV8, and IGLV9). A touchdown PCR amplification protocol was used for temperature cycling.

Following the reaction, PCR amplification products were treated with Exonuclease1 (Exo) and Shrimp Alkaline Phosphatase (SAP) to remove excess nucleotides and primers from each of the PCR amplification reactions (U.S. Biologicals, Marblehead, Mass.). Initial PCR amplification products were directly sequenced to determine the variable sequences of both the heavy chains and light chains using Sanger sequencing. Second nested PCR amplifications were performed using germline-matched heavy chain and light chain variable oligonucleotides in order to insert a mammalian signal and constant region cloning sequences using the following oligonucleotide primers.

sVH1a: (SEQ ID NO: 81)
CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT

GGAGTACATTACAGG

sVH2: (SEQ ID NO: 82)
CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT

GGAGTACATTACAGATCACCT

67

-continued

sVH3vv: (SEQ ID NO: 83)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAG

sVH3g1: (SEQ ID NO: 84)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCAGAGG

sVH4: (SEQ ID NO: 85)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGGTGCAGCTGCAGG

sVH5: (SEQ ID NO: 86)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCAGAGGTGCA

sVH6: (SEQ ID NO: 87)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGGTACAGC

sVH7: (SEQ ID NO: 88)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGGTGCA

sVK1: (SEQ ID NO: 89)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCAGACATCCAGATGACCCAGTCTCCATCCTCCCTG

sVK2: (SEQ ID NO: 90)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCAGATATTGTGATGACTCAGTCTCACTCTCCCTGC

sVK3: (SEQ ID NO: 91)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCAGAAATTGTGTTGACACAGTCTCCAGCCACCTGTCTTT
 G

sVK4: (SEQ ID NO: 92)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCAGACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGT
 G

sVK5: (SEQ ID NO: 93)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCAGAAACGACACTCACGCGAGTCTCCAGC

sVK6: (SEQ ID NO: 94)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCAGAAATTGTGCTGACTCAGTCTCCAGACTTTTCG

68

-continued

sVL1: (SEQ ID NO: 95)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGTCTGTGYTGACKCAGCCRCCTC

sVL2: (SEQ ID NO: 96)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGTCTGCCCTGACTCAGCCT

sVL3: (SEQ ID NO: 97)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCATCCTATGAGCTGACWCAGSHVCCCKC

sVL4: (SEQ ID NO: 98)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGCCTGTGCTGACTCARTCVCCCTC

sVL5: (SEQ ID NO: 99)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGCCTGTGCTGACTCAGCCAACTTC

sVL6: (SEQ ID NO: 100)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCAAATTTTATGCTGACTCAGCCCCAC

sVL7: (SEQ ID NO: 101)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGGCTGTGGTGACTCAGGAGCCC

sVL8: (SEQ ID NO: 102)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGACTGTGGTGACCCAGGAGCC

wVL9: (SEQ ID NO: 103)
 CCACCATGGGATGGTCATGTATCATCCTTTTCTAGTAGCAACTGCAACT
 GGAGTACATTCACAGCCTGTGCTGACTCAGCCACC

Heavy constant: (SEQ ID NO: 104)
 GCCAGGGGGAAGACCGATG

Kappa constant: (SEQ ID NO: 105)
 CTGGGATAGAAGTTATTTCAGCAGGCACACAACAGAAGCAGTTCCAGATT
 CAACTGCTC

Lambda constant: (SEQ ID NO: 80)
 CTTGRAGCTCCTCAGAGGAG

PCR amplification reactions were set up using PrimeStar HS DNA Polymerase with GC (Takara Bio, Shiga, Japan) according to the manufacturer's recommendation. Following the PCR amplification reactions, the amplification products were treated with Exo/SAP as described above. Heavy variable chain and light variable chain encoding PCR amplification products were inserted into a mammalian expression vector using restriction endonuclease free procedures. 20 μ l of the PCR amplification products were annealed onto single stranded DNA human templates for IgG₁, kappa, and lambda chain using the Kunkel mutagenesis protocol. (See Kunkel

(1985) PNAS 82:488-492.) Correctly inserted constructs were confirmed by DNA sequencing. Plasmids containing nucleic acids encoding heavy chains and light chains were co-transfected into 293T human embryonic kidney cells using Eugene transfection reagent (Roche Diagnostic, Indianapolis, Ind.) for transient expression, and analyzed for expression and binding as described below in Example 4.

Example 4

Hemagglutinin ELISA Screening Assay

The ability of each monoclonal anti-hemagglutinin antibody obtained as described above to bind various hemagglutinin subtypes was examined by ELISA as follows. Various hemagglutinin-expressing plasmids were transfected into 293T cells as described above. These included hemagglutinin H1 from H1N1/South Carolina/1918, hemagglutinin H3 from H3N2/Perth/2009, hemagglutinin H5 from H5N1/Viet/2004, and hemagglutinin H7 from H7N7/Netherlands/2003 influenza A viruses. After two days, cells were lysed in 50 mM Tris, pH 8, 5 mM EDTA, 150 mM NaCl, 1% Triton X-100 plus protease inhibitor cocktail (Roche). Nuclei were cleared by centrifugation and the resulting lysates were stored at -80° C.

For ELISA screening, 384-well plates (Nunc MaxiSorp) were coated with 5 µg/ml Galanthus nivalis lectin (Sigma) in PBS. The plates were washed and then coated with dilutions of the cell lysates containing various expressed hemagglutinins. The plates were washed and incubated with various dilutions of the anti-hemagglutinin antibodies and subsequently with a goat-anti-human-HRP secondary antibody (Jackson). Plates were washed and processed for TMB (3,3', 5,5'-tetramethylbenzidine) substrate detection.

Approximately 950 plasmablasts were obtained from single-cell sorting described above in Example 2. Of this, 840 monoclonal antibodies were transiently expressed in 293T cells and screened by ELISA for binding to hemagglutinin subtypes H1, H3, H5, and H7, resulting in 82 monoclonal antibodies that bound influenza A virus Group1 or Group2 hemagglutinin, and 20 monoclonal antibodies that bound both influenza A virus Group1 and Group2 hemagglutinins

Example 5

In Vitro Influenza A Virus Neutralization

The ability of the anti-hemagglutinin antibodies of the present invention to elicit broad hemagglutinin subtype binding and neutralization of a panel of influenza A Group1 and Group2 virus isolates in vitro was examined as follows.

MDCK cells were grown in DMEM media supplemented with 10% FBS as a single 25% confluent monolayer in 96-well black with clear bottom imaging plates (Costar 3904). Each influenza A virus subtype/strain was diluted in influenza media (DMEM+0.2% BSA, 2 µg/ml TPCK treated Trypsin) to an MOI of 1 and incubated for 1 hour at 37° C. with varying concentrations (ranging from 0.02 nM to 1,600 nM) of each antibody. Each antibody/influenza virus mixture was allowed to infect MDCK cells for 16 hours at 37° C. in a 5% CO₂ incubator prior to fixation of the cells with cold 100% ethanol. The fixed cells were then stained with Hoechst 33342 (Invitrogen, Cat#H3570) to visualize cell nuclei and determine total cell number. The cells were also stained with a broadly reactive monoclonal antibody (Millipore Cat# MAB8258) specific for influenza A virus nucleoprotein in order to determine the number of infected cells.

Cells were imaged using the Image Express Micro (Molecular Devices) and data images were analyzed using MetaXpress 3.1 software. The percentage of infected cells was determined and plotted on the Y-axis versus the Log 10 antibody concentration on the X-axis. All neutralization assays were completed in triplicate. Data were fit using a nonlinear regression dose-response curve and are presented in FIG. 3 as IC₅₀ values in nM with 95% confidence intervals (95% CI). The hemagglutinin (HA) subtype of each influenza A virus strain is provided in the table shown in FIG. 3.

In vitro neutralization dose-response curves were generated using various concentrations of the monoclonal antibodies described herein against a broad panel of influenza A Group1 and Group2 virus strains. FIGS. 4A and 4B show neutralization curves of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) against a panel of influenza A Group1 and Group2 virus strains, respectively. As shown in FIGS. 4A and 4B, mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) was effective at in vitro neutralization of all influenza A virus strains tested. (See also FIG. 3.) Additionally, FIGS. 5A and 5B show neutralization curves of mAb 81.39 SVSH-NYP ("SVSH" disclosed as SEQ ID NO: 171) against a panel of influenza A Group1 and Group2 virus strains, respectively. As shown in FIGS. 5A and 5B, mAb 81.39 SVSH-NYP ("SVSH" disclosed as SEQ ID NO: 171) was effective at the in vitro neutralization of all influenza A virus strains tested. (See also FIG. 3.)

Four anti-hemagglutinin antibodies of the present invention (specifically mAb 39.18 B11, mAb 36.89, mAb9.01F3, and mAb23.06C2) were effective in vitro at neutralization of either Group1 or Group2 influenza A virus strains, but not both. Specifically, mAb 39.18 B11 was effective at in vitro neutralization of the entire Group1 influenza A virus panel examined, but was not able to neutralize Group2 influenza A virus strains. (See FIG. 6 and FIG. 3.) Conversely, mAb 36.89, mAb9.01F3, and mAb23.06C2 were able to neutralize the entire Group2 influenza A virus panel examined, but were not able to neutralize any Group1 influenza A virus isolate tested. (See FIGS. 7, 8, and 9, showing in vitro neutralization curves for mAb 36.89, mAb9.01F3, and mAb23.06C2, respectively; also see FIG. 3.)

Taken together, these results showed that monoclonal antibodies of the present invention were able to neutralize in a dose-dependent manner various influenza A virus isolates/strains in vitro. Additionally, these results showed that the plasmablast enrichment methodology described herein resulted in the identification of monoclonal antibodies capable of neutralizing both Group1 and Group2 influenza A virus strains from only 950 isolated plasmablasts.

In vitro neutralization studies were also performed using a pseudotype virus engineered to express hemagglutinin H5 to test the efficacy of an antibody of the present invention at neutralizing H5N1 influenza A virus. In particular, an HIV pseudotype virus bearing the H5 hemagglutinin surface protein was tested for neutralization with mAb 39.29 NCv1 on 293T cells as follows. The H5 pseudotype virus was produced by co-transfection of 293T cells with three plasmids: Δ8.9, FCMV-GFP, and a plasmid expressing hemagglutinin H5 from influenza A virus isolate H5N1/Vietnam/1203/2004. Virus was purified by ultra-centrifugation through 20% sucrose.

For infection, pseudotype virus was incubated with various amounts of mAb 39.29 NCv1 before adding to target 293T cells cultured in 96-well plates. After two days, the number of infected cells was determined by counting GFP positive cells. Infection was normalized to the number of infected cells at the lowest antibody concentration used. The results are pre-

71

sented in FIG. 10. As shown in FIG. 10, mAb 39.29 NCv1 displayed a dose-dependent in vitro neutralization against the pseudotype virus expressing hemagglutinin H5 surface protein. These data suggested that antibodies of the present invention would be effective at treatment and prevention of H5N1 influenza A virus strains.

An equine influenza virus was also tested for the ability of antibodies of the present invention to exhibit in vitro neutralization activity as follows. H7N7 A/Equine/1/Prague/56 influenza A virus was passed on MDCK cells until it achieved a high degree of infectivity. The resulting H7N7 A/Equine/1/Prague/56 influenza A virus was used in neutralization assays (using methods as described above for mAb 39.29 NCv1) on MDCK cells. The results of these experiments are presented in FIG. 11. As shown in FIG. 11, mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) displayed a dose-dependent in vitro neutralization against the H7N7 A/Equine/1/Prague/56 influenza virus expressing hemagglutinin H7 surface protein.

Taken together, these results showed that anti-hemagglutinin antibodies of the present invention exhibited dose-dependent neutralization activity against a variety of influenza A virus strains. Specifically, two anti-hemagglutinin antibodies (mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) and mAb 81.39 SVSH-NYP ("SVSH" disclosed as SEQ ID NO: 171)) were effective at neutralizing all influenza A virus strains examined, including neutralization of both Group1 influenza A virus strains (A/CA/7/2009, A/Brisbane/59/2007, A/Solomon/3/2006, A/New Caledonia/20/1999, A/PR/8/1934, and A/Japan/305/1957) and Group2 influenza A virus strains (A/Victoria/361/2011, A/Perth/16/2009, A/Brisbane/10/2007, A/Wisconsin/67/2005, A/Victoria/3/1975, A/Port Chalmers/1/1973, A/HK/8/1968, and A/Aichi/2/1968).

Additionally, these results showed that anti-hemagglutinin antibodies of the present invention (e.g., mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) (FIGS. 4A and 4B) and mAb 81.39 SVSH-NYP ("SVSH" disclosed as SEQ ID NO: 171) (FIGS. 5A and 5B)) were effective at neutralization of a variety of different seasonal H1N1 influenza A virus strains, H3N2 influenza A virus strains, a H2N2 influenza A virus strain, and the influenza A virus strain associated with the 1957 Japan pandemic (A/Japan/305/1957). These results indicated that antibodies of the present invention are effective in the treatment and prevention of seasonal influenza A virus infection and influenza A virus strains associated with influenza pandemics.

Example 6

In Vivo Efficacy of mAb 39.29 NWPP ("NWPP" Disclosed as SEQ ID NO: 177) in Mice

The in vivo efficacy of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) to influenza A virus infection in mice was performed as follows. DBA/2J mice (Jackson Lab, Bar Harbor, Me.) were infected intranasally with 50 μ l of various influenza A virus strains diluted in influenza media (DMEM, 0.2% BSA, 2 μ g/mL TPCK-treated trypsin) at the minimum LD₁₀₀ dose. Four different influenza A virus strains exhibiting a range of in vitro IC₅₀ values were used in this series of experiments, including: H1N1 A/PR/8/1934 (Genentech; IC₅₀ 2.0 nM), used at 40 PFU per mouse; H3N2 A/Hong Kong/1/1968 (ViraPur, San Diego, Calif.; IC₅₀ 45.1 nM), used at 3 PFU per mouse; H3N2 A/Port Chalmers/1/1973 (ViraPur, San Diego, Calif.; IC₅₀ 2.2 nM), used at 1.5 \times 10⁴ PFU per mouse; and H3N2 A/Aichi/2/1968 (ViraPur, San Diego, Calif.; IC₅₀ 35 nM), used at 2 \times 10² PFU per mouse.

72

Influenza virus infection was allowed to progress for 72 hours prior to the intravenous administration of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177).

After 72 hours post influenza virus A infection, various amounts of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) were administered intravenously to the mice at a dose of 900 μ g/mouse (approximately 45 mg/kg), 300 μ g/mouse (approximately 15 mg/kg), and 100 μ g/mouse (approximately 5 mg/kg) in 200 μ l PBS. Control treated animals were administered mAb gD5237 (a monoclonal antibody specific for glycoprotein D of herpes simplex virus (HSV)) at the highest tested equivalent dose of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) (i.e., approximately 45 mg/kg). Mice were monitored daily for body conditioning and survival, and also weighed daily, until 21 days after infection. All mAb39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) doses vs. control in all four influenza A virus strain infections gave a Log-rank test of P<0.01.

FIGS. 12A, 12B, 12C, and 12D show percent survival (over time, in days) of mice administered various amounts of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) 72 hours after infection with influenza A virus A/PR/8/1934, A/Port Chalmers/1/1973, A/Hong Kong/1/1968, and A/Aichi/2/1968, respectively. As shown in FIGS. 12A, 12B, 12C, and 12D, 100% mortality was observed by day 14 in infected mice administered control antibody. However, infected mice administered monoclonal antibody of the present invention showed increased survival. In particular, 100% survival was observed in mice infected with influenza virus A/Port Chalmers/1/1973 or influenza virus A/Aichi/2/1968 at all doses of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) tested. (See FIGS. 12B and 12D.)

These results showed that monoclonal antibodies of the present invention are effective at treating various influenza A virus infections. Additionally, these data showed that monoclonal antibodies of the present invention were effective at treating influenza A virus infection when administered up to at least 72 hours post influenza A virus infection.

Example 7

In Vivo Efficacy of mAb 39.29 NCv1 in Mice

To test the in vivo efficacy of mAb 39.29 NCv1 in mice, the antibody was administered i.v. to mice infected with four different influenza A virus isolates that exhibited a range of in vitro IC₅₀ values. DBA/2J mice (Jackson Lab, Bar Harbor, Me.) were infected intranasally with 50 μ l of different influenza A virus strains diluted into influenza media (DMEM, 0.2% BSA, 2 μ g/mL TPCK treated trypsin) at the minimum LD₁₀₀ dose.

In one set of experiments, influenza A virus isolate H1N1 A/PR/8/1934 was used at 40 PFU per mouse. At 72 hours post infection, anti-hemagglutinin mAb 39.29 NCv1 was administered intravenously at approximately 15 mg/kg, approximately 5 mg/kg, approximately 1.7 mg/kg, or approximately 0.56 mg/kg in 200 μ l PBS intravenously. Control treated animals were given mAb gD5237, which is specific for glycoprotein D of HSV at the highest tested equivalent dose of mAb 39.29 NCv1. Mice were monitored for body conditioning and survival, and weighed until 21 days after infection.

For the H1N1 A/PR/8/1934 infected mice, a single i.v. dose of mAb 39.29 NCv1 at 15 mg/kg per mouse was efficacious compared to that observed with control IgG antibody. (See FIG. 13.) Specifically, 100% mortality was observed in the control treatment group by day 12, while a single dose of 15 mg/kg of mAb 39.29 NCv1 saved 87.5% of the infected mice.

73

A threefold lower dose of 100 µg per mouse (approximately 5 mg/kg) of mAb 39.29 NCv1 exhibited some efficacy, being able to protect 25% of animals from the lethal challenge, while doses of approximately 1.7 mg/kg or approximately 0.56 mg/kg showed minimal efficacy beyond that observed in the control treatment group. (See FIG. 13.)

In another set of experiments, *in vivo* efficacy of mAb 39.29 NCv1 was further examined against mouse-adapted H3N2 Hong Kong influenza A virus strain (H3N2 A/Hong Kong/1/1968), which has a tenfold higher *in vitro* IC₅₀ than A/PR8/1934. As observed in previous experiments described above, mice treated with control antibody following influenza A virus infection showed 100% mortality by day 12. (See FIG. 14.) However, a single dose of mAb 39.29 NCv1 at approximately 45 mg/kg or approximately 15 mg/kg was able to protect 87.5% and 75% of the mice, respectively. The minimum efficacious dose of 15 mg/kg *in vivo* of mAb 39.29 NCv1 in both the A/PR8/1934 and the A/Hong Kong/1/1968 influenza A virus infection models is very similar despite the observed contrast in mAb 39.29 NCv1 *in vitro* IC₅₀ values between these two strains. (See FIGS. 3 and 14.)

To further explore the *in vivo* efficacy of mAb 39.29 NCv1, a dose titration of mAb 39.29 NCv1 was tested against two additional influenza A virus strains, Port Chalmers (H3N2 A/Port Chalmers/1/1973) and Aichi (H3N2 A/Aichi/2/1968). mAb 39.29 NCv1 has an *in vitro* IC₅₀ against Port Chalmers of 2.9 nM, which is very similar to that of A/PR8/1934, while Aichi has an *in vitro* IC₅₀ of 35.0 nM, a value closer to that of A/Hong Kong/1/1968. As shown in FIG. 15 and FIG. 16, 100% mortality was observed in the control treated animals by day 12 and day 10 for the Port Chalmers and Aichi models, respectively. Monoclonal antibody 39.29 NCv1 exhibited very efficacious against both influenza A virus strains at all tested doses (e.g., 45 mg/kg, 15 mg/kg, 5 mg/kg, and 1.7 mg/kg).

These data indicated, in part, that little correlation existed between the *in vitro* IC₅₀ of mAb 39.29 NCv1 and the *in vivo* minimum efficacious dose. None-the-less, a single dose of 15 mg/kg administered *i.v.* 72 hours post infection was efficacious in all four influenza A virus mouse models despite the range of *in vitro* IC₅₀ values for these influenza A virus strains.

Example 8

In Vivo Efficacy of mAb 39.29 and Oseltamivir in Severe Influenza A Virus Infection in Mice

To compare the efficacy of anti-hemagglutinin antibodies of the present invention to that of oseltamivir phosphate (Tamiflu®) in mice, the following studies were performed. Balb/c mice (Charles River Laboratories, Hollister, Calif.) at 6-weeks old were infected intranasally with 50 µl H1N1 A/PR8/1934 at 100× the lethal dose (5×10⁴ PFU/mouse). At 48 hours post infection, anti-hemagglutinin antibody 39.29 (a 50:50 mixture of mAb 39.29 D8C2 and mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177)) was administered as a single dose of approximately 15 mg/kg or control IgG in 200 µl PBS intravenously. In these experiments, an oseltamivir dosing regimen consisting of 2 mg dosed twice daily (BID) for five days was compared with a single 300 µg *i.v.* dose (~15 mg/kg) of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177). A Log-rank test of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) or oseltamivir vs. control gave p<0.01 and a maximum likelihood test of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) vs.

74

oseltamivir gave p<0.05. (Oseltamivir (i.e., Tamiflu®) was obtained from Toronto Research Chemicals, Cat. No. 0701000.)

As shown in FIG. 17, 100% mortality was observed by day 9 in control-IgG (mAb gD5237) treated animals. BID treatment of oseltamivir for 5 days only protected 37.5% of mice from lethality. However, a single 15 mg/kg dose of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) mixture protected 87.5% of the infected animals from the lethal influenza A virus challenge. (See FIG. 17.) The fully efficacious 15 mg/kg dose of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) mixture performed better than oseltamivir in mice severely infected with influenza A virus.

These results showed that a single dose of a monoclonal antibody of the present invention was more effective at treating influenza A virus infection than a 5-day treatment with oseltamivir.

Example 9

In Vivo Efficacy of mAb 39.29 NWPP ("NWPP" Disclosed as SEQ ID NO: 177) in Mice with and without Co-Administration of Oseltamivir

Administration of oseltamivir is effective at reducing human influenza A virus infection if given within 48 hours after symptom onset. Unfortunately, oseltamivir shows minimal efficacy in patients who have been symptomatic for more than 48 hours. Therefore, the following experiments were performed to test if co-administration of a monoclonal antibody of the present invention and oseltamivir showed improved efficacy over either treatment alone. These experiments were performed using the severe mouse influenza infection model described above in Example 8. Briefly, female Balb/C mice (Charles River Laboratories) were infected with 100× the lethal dose (5×10⁴ pfu) of A/PR8/1934 72-hours prior to *i.v.* administration of a single dose of 100 µg mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) (approximately 6 mg/kg, a previously-determined sub-efficacious dose), control IgG, 2 mg BID oseltamivir, or a combination of a single dose of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) and oseltamivir treatment for 5 days. A Log-rank test of the combination treatment vs. mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) or oseltamivir gives p<0.01.

As expected, control IgG treated animals exhibited 100% mortality 9 days post infection. (See FIG. 18.) The mortality observed for control-treated animals was very similar to the groups receiving only oseltamivir or a sub-efficacious dose of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177). However, co-administration of a sub-efficacious dose of mAb 39.29 NWPP ("NWPP" disclosed as SEQ ID NO: 177) plus oseltamivir significantly improved survival compared to that observed in either treatment alone, resulting in 87.5% survival. (See FIG. 18.)

These results showed that a synergistic effect on the treatment of influenza A virus infection occurred during combination therapy using a monoclonal antibody of the present invention used in combination with oseltamivir, a neuraminidase inhibitor.

Example 10

Anti-Hemagglutinin Antibodies of the Present Invention Perform Better than Oseltamivir in a Ferret H5N1 Influenza A Virus Infection Model

Ferret influenza A virus infection models are often used to examine prophylactic and therapeutic efficacy of anti-infl-

enza therapeutics. Ferrets are considered a clinically relevant animal model for human influenza A virus infection. (See Matsuoka et al., (2009) *Current Protocols in Microbiology*, Chapter 15, Unit 15G 12.)

To examine the in vivo efficacy of mAb 39.29 D8C2 and mAb 81.39 B1C1 against a human isolate of H5N1 influenza A virus in ferrets, the following studies were performed. The ferret H5N1 study was completed under contract at the Lovelace Respiratory Research Institute (Albuquerque, N. Mex.). Male ferrets (*Mustela putorius furo*) were challenged with an intranasal dose of 1×10^3 pfu of the highly virulent H5N1 A/Vietnam/1203/04 influenza A virus strain (LD90 dose). Animals were infected 48 or 72 hours prior to receiving antibody by i.v. or oseltamivir (Tamiflu®) by oral gavage. The control treated animals received a 25 mg/kg i.v. dose of mAb gD5237, a monoclonal antibody specific for glycoprotein D of HSV. The anti-influenza treated animals received a single 25 mg/kg i.v. dose of either mAb 39.29 D8C2 or mAb 81.39 B1C1 at 48 or 72 hours post influenza virus infection. Each antibody treatment group included 10 ferrets. The oseltamivir treated animals received a twice-daily oral dose of 25 mg/kg for 5 days. Animals were monitored daily for weight loss, fever, and, body conditioning.

Consistent with an H5N1 infection, the majority of infected ferrets showed early signs of upper respiratory disease by 48 hours post infection. As expected with a lethal dose of H5N1, the negative control antibody treatment group exhibited 90% mortality by 14 days post inoculation. (See FIGS. 19A and 19B.)

In contrast, ferrets that received a single dose of mAb 39.29 D8C2 at either 48 or 72 hours post influenza virus infection showed 80% and 90% survival (20% and 10% mortality), respectively. (See FIG. 19A.) Likewise, ferrets that received a single dose of mAb 81.39 B1C1 at either 48 or 72 hours post infection showed 100% and 80% survival (0% and 20% mortality), respectively. (See FIG. 19B.) Irrespective of treatment initiation time, the oseltamivir treated groups showed 50% mortality.

These results showed that broadly neutralizing anti-hemagglutinin antibodies of the present invention were highly protective in the treatment of severe influenza A virus H5N1 infection in ferrets and performed better than oseltamivir when administered at either 48 and 72 hours post influenza A virus infection.

Example 11

Crystallization and Data Collection

In order to examine the structural basis for hemagglutinin cross-reactivity of the antibodies of the present invention, mAb 39.29 NCv1 Fab fragment was co-crystallized with recombinant hemagglutinin H3 from the human influenza A virus strain A/Perth/16/2009 as follows.

Protein Expression and Purification

To better understand the structural basis for hemagglutinin neutralization, the crystal structure of mAb 39.29 NCv1 Fab fragment in complex with hemagglutinin was determined as follows. Nucleic acid encoding the extracellular domain of Perth H3 hemagglutinin (H3HA, A/Perth/16/2009, amino acid residues 25-520 (SEQ ID NO: 226 for full-length hemagglutinin H3 (H3HA) amino acid sequence) was cloned into pACGP67 vector (BD Biosciences) in-frame with a thrombin cleavage site (LVPRGS, SEQ ID NO: 106), trimerization "foldon" sequence (PGSGYI-PEAPRDGQAYVRKDGEEVLLSTFLG, SEQ ID NO: 107), and a C-terminal 6xHis tag (SEQ ID NO: 108).

Recombinant baculovirus was generated by co-transfection of Sf9 cells with the H3HA-pACGP67 vector and linearized baculovirus DNA (Pharmingen).

To generate recombinant H3HA protein, *Trichoplusia ni* PRO cells were infected with the recombinant baculovirus using an MOI of 1 and grown for 72 hours at 27° C. Cell supernatants were treated with 50 mM Tris-HCl, pH 7.5, 5 mM CaCl₂, and 1 mM NiCl₂ followed by centrifugation and filtering. Media was then concentrated and buffer exchanged into 10 mM Tris, pH 8.0, and 150 mM NaCl (TBS) containing 20 mM imidazole by tangential flow filtration, and protein captured with Ni-agarose and eluted into TBS containing 200 mM imidazole. The foldon tag was cleaved overnight with thrombin, and H3HA was concentrated and further purified on a Superdex 200 16/60 size exclusion column equilibrated in TBS.

To generate the hemagglutinin-Fab complex, the mAb 39.29 NCv1 Fab (under control of the PhoA promoter) was expressed in *E. coli* overnight at 30° C. The cells were pelleted by centrifugation at 6,000 rpm for 15 minutes and lysed by micro-fluidization in PBS supplemented with 25 mM EDTA and 1 mM PMSF. Cell debris was removed by centrifugation at 10,000 rpm for 1 hour at 4° C. The resulting supernatant was passed through a Protein G column and Fab eluted with 0.58% acetic acid. Further purification of mAb 39.29 NCv1 Fab was achieved by SP sepharose chromatography using a gradient from 0 to 1 M NaCl in 20 mM MES, pH 5.5. To generate the HA/39.29 complex, H3HA was incubated overnight with excess mAb 39.29 NCv1 Fab, followed by concentration and 5200 size exclusion chromatography in TBS to isolate the complex. The complex was concentrated to 10 mg/ml for crystallization trials.

Crystallization

Crystal generation for the H3HA/39.29 NCv1 Fab complex were found in 0.1M Phosphate/Citrate buffer, pH 4.2, using 40% PEG 300 as precipitant (condition C6, the JCSG+ sparse matrix screen, Qiagen). Diffraction quality crystals were ultimately grown at 19° C. in sitting drops containing 0.1 µl protein and 0.1 µl 0.1M Phosphate/Citrate, pH 4.2, 40% PEG 300, and 0.7% 1-butanol. Crystals were cryoprotected in mother liquor followed by flash freezing and storage in liquid nitrogen. Data was collected under cryo-cooled conditions at the Canadian Light Source beamline CMCF-081D and processed using MOSFLM and SCALA. The crystal belonged to the I213 space group, with unit cell dimensions of a=b=c=204.4 and $\alpha=\beta=\gamma=90^\circ$.

Structure Determination

Initial phases were obtained by molecular replacement with PHASER using the structure of a H3HA (PDB 3SDY) as a search model. Subsequently the Fc and Fv portions of the Fab were placed separately using PHASER, and underwent initial rounds of rigid body refinement with Phenix. The model went through several iterative rounds of adjustment with COOT and simulated annealing, coordinate, and b-factor refinement with Phenix. Sugar molecules found at Asn-linked glycosylation sites were added using the CarboLoad package from Phenix, and final rounds of refinement were carried out using REFMAC5. The final model was refined at 3.1 Å with R/Rfree values of 19.9 and 25.9%, respectively. Ramachandran statistics calculated by Molprobity indicate 89.7% of the residues lie in favored regions with 1.1% outliers. Contacts were analyzed using the Protein Interfaces, Surfaces, and Assemblies (PISA) software and structural figures were prepared with PYMOL.

Structural Characterization of the 39.29 Epitope on
H3 Hemagglutinin

As described above in Example 11, mAb 39.29 NCv1 Fab fragment was co-crystallized with recombinant H3 hemagglutinin from the human influenza A virus strain A/Perth/16/2009. The crystal structure of the antibody/hemagglutinin complex was determined at a resolution of 3.1 Å. The overall structure of A/Perth/16/2009 H3 hemagglutinin was similar to previously determined hemagglutinin structures with the exception of slight rearrangements and disorder in the HA2 helix 1/helix 2 linker. Disorder at these locations has been seen previously under low pH crystallization conditions, which is consistent with this complex being crystallized at pH 4.2 (Ekiert et al., (2011) *Science* 333:843-850). The crystal structure of the antibody/HA complex showed a single mAb 39.29 Fab molecule bound to each monomer of the uncleaved H3 HA trimer. Both the light chain and heavy chain fragments of mAb 39.29 NCv1 Fab fragments were well resolved throughout, allowing close examination of the Fv interaction with HA.

The epitope for mAb 39.29 NCv1 was determined to be on the stalk region of H3 hemagglutinin, roughly on top of the HA2 helix A. This region of the hemagglutinin stalk was first identified as a broadly neutralizing epitope for influenza A viruses expressing Group1 hemagglutinin subtypes (Ekiert et al., (2009) *Science* 324:246-251; Sui et al., (2009) *Nature Structural & Molecular Biology* 16:265-273)), and more recently as a neutralizing epitope for influenza A virus strains carrying Group1 and Group2 hemagglutinin subtypes (Corti et al., (2011) *Science* 333:850-856). mAb 39.29 NCv1 antibody uses extensive heavy and light chain contacts to bury approximately 1175 Å² of the hemagglutinin stalk surface area. The heavy chain of mAb 39.29 NCv1 contributes to binding largely through an extended hydrophobic CDRH3 loop that inserts into a shallow nonpolar groove adjacent to HA2 helix A and underneath a conserved Group2 hemagglutinin glycosylation site at Asn54. This CDRH3 loop extends Phe99 side-chain out to interact with H3 hemagglutinin Thr334, Ile390, and Ile393, while making main chain polar contacts with the GlcNAc attached to H3 hemagglutinin Asn54. The CDRH3 loop of mAb 39.29 NCv1 also makes a β-turn at Gly100, which is likely stabilized by inter-loop main chain contacts between Val98 and Ile100A. Ile100A faces downward to interact with a conserved H3 hemagglutinin Trp366, while Val98 and Pro100C also make van der Waals contacts with the H3 hemagglutinin stalk. Residing at the heavy/light chain interface, Pro100D and Trp100E terminate the long CDRH3 loop and act to anchor the loop in place.

The light chain of mAb 39.29 NCv1 also contributes significantly to the interaction with the H3 hemagglutinin stalk, making contacts with the H3 hemagglutinin stalk with all three light chain CDR loops as well as framework residues. Of the approximately 1100 Å² hemagglutinin buried surface area, ~60% is contributed by the light chain (640 Å² vs 480 Å² for light chain and heavy chain, respectively). The CDRL1 Asn32 makes hydrogen bond with H3 HA2 helix A residues Asp391 and Asn394, while CDRL1 His31 stacks against the H3 hemagglutinin Asn376 sidechain. Ser52 in the CDRL2 loop also makes a polar contact with Asn398. Within the CDRL3 loop, the backbone of Asn93 contacts Asp391 while Trp94 makes a cation-π interaction with Lys384 in the HA2 helix A. Interestingly, mAb 39.29 also makes a number of framework contacts with hemagglutinin, primarily through backbone interactions of the SGSGSG repeat (SEQ ID NO:

109) in beta-strand 6 of the IgKV3 with amino acid residues 403 to 405 in the H3 hemagglutinin polypeptide. Ser67 of mAb 39.29 NCv1 also makes polar interactions with Asp48 and Thr404 of H3 hemagglutinin.

All three mAb 39.89 NCv1 light chain CDR loops contribute to binding of the H3 HA stalk epitope, accounting for approximately 60% of the total buried surface area. This large dependence of light chain contacts is unique among known hemagglutinin Group1 and Group2 binding and neutralizing antibodies, with antibody F16v3 light chain contributing to only 20% to the buried surface area and antibody CR9114 light chain not making contact with the epitope.

Although structurally conserved, Group1 and Group2 hemagglutinin subtypes diverge significantly at the primary amino acid sequence level. To compare mAb 39.29 NCv1 H3HA contact residues with other hemagglutinin subtypes, we aligned the amino acid sequence of H3 hemagglutinin from influenza virus A/Perth/16/2009 with representative hemagglutinin amino acid sequences from other influenza virus strains: H1HA from A/California/07/2009; H2HA from A/Japan/305/1957; H5HA from A/Vietnam/1203/2004; and H7HA from A/chicken/NSW/1/1997. The amino acid numbering of H3 hemagglutinin from A/Perth/16/2009 in the crystal structure matches the hemagglutinin H3 sequence used in the alignment. The hemagglutinin sequence alignment was generated using clustalW and the amino acid sequences corresponding to hemagglutinin H1 from A/California/07/2009, hemagglutinin H2 from A/Japan/305/1957, hemagglutinin H3 from A/Perth/19/2009, hemagglutinin H5 from A/Vietnam/1203/2004, and hemagglutinin H7 from A/chicken/NSW/1/1997. The crystal structure was used to determine the contact residues between the 39.29 NCv1 Fab fragment and the stalk of hemagglutinin H3.

The alignment is presented in FIG. 20. Hemagglutinin contact residues (shaded in grey) are defined as residues within 4.5 Å of mAb 39.29 NCv1. Each amino acid residue that had greater than 50% of its available surface area buried by mAb 39.29 NCv1 Fab is marked with an asterisk.

A high degree of sequence conservation is observed among the contact residues that contribute significantly to the binding of mAb 39.29 NCv1 to this epitope. (See FIG. 20.) This observation suggests that mAb 39.29 NCv1 binds Group1 and Group2 hemagglutinin molecules via the same stalk epitope seen in the crystal structure described above. This epitope is similar to a hemagglutinin epitope identified for F16v3 anti-hemagglutinin antibody (Corti et al., (2011), supra). However, mAb 39.29 NCv1 binds in a different orientation with respect to the hemagglutinin stalk than does F16v3. Comparison of the 39.29 NCv1, F16v3, and CR9114 structures in complex with HA revealed that all three antibodies bind an epitope that includes the HA2 helix A and adjacent non-polar groups. However, each of the three antibodies has a unique binding orientation, with each heavy chain bound to a similar topographical position on HA but with light chain positioning rotated by ~60° (F16v3) or ~120° (CR9114) when compared to 39.29 NCv1. Also unique to mAb 39.29 NCv1, the IgKV3 light chain SGSGSG repeat (SEQ ID NO: 109) in beta-strand 6 frame-work makes contact with H3 HA. Therefore, the 39.29 structure represents a third solution to the binding of this highly conserved epitope and solidifies the importance of engaging the HA2 helix A for broad neutralization of influenza A virus.

The crystallography data of mAb 39.29 in complex with H3 hemagglutinin from the human influenza A virus strain A/Perth/16/2009 revealed the following contact positions: 34, 36, 54, 70, 292, 294, 305, 307, 334, 363, 364, 365, 366, 379, 380, 382, 383, 384, 386, 387, 390, 391, 393, 394, 395,

397, 398, 401, 403, 404, and 405. Antibody FI6v3 showed the following contact positions: 334, 352, 356, 363, 364, 365, 366, 381, 383, 384, 386, 387, 388, 390, 391, 393, 394, 397, 398, 401, and 402. Amino acid residue positions correspond to H3 hemagglutinin from influenza A virus strain A/Perth/16/2009 (SEQ ID NO:226). (See International Application Publication Nos: WO 2010/010466 and WO 2013/011347; Corti et al. (2011) Science 333:850-856.) While some overlap is observed, mAb 39.29 showed a greater number of contact positions within hemagglutinin than FI6v3.

The fact that mAb 39.29 NCv1 and FI6v3 antibody CDRs have no sequence homology and that both antibodies engage a similar but not identical stalk epitope in different ways suggests that there are various ways for antibodies to bind the conserved stalk epitope and broadly neutralize influenza A viruses.

Example 13

Competition ELISA

Competition ELISA assays were developed using hemagglutinin H1 from influenza virus A/WSN/1933 and hemagglutinin H3 from influenza virus A/Hong Kong/8/1968. Hemagglutinin-coated ELISA plates were allowed to bind test antibody at various concentrations (X-axis) prior to the addition of saturating concentrations of biotin labeled mAb 39.29. If the test antibody competed for the hemagglutinin epitope of mAb 39.29, the biotin ELISA signal (Y-axis) was decreased as a function of increasing test antibody concentration. The binding data were fit with a non-linear dose response curve to determine the EC₅₀ value given in nM.

mAb 39.29 IgG was biotinylated through amine coupling according to the manufacturer's recommended protocol (Sulfo-NHS-LC-LC, Pierce, Rockford, Ill.). Final stock concentration of the biotinylated mAb was 13.2 mM. To determine the optimal concentration for usage, the biotinylated 39.29 was serially titrated against immobilized H1 hemagglutinin from influenza A virus A/WSN/1933 and H3 hemagglutinin from influenza A virus A/Hong Kong/8/1968. Recombinant hemagglutinin H1 and H3 proteins were diluted to 2 µg/ml in phosphate buffered saline (PBS) and dispensed (100 µl) onto 96-well Nunc Maxisorp plates (Nunc, Rochester, N.Y.). The plates were coated overnight at 4° C., rinsed in PBS, and then blocked for 1-hour at room temperature with PBS containing 1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, Mo.).

Each plate then received 100 µl of serially diluted biotinylated mAb 39.29 starting at an initial concentration of 88 nM with 1/3 dilutions in PBS containing 1.0% BSA and 0.05% Polysorbate 20 (Sigma-Aldrich). After one hour incubation, the plates were washed and then incubated with 100 µl of a 1:5000 dilution of streptavidin-conjugated horseradish peroxidase (Caltag Laboratories, Carlsbad, Calif.) for 30 minutes at room temperature. Following the incubation, the plates were washed and developed with 100 µl of TMB substrate (Kirkegaard and Perry Laboratories, Inc. Gaithersburg, Md.). Plates were read on a SpectraMax plate reader (Molecular Devices, Sunnyvale, Calif.) at O.D. 450 nM. The optimal concentration of biotinylated mAb was determined to be 1 nM.

Various concentration α-axis) of monoclonal antibodies 39.18, 36.89, 81.39 39.29, mAb 9, mAb 23 of the present invention and control IgG were incubated with the hemagglutinin-coated plates for 30 minutes at room temperature. Initial concentration was 200 nM followed by 3 fold serial dilutions. Biotinylated mAb 39.29 was added to a final sub-

saturating concentration of 1 nM. Following one hour incubation, the plates were washed and incubated with 100 µl of a 1:5000 dilution of Streptavidin-conjugated horseradish peroxidase for 45-minutes. Plates were washed and then develop with TMB solution. If the test antibody competed for the HA epitope of mAb 39.29, the biotin ELISA signal (Y-axis) was decreased as a function of increasing test antibody concentration. The binding data were fit with a non-linear dose response curve to determine the EC₅₀ value given in nM.

FIGS. 21A and 21B show results of competition ELISA analysis of the mAbs for binding to H1HA from A/NWS/1933 (FIG. 21A) or H3HA from A/HK/8/1968 (FIG. 21B). The results showed that mAb 39.29, mAb 81.39, mAb 39.18, and mAb 36.89 all bind to an overlapping hemagglutinin stalk epitope (FIGS. 21A and 21B). Specifically, mAb 81.39 and mAb 39.18 compete for binding of mAb 39.29 on the stalk of hemagglutinin H1 (FIG. 21A), while mAb 81.39 and mAb 36.89 compete for binding with mAb 39.29 for the identified stalk epitope on hemagglutinin H3 (FIG. 21B).

By using competition ELISA assays it was established that monoclonal antibodies 81.39, 39.18, 36.89, mAb 9, and mAb 23 bind to the highly conserved stalk epitope of hemagglutinin identified by the structural analysis. Specifically, the mAb 81.39 and mAb 39.18 compete for binding of mAb 39.29 on the stalk of the Group1 H1 hemagglutinin. Additionally, mAb 81.39, mAb 36.89, mAb 9, and mAb 23 compete for binding with mAb 39.29 for the identified stalk epitope on the Group2 H3 hemagglutinin. As predicted, since mAb 39.18 neutralizes only Group1 Influenza A isolates, it does not compete for binding of the mAb 39.29 epitope on Group2 hemagglutinin. Likewise, mAb 36.89, mAb 9, and mAb 23 only neutralize Group2 Influenza A isolates and therefore do not compete for binding of mAb 39.29 on Group1 H1 hemagglutinin. The data from these experiments is further summarized in Table 3 below.

TABLE 3

Influenza Isolate	HA Subtype	mAb 39.18	mAb 39.29	mAb 81.39	mAb 36.89	mAb 9	mAb 23
A/NWS/1933	Grp1/H1	0.88	2.8	2.15	—	—	—
A/HK/8/1968	Grp2/H3	—	2.54	4.21	1.32	8.42	1.84

EC₅₀ given in nM

— Indicates EC₅₀ > 200 nM

Example 14

Safety and Pharmacokinetics of Anti-Influenza a Virus Antibody in Healthy Volunteers

A phase 1 single-ascending dose study of mAb 39.29-NWPP in healthy human male and female subjects 18 years of age or older was performed. Initial dosing to investigate the safety, tolerability, and pharmacokinetics in healthy adult subjects was performed by i.v. administration of a single dose (1.5 mg/kg, 5 mg/kg, 15 mg/kg, or 45 mg/kg) of mAb39.29. mAb39.29 was safe and well-tolerated at all dose levels after a follow-up period of at least 58 days for the 45 mg/kg dose level and 120 days for the 1.5 mg/kg dose level. No serious adverse events related to study drug were reported.

Serum concentrations of mAb 39.29 exhibited a biphasic disposition with an initial rapid distribution phase followed by a slow elimination phase. mAb39.29 demonstrated linear pharmacokinetics (PK). The mean C_{max} increased in a dose-

81

proportional manner of 33.5 µg/mL for the 1.5 mg/kg dose group and 1180 µg/mL for the 45 mg/kg dose group. Similarly, the group mean $AUC_{0-\infty}$ was 518 and 5530 µg/mL*day for the 1.5 mg/kg and 15 mg/kg dose groups, respectively, and is approximately dose proportional. On the basis of the available PK data in healthy male and female subjects, mAb 39.29 appeared to have a PK profile consistent with that of a typical IgG1 human antibody with a mean half-life of approximately 20 days (Mean Range 19.3-22.2).

Example 15

Phase 2 Study of Anti-Influenza A Virus Hemagglutinin Antibody

A phase 2 clinical study of an anti-influenza A virus hemagglutinin antibody of the present invention is performed as follows. Hospitalized individuals having influenza A virus infection are administered an anti-influenza A virus hemagglutinin antibody of the present invention by intravenous administration, at a dose of 1.5 mg/kg, 5 mg/kg, 15 mg/kg, or 45 mg/kg. Alternatively, individuals are administered antibody at a fixed dose of 120 mg, 400 mg, 1200 mg, or 3600 mg. Individuals may also be administered oseltamivir (Tamiflu®) (current standard of care) prior to, at the time of, or subsequent to administration of the anti-influenza A virus hemagglutinin antibody. Generally, a one-time dosing regimen of the antibody is used, although subsequent doses are contemplated.

Administration of an anti-influenza A virus hemagglutinin antibody of the present invention shows efficacy at treating

82

influenza A virus infection, including reduction of influenza A virus infectivity, reduction in the length of hospital stay, reduction or prevention of the need for intensive care unit use, reduction or prevention of the need for assisted or mechanical ventilation, or reduction or prevention of the need for supplemental oxygen use.

Administration of an anti-influenza A virus hemagglutinin antibody of the present invention results shows efficacy at treating influenza A virus infection by reduction of time to normalization of respiratory function (such as a reduction of time to normalization of respiratory rate, or a reduction of time to normalization of oxygen saturation), reduction of time to return to normal oxygen saturation, e.g., to an oxygen saturation of about 92% or greater, as measured over a 24 hour period without supplemental oxygen administration, or reduction of time to normalization of vital signs, such as heart rate, blood pressure, respiratory rate, and temperature.

Statistical Analyses

Statistics were calculated using JMP version 9.0.2 software (SAS Institute). Survival experiments were compared using log-rank test. P values < 0.05 were considered significant. IC_{50} curves and values were plotted and calculated using Graphpad Prism version 5.0 software.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 245

<210> SEQ ID NO 1

<211> LENGTH: 38

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 1

atcgtttcat aagcgcgcca ggtgcagctg gtgcagtc

38

<210> SEQ ID NO 2

<211> LENGTH: 38

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 2

atcgtttcat aagcgcgcca grtcaccttg aaggagtc

38

<210> SEQ ID NO 3

<211> LENGTH: 38

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 3

atcgtttcat aagcgcgcca ggtgcagctg gtggagtc

38

-continued

<210> SEQ ID NO 4
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 4

atcgtttcat aagcgcgccca ggtgcagctg gtggagtc 38

<210> SEQ ID NO 5
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 5

atcgtttcat aagcgcgcga agtgcagctg gtggagtc 38

<210> SEQ ID NO 6
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 6

atcgtttcat aagcgcgccca ggtgcagctg caggagtc 38

<210> SEQ ID NO 7
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 7

atcgtttcat aagcgcgccca gctgcagctg caggagtc 38

<210> SEQ ID NO 8
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 8

atcgtttcat aagcgcgcga rgtgcagctg gtgcagtc 38

<210> SEQ ID NO 9
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 9

atcgtttcat aagcgcgccca ggtacagctg cagcagtc 38

-continued

<210> SEQ ID NO 10
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 10

atcgtttcat aagcgcgccca ggtgcagctg gtgcaatc 38

<210> SEQ ID NO 11
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 11

atcgtttcat aagcgcgccca ggtccagctt gtgcagtc 38

<210> SEQ ID NO 12
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 12

atcgtttcat aagcgcgccca ggttcagctg gtgcagtc 38

<210> SEQ ID NO 13
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 13

atcgtttcat aagcgcgccca ggtccagctg gtacagtc 38

<210> SEQ ID NO 14
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 14

atcgtttcat aagcgcgccca gatgcagctg gtgcagtc 38

<210> SEQ ID NO 15
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 15

atcgtttcat aagcgcgccca aatccagctg gtgcagtc 38

-continued

<210> SEQ ID NO 16
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 16

atcgtttcat aagcgcgcga ggtccagctg gtgcagtc 38

<210> SEQ ID NO 17
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 17

atcgtttcat aagcgcgcga ggtgcagctg ttggagtc 38

<210> SEQ ID NO 18
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 18

atcgtttcat aagcgcgcga ggtgcagctg gtggagac 38

<210> SEQ ID NO 19
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 19

atcgtttcat aagcgcgcga ggtgcagcta cagcagtg 38

<210> SEQ ID NO 20
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 20

gacattctac gagctagctg aggagacagt gaccagggt 39

<210> SEQ ID NO 21
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 21

gacattctac gagctagctg aggagacagt gaccagggt 39

<210> SEQ ID NO 22

-continued

```

<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 22

gacattctac gagctagctg aagagacggt gaccattgtc          40


<210> SEQ ID NO 23
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 23

gacattctac gagctagctg aggagacggt gaccgtgg          38


<210> SEQ ID NO 24
<211> LENGTH: 79
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 24

tctcctcagc tagcggtggc ggcgggtccg gaggtggtgg ttctggcggg ggtggcagcg      60
acatccagwt gacccagtc          79


<210> SEQ ID NO 25
<211> LENGTH: 79
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 25

tctcctcagc tagcggtggc ggcgggtccg gaggtggtgg ttctggcggg ggtggcagcg      60
atgttgtgat gactcagtc          79


<210> SEQ ID NO 26
<211> LENGTH: 79
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 26

tctcctcagc tagcggtggc ggcgggtccg gaggtggtgg ttctggcggg ggtggcagcg      60
aaattgtgwt gacrcagtc          79


<210> SEQ ID NO 27
<211> LENGTH: 79
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      primer

<400> SEQUENCE: 27

```

-continued

tctctctcagc tagcggtggc gccgggttccg gaggtggtgg ttctggcggt ggtggcagcg 60

atattgtgat gacccacac 79

<210> SEQ ID NO 28

<211> LENGTH: 79

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 28

tctctctcagc tagcggtggc gccgggttccg gaggtggtgg ttctggcggt ggtggcagcg 60

aaacgacact cacgcagtc 79

<210> SEQ ID NO 29

<211> LENGTH: 79

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 29

tctctctcagc tagcggtggc gccgggttccg gaggtggtgg ttctggcggt ggtggcagcg 60

aaattgtgct gactcagtc 79

<210> SEQ ID NO 30

<211> LENGTH: 38

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 30

agttcatgcc atggttttga tttccacctt ggtccctt 38

<210> SEQ ID NO 31

<211> LENGTH: 36

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 31

agttcatgcc atggttttga tttccacctt ggtccc 36

<210> SEQ ID NO 32

<211> LENGTH: 38

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 32

agttcatgcc atggttttga tatccacttt ggtcccag 38

<210> SEQ ID NO 33

<211> LENGTH: 37

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 33

agttcatgcc atggttttga tctccagctt ggccctt 37

<210> SEQ ID NO 34
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 34

agttcatgcc atggttttta tctccagctg tgccctt 38

<210> SEQ ID NO 35
<211> LENGTH: 79
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 35

tctctcagc tagcggtggc gccggttccg gaggtggtgg ttctggcggt ggtggcagcc 60

agttctgtgt gactcagcc 79

<210> SEQ ID NO 36
<211> LENGTH: 79
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 36

tctctcagc tagcggtggc gccggttccg gaggtggtgg ttctggcggt ggtggcagcc 60

agttctgtgt gactcagcc 79

<210> SEQ ID NO 37
<211> LENGTH: 79
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 37

tctctcagc tagcggtggc gccggttccg gaggtggtgg ttctggcggt ggtggcagcc 60

agttctgtgt gactcagcc 79

<210> SEQ ID NO 38
<211> LENGTH: 79
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 38

tctctcagc tagcggtggc gccggttccg gaggtggtgg ttctggcggt ggtggcagcc 60

-continued

artctgccct gactcagcc 79

<210> SEQ ID NO 39
 <211> LENGTH: 79
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 primer

<400> SEQUENCE: 39

tctctcagc tagcggtggc gccgggtccg gaggtggtgg ttctggcggt ggtggcagct 60

cctatgwgt gactcagcc 79

<210> SEQ ID NO 40
 <211> LENGTH: 79
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 primer

<400> SEQUENCE: 40

tctctcagc tagcggtggc gccgggtccg gaggtggtgg ttctggcggt ggtggcagct 60

cttctgagct gactcagga 79

<210> SEQ ID NO 41
 <211> LENGTH: 79
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 primer

<400> SEQUENCE: 41

tctctcagc tagcggtggc gccgggtccg gaggtggtgg ttctggcggt ggtggcagcc 60

acgttatact gactcaacc 79

<210> SEQ ID NO 42
 <211> LENGTH: 79
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 primer

<400> SEQUENCE: 42

tctctcagc tagcggtggc gccgggtccg gaggtggtgg ttctggcggt ggtggcagcc 60

aggctgtgct gactcagcc 79

<210> SEQ ID NO 43
 <211> LENGTH: 79
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 primer

<400> SEQUENCE: 43

tctctcagc tagcggtggc gccgggtccg gaggtggtgg ttctggcggt ggtggcagca 60

attttatgct gactcagcc 79

<210> SEQ ID NO 44

-continued

<210> SEQ ID NO 50
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 50

agttcatgcc atggttttga t 21

<210> SEQ ID NO 51
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 51

agttcatgcc atggtkagga c 21

<210> SEQ ID NO 52
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 52

gaagtagtcc ttgaccaggc ag 22

<210> SEQ ID NO 53
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 53

ctcagcgtca gggtygtgct gag 23

<210> SEQ ID NO 54
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 54

gggtktggtg gtctccac 18

<210> SEQ ID NO 55
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 55

caggtgcagc tgggtcagtc tggggc 26

-continued

<210> SEQ ID NO 56
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 56

caggtccagc tgggtgcagtc tggggc 26

<210> SEQ ID NO 57
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 57

caggtcacct tgaaggagtc tgggcc 26

<210> SEQ ID NO 58
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 58

gaggtgcagc tgggtggagtc tggggg 26

<210> SEQ ID NO 59
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 59

caggtgcagc tgcaggagtc gggccc 26

<210> SEQ ID NO 60
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 60

gaggtgcagc tgggtgcagtc tgg 23

<210> SEQ ID NO 61
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 61

caggtacagc tgcagcagtc aggtcc 26

-continued

<210> SEQ ID NO 62
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 62

cagggtgcagc tgggtgcaatc tgg 23

<210> SEQ ID NO 63
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 63

ghcatccrgw tgacccagtc tc 22

<210> SEQ ID NO 64
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 64

gatrttgtga tgacycagwc tc 22

<210> SEQ ID NO 65
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 65

gaaatwgtrw tgacrcagtc tc 22

<210> SEQ ID NO 66
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 66

gacatcgtga tgacccagtc tcc 23

<210> SEQ ID NO 67
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 67

gaaacgacac tcacgcagtc tc 22

<210> SEQ ID NO 68

-continued

<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 68

gawrttgtgm tgacwcagtc tc 22

<210> SEQ ID NO 69
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 69

cagtctgtgy tgackcagcc rccctc 26

<210> SEQ ID NO 70
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 70

cagtctgccc tgactcagcc t 21

<210> SEQ ID NO 71
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 71

tcctatgagc tgacwcagsh vccckc 26

<210> SEQ ID NO 72
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 72

cagcctgtgc tgactcartc vccctc 26

<210> SEQ ID NO 73
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 73

cagcctgtgc tgactcagcc aacttc 26

<210> SEQ ID NO 74
<211> LENGTH: 24

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 74

aattttatgc tgactcagcc ccac 24

<210> SEQ ID NO 75
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 75

caggctgtgg tgactcagga gcc 24

<210> SEQ ID NO 76
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 76

cagactgtgg tgaccagga gcc 23

<210> SEQ ID NO 77
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 77

cagcctgtgc tgactcagcc acc 23

<210> SEQ ID NO 78
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 78

gcagcccagg gcs gctgtgc 20

<210> SEQ ID NO 79
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 79

gcacacaaca gaggcagttc cag 23

<210> SEQ ID NO 80
<211> LENGTH: 20
<212> TYPE: DNA

-continued

```

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 80

cttgragctc ctcagaggag                                20

<210> SEQ ID NO 81
<211> LENGTH: 66
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 81

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt    60
cacagg                                           66

<210> SEQ ID NO 82
<211> LENGTH: 72
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 82

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt    60
cacagatcac ct                                           72

<210> SEQ ID NO 83
<211> LENGTH: 65
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 83

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt    60
cacag                                           65

<210> SEQ ID NO 84
<211> LENGTH: 66
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 84

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt    60
cagagg                                           66

<210> SEQ ID NO 85
<211> LENGTH: 78
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 85

```

-continued

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60

cacaggtgca gctgcagg 78

<210> SEQ ID NO 86

<211> LENGTH: 70

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 86

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60

cagaggtgca 70

<210> SEQ ID NO 87

<211> LENGTH: 72

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 87

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60

cacaggtaca gc 72

<210> SEQ ID NO 88

<211> LENGTH: 70

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 88

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60

cacaggtgca 70

<210> SEQ ID NO 89

<211> LENGTH: 95

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 89

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60

cagacatcca gatgaccag tctccatcct cctg 95

<210> SEQ ID NO 90

<211> LENGTH: 95

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 90

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60

cagatattgt gatgactcag tctcactctc cctgc 95

-continued

<210> SEQ ID NO 91
<211> LENGTH: 101
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 91

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60
cagaaattgt gttgacacag tctccagcca cctgtcttt g 101

<210> SEQ ID NO 92
<211> LENGTH: 101
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 92

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60
cagacatcgt gatgaccag tctccagact cctggctgt g 101

<210> SEQ ID NO 93
<211> LENGTH: 88
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 93

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60
cagaaacgac actcacgcag tctccagc 88

<210> SEQ ID NO 94
<211> LENGTH: 94
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 94

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60
cagaaattgt gctgactcag tctccagact ttcg 94

<210> SEQ ID NO 95
<211> LENGTH: 88
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 95

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt 60
cacagtctgt gytgackcag cccccc 88

<210> SEQ ID NO 96
<211> LENGTH: 83

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 96

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt      60
cacagtctgc cctgactcag cct                                              83

<210> SEQ ID NO 97
<211> LENGTH: 88
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 97

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt      60
catcctatga gctgacwcag shvccckc                                         88

<210> SEQ ID NO 98
<211> LENGTH: 88
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 98

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt      60
cacagcctgt gctgactcar tcvccctc                                         88

<210> SEQ ID NO 99
<211> LENGTH: 88
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 99

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt      60
cacagcctgt gctgactcag ccaacttc                                         88

<210> SEQ ID NO 100
<211> LENGTH: 86
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
        primer

<400> SEQUENCE: 100

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt      60
caaattttat gctgactcag ccccac                                           86

<210> SEQ ID NO 101
<211> LENGTH: 86
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

```

-continued

```

    primer

<400> SEQUENCE: 101

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt      60
cacaggctgt ggtgactcag gagccc                                           86

<210> SEQ ID NO 102
<211> LENGTH: 85
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
    primer

<400> SEQUENCE: 102

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt      60
cacagactgt ggtgacccag gagcc                                           85

<210> SEQ ID NO 103
<211> LENGTH: 85
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
    primer

<400> SEQUENCE: 103

ccaccatggg atggtcatgt atcatccttt ttctagtagc aactgcaact ggagtacatt      60
cacagcctgt gctgactcag ccacc                                           85

<210> SEQ ID NO 104
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
    primer

<400> SEQUENCE: 104

gccaggggga agaccgatg                                           19

<210> SEQ ID NO 105
<211> LENGTH: 59
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
    primer

<400> SEQUENCE: 105

ctgggataga agttattcag caggcacaca acagaagcag ttccagatgt caactgctc      59

<210> SEQ ID NO 106
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
    peptide

<400> SEQUENCE: 106

Leu Val Pro Arg Gly Ser
1          5

```

-continued

<210> SEQ ID NO 107
<211> LENGTH: 31
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 107

Pro Gly Ser Gly Tyr Ile Pro Glu Ala Pro Arg Asp Gly Gln Ala Tyr
1 5 10 15
Val Arg Lys Asp Gly Glu Trp Val Leu Leu Ser Thr Phe Leu Gly
20 25 30

<210> SEQ ID NO 108
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 6xHis tag

<400> SEQUENCE: 108

His His His His His His
1 5

<210> SEQ ID NO 109
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 109

Ser Gly Ser Gly Ser Gly
1 5

<210> SEQ ID NO 110
<211> LENGTH: 455
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 110

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe His Asn Arg
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Leu Ile Tyr Phe Asp Gly Ser Lys Gln Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Val Pro Gly Pro Ile Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
100 105 110
Asp His Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125

Lys 130	Pro	Ser	Val	Phe	Pro 135	Leu	Ala	Pro	Ser	Ser 140	Lys	Ser	Thr	Ser	
Gly 145	Gly	Thr	Ala	Ala	Leu 150	Gly	Cys	Leu	Val	Lys 155	Asp	Tyr	Phe	Pro	Glu 160
Pro	Val	Thr	Val	Ser 165	Trp	Asn	Ser	Gly	Ala 170	Leu	Thr	Ser	Gly	Val 175	His
Thr	Phe	Pro	Ala 180	Val	Leu	Gln	Ser	Ser	Gly 185	Leu	Tyr	Ser	Leu 190	Ser	Ser
Val	Val	Thr 195	Val	Pro	Ser	Ser	Ser 200	Leu	Gly	Thr	Gln	Thr 205	Tyr	Ile	Cys
Asn 210	Val	Asn	His	Lys	Pro	Ser 215	Asn	Thr	Lys	Val	Asp 220	Lys	Lys	Val	Glu
Pro 225	Lys	Ser	Cys	Asp	Lys 230	Thr	His	Thr	Cys	Pro 235	Pro	Cys	Pro	Ala	Pro 240
Glu	Leu	Leu	Gly	Gly 245	Pro	Ser	Val	Phe	Leu 250	Phe	Pro	Pro	Lys	Pro 255	Lys
Asp	Thr	Leu	Met 260	Ile	Ser	Arg	Thr	Pro 265	Glu	Val	Thr	Cys 270	Val	Val	Val
Asp	Val	Ser 275	His	Glu	Asp	Pro	Glu 280	Val	Lys	Phe	Asn	Trp 285	Tyr	Val	Asp
Gly 290	Val	Glu	Val	His	Asn 295	Ala	Lys	Thr	Lys	Pro 300	Arg	Glu	Glu	Gln	Tyr
Asn 305	Ser	Thr	Tyr	Arg	Val 310	Val	Ser	Val	Leu	Thr 315	Val	Leu	His	Gln	Asp 320
Trp	Leu	Asn	Gly	Lys 325	Glu	Tyr	Lys	Cys	Lys 330	Val	Ser	Asn	Lys	Ala 335	Leu
Pro	Ala	Pro	Ile 340	Glu	Lys	Thr	Ile	Ser 345	Lys	Ala	Lys	Gly	Gln 350	Pro	Arg
Glu	Pro	Gln 355	Val	Tyr	Thr	Leu	Pro 360	Pro	Ser	Arg	Glu	Glu 365	Met	Thr	Lys
Asn 370	Gln	Val	Ser	Leu	Thr	Cys 375	Leu	Val	Lys	Gly 380	Phe	Tyr	Pro	Ser	Asp
Ile 385	Ala	Val	Glu	Trp	Glu 390	Ser	Asn	Gly	Gln	Pro 395	Glu	Asn	Asn	Tyr	Lys 400
Thr	Thr	Pro	Pro 405	Val	Leu	Asp	Ser	Asp	Gly 410	Ser	Phe	Phe	Leu	Tyr 415	Ser
Lys	Leu	Thr 420	Val	Asp	Lys	Ser	Arg	Trp 425	Gln	Gln	Gly	Asn 430	Val	Phe	Ser
Cys	Ser	Val 435	Met	His	Glu	Ala	Leu 440	His	Asn	His	Tyr	Thr 445	Gln	Lys	Ser
Leu 450	Ser	Leu	Ser	Pro	Gly 455	Lys									

<400> SEQUENCE: 111

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe His Asn Arg
20 25 30

-continued

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Leu Ile Tyr Phe Asp Gly Ser Lys Gln Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Phe
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Val Pro Gly Pro Ile Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
 100 105 110

Asp His Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser
 115 120 125

<210> SEQ ID NO 112
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 112

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Asn
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
 85 90 95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys Arg Thr Val
 100 105 110

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 115 120 125

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 145 150 155 160

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 165 170 175

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 180 185 190

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 195 200 205

Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> SEQ ID NO 113
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

polypeptide

<400> SEQUENCE: 113

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Asn
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45
 Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
 85 90 95
 Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 114

<211> LENGTH: 455

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 114

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe His Asn Arg
 20 25 30
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Leu Ile Tyr Phe Asp Gly Ser Lys Gln Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Phe
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Val Pro Gly Pro Ile Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
 100 105 110
 Asp His Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser Ala Ser Thr
 115 120 125
 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
 130 135 140
 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
 145 150 155 160
 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
 165 170 175
 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
 180 185 190
 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
 195 200 205
 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
 210 215 220
 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro

-continued

225	230	235	240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys	245	250	255
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val	260	265	270
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp	275	280	285
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr	290	295	300
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp	305	310	315
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu	325	330	335
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg	340	345	350
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys	355	360	365
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp	370	375	380
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys	385	390	395
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser	405	410	415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser	420	425	430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser	435	440	445
Leu Ser Leu Ser Pro Gly Lys	450	455	

<210> SEQ ID NO 115

<211> LENGTH: 125

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 115

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg	1	5	10	15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe His Asn Arg	20	25	30	
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val	35	40	45	
Ala Leu Ile Tyr Phe Asp Gly Ser Lys Gln Tyr Tyr Ala Asp Ser Val	50	55	60	
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Phe	65	70	75	80
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys	85	90	95	
Ala Val Pro Gly Pro Ile Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe	100	105	110	
Asp His Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser	115	120	125	

-continued

<210> SEQ ID NO 116
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 116

```

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1           5           10           15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser His Asn
20          25          30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
35          40          45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50          55          60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
65          70          75          80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Tyr Pro Pro
85          90          95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys Arg Thr Val
100         105         110

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
115         120         125

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
130         135         140

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
145         150         155         160

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
165         170         175

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
180         185         190

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
195         200         205

Lys Ser Phe Asn Arg Gly Glu Cys
210         215

```

<210> SEQ ID NO 117
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 117

```

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1           5           10           15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser His Asn
20          25          30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
35          40          45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50          55          60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
65          70          75          80

```

-continued

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Tyr Pro Pro
85 90 95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 118
<211> LENGTH: 216
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 118

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
35 40 45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
85 90 95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys Arg Thr Val
100 105 110

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
115 120 125

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
130 135 140

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
145 150 155 160

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
165 170 175

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
180 185 190

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
195 200 205

Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> SEQ ID NO 119
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 119

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
35 40 45

-continued

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
85 90 95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 120
<211> LENGTH: 349
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide

<400> SEQUENCE: 120

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe His Asn Arg
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Leu Ile Tyr Phe Asp Gly Ser Lys Gln Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Phe
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Val Pro Gly Pro Ile Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
100 105 110

Asp His Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser Ala Ser Thr
115 120 125

Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130 135 140

Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145 150 155 160

Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165 170 175

Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180 185 190

Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195 200 205

Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210 215 220

Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
225 230 235 240

Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
245 250 255

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
260 265 270

Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
275 280 285

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
290 295 300

-continued

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
305 310 315 320

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
325 330 335

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
340 345

<210> SEQ ID NO 121

<211> LENGTH: 216

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 121

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
35 40 45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
85 90 95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys Arg Thr Val
100 105 110

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
115 120 125

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
130 135 140

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
145 150 155 160

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
165 170 175

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
180 185 190

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
195 200 205

Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> SEQ ID NO 122

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 122

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30

-continued

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
 85 90 95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 123

<211> LENGTH: 216

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 123

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp His Asn
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
 85 90 95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys Arg Thr Val
 100 105 110

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 115 120 125

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 145 150 155 160

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 165 170 175

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 180 185 190

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 195 200 205

Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> SEQ ID NO 124

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 124

-continued

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp His Asn
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45
 Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
 85 90 95
 Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 125
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 125

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser His Asn
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45
 Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
 85 90 95
 Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys Arg Thr Val
 100 105 110
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 115 120 125
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140
 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 145 150 155 160
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 165 170 175
 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 180 185 190
 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 195 200 205
 Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> SEQ ID NO 126
 <211> LENGTH: 109
 <212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 126

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser His Asn
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45
 Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Trp Pro Pro
 85 90 95
 Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 127

<211> LENGTH: 216

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 127

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser His Asn
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45
 Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Phe Pro Pro
 85 90 95
 Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys Arg Thr Val
 100 105 110
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 115 120 125
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140
 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 145 150 155 160
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 165 170 175
 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 180 185 190
 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 195 200 205
 Lys Ser Phe Asn Arg Gly Glu Cys

-continued

210 215

<210> SEQ ID NO 128
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 128

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser His Asn
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Phe Pro Pro
 85 90 95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 129
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 129

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Asn
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
 35 40 45

Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Phe Pro Pro
 85 90 95

Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys Arg Thr Val
 100 105 110

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 115 120 125

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 145 150 155 160

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 165 170 175

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys

-continued

180	185	190
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr		
195	200	205
Lys Ser Phe Asn Arg Gly Glu Cys		
210	215	

<210> SEQ ID NO 130
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 130

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
35 40 45
Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Phe Pro Pro
85 90 95
Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 131
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 131

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
35 40 45
Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Tyr Pro Pro
85 90 95
Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys Arg Thr Val
100 105 110
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
115 120 125
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
130 135 140
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn

-continued

145	150	155	160
Ser Gln Glu Ser Val Thr	Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser		
	165	170	175
Leu Ser Ser Thr Leu Thr	Leu Ser Lys Ala Asp Tyr Glu Lys His Lys		
	180	185	190
Val Tyr Ala Cys Glu Val Thr	His Gln Gly Leu Ser Ser Pro Val Thr		
	195	200	205
Lys Ser Phe Asn Arg Gly	Glu Cys		
	210	215	

<210> SEQ ID NO 132
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 132

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asp Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val
35 40 45
Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Thr Asn Tyr Pro Pro
85 90 95
Arg Leu Thr Phe Gly Gly Gly Ser Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 133
 <211> LENGTH: 455
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 133

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Lys
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr
20 25 30
Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Thr Leu Ile Ser Tyr Asp Gly Ala Asn Gln Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Val Pro Gly Pro Val Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
100 105 110
Asp Asn Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser Ala Ser Thr

-continued

115					120					125					
Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser
130						135					140				
Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu
145					150					155					160
Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His
				165					170					175	
Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser
		180					185					190			
Val	Val	Thr	Val	Pro	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	
		195				200					205				
Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu
210					215					220					
Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro
225					230					235					240
Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys
			245						250					255	
Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val
		260					265					270			
Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp
		275				280					285				
Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr
290					295					300					
Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp
305					310					315					320
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu
			325						330					335	
Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg
		340					345						350		
Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys
		355				360					365				
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp
370					375					380					
Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys
385					390					395					400
Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser
			405						410					415	
Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser
		420					425					430			
Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser
		435				440					445				
Leu	Ser	Leu	Ser	Pro	Gly	Lys									
450					455										

<210> SEQ ID NO 134

<211> LENGTH: 125

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 134

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Lys
1				5					10					15	

-continued

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr
 20 25 30

Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Thr Leu Ile Ser Tyr Asp Gly Ala Asn Gln Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Val Pro Gly Pro Val Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
 100 105 110

Asp Asn Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser
 115 120 125

<210> SEQ ID NO 135
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 135

Glu Thr Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45

Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Trp Pro Pro
 85 90 95

Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
 100 105 110

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 115 120 125

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 145 150 155 160

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 165 170 175

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 180 185 190

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 195 200 205

Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> SEQ ID NO 136
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 136

```

Glu Thr Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1          5          10          15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn
20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35          40          45
Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
50          55          60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser
65          70          75          80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Trp Pro Pro
85          90          95
Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100         105

```

<210> SEQ ID NO 137

<211> LENGTH: 455

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 137

```

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys
1          5          10          15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr
20          25          30
Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35          40          45
Thr Leu Ile Ser Tyr Asp Gly Ala Asn Gln Tyr Tyr Ala Asp Ser Val
50          55          60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
65          70          75          80
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85          90          95
Ala Val Pro Gly Pro Val Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
100         105         110
Asp Asn Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser Ala Ser Thr
115         120         125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
130         135         140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145         150         155         160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
165         170         175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
180         185         190
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
195         200         205
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
210         215         220

```

-continued

Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
 225 230 235 240
 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 245 250 255
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 260 265 270
 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 275 280 285
 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
 290 295 300
 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
 305 310 315 320
 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
 325 330 335
 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
 340 345 350
 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
 355 360 365
 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 370 375 380
 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
 385 390 395 400
 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 405 410 415
 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
 420 425 430
 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
 435 440 445
 Leu Ser Leu Ser Pro Gly Lys
 450 455

<210> SEQ ID NO 138

<211> LENGTH: 125

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 138

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr
 20 25 30
 Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Thr Leu Ile Ser Tyr Asp Gly Ala Asn Gln Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Val Pro Gly Pro Val Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
 100 105 110
 Asp Asn Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser

-continued

115	120	125
<210> SEQ ID NO 139		
<211> LENGTH: 216		
<212> TYPE: PRT		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide		
<400> SEQUENCE: 139		
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly		
1 5 10 15		
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn		
20 25 30		
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile		
35 40 45		
Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly		
50 55 60		
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser		
65 70 75 80		
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Trp Pro Pro		
85 90 95		
Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val		
100 105 110		
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys		
115 120 125		
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg		
130 135 140		
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn		
145 150 155 160		
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser		
165 170 175		
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys		
180 185 190		
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr		
195 200 205		
Lys Ser Phe Asn Arg Gly Glu Cys		
210 215		
<210> SEQ ID NO 140		
<211> LENGTH: 109		
<212> TYPE: PRT		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide		
<400> SEQUENCE: 140		
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly		
1 5 10 15		
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn		
20 25 30		
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile		
35 40 45		
Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly		
50 55 60		
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser		

-continued

65	70	75	80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Trp Pro Pro	85	90	95
Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys	100	105	

<210> SEQ ID NO 141
 <211> LENGTH: 455
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 141

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys	1	5	10	15
Ser Pro Arg Leu Ser Cys Ala Ala Ser Gly Pro Thr Phe Ser Ser Tyr	20	25	30	
Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val	35	40	45	
Thr Leu Ile Ser Tyr Asp Gly Ala Asn Gln Tyr Tyr Ala Asp Ser Val	50	55	60	
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr	65	70	75	80
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys	85	90	95	
Ala Val Pro Gly Pro Val Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe	100	105	110	
Asp Asn Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser Ala Ser Thr	115	120	125	
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser	130	135	140	
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu	145	150	155	160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His	165	170	175	
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser	180	185	190	
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys	195	200	205	
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu	210	215	220	
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro	225	230	235	240
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys	245	250	255	
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val	260	265	270	
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp	275	280	285	
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr	290	295	300	
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp	305	310	315	320

Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	
				325									330	335		
Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	
				340									345	350		
Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	
				355									360	365		
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	
				370									375	380		
Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	
385												390	395			400
Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	
				405									410	415		
Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	
				420									425	430		
Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	
				435									440	445		
Leu	Ser	Leu	Ser	Pro	Gly	Lys										
450				455												

```
<210> SEQ ID NO 142
<211> LENGTH: 125
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide
```

<400> SEQUENCE: 142

Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Lys
1			5						10					15	
Ser	Pro	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Pro	Thr	Phe	Ser	Ser	Tyr
			20					25					30		
Ala	Val	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Thr	Leu	Ile	Ser	Tyr	Asp	Gly	Ala	Asn	Gln	Tyr	Tyr	Ala	Asp	Ser	Val
	50					55					60				
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Val	Tyr
65					70					75					80
Leu	Gln	Met	Asn	Ser	Leu	Arg	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
			85						90					95	
Ala	Val	Pro	Gly	Pro	Val	Phe	Gly	Ile	Phe	Pro	Pro	Trp	Ser	Tyr	Phe
			100					105					110		
Asp	Asn	Trp	Gly	Gln	Gly	Ile	Leu	Val	Thr	Val	Ser	Ser			
		115					120					125			

```
<210> SEQ ID NO 143
<211> LENGTH: 216
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      polypeptide
```

<400> SEQUENCE: 143

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn
20 25 30

-continued

```

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
   35                               40               45

Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
   50                               55               60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Pro
   65                               70               75               80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Trp Pro Pro
   85                               90               95

Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
  100                               105              110

Ala Ala Pro Ser Val Ser Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
  115                               120              125

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
  130                               135              140

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
  145                               150              155              160

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
  165                               170              175

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
  180                               185              190

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
  195                               200              205

Lys Ser Phe Asn Arg Gly Glu Cys
  210                               215

```

```

<210> SEQ ID NO 144
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      polypeptide

```

```

<400> SEQUENCE: 144

```

```

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1           5           10           15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn
 20           25           30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35           40           45

Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
 50           55           60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Pro
 65           70           75           80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Trp Pro Pro
 85           90           95

Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100          105

```

```

<210> SEQ ID NO 145
<211> LENGTH: 216
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      polypeptide

```

```

<400> SEQUENCE: 145

```

-continued

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Trp Pro Pro
 85 90 95
 Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
 100 105 110
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 115 120 125
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140
 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 145 150 155 160
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 165 170 175
 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 180 185 190
 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 195 200 205
 Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> SEQ ID NO 146
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 146

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Trp Pro Pro
 85 90 95
 Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 147
 <211> LENGTH: 455
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 147

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr
 20 25 30
 Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Thr Leu Ile Ser Tyr Asp Gly Ala Asn Gln Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Val Pro Gly Pro Val Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
 100 105 110
 Asp Asn Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser Ala Ser Thr
 115 120 125
 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
 130 135 140
 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
 145 150 155 160
 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
 165 170 175
 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
 180 185 190
 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
 195 200 205
 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
 210 215 220
 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
 225 230 235 240
 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 245 250 255
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 260 265 270
 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 275 280 285
 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
 290 295 300
 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
 305 310 315 320
 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
 325 330 335
 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
 340 345 350
 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
 355 360 365
 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 370 375 380
 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys

-continued

385	390	395	400
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser			
	405	410	415
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser			
	420	425	430
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser			
	435	440	445
Leu Ser Leu Ser Pro Gly Lys			
	450	455	

<210> SEQ ID NO 148
 <211> LENGTH: 125
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 148

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys			
1	5	10	15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr			
	20	25	30
Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val			
	35	40	45
Thr Leu Ile Ser Tyr Asp Gly Ala Asn Gln Tyr Tyr Ala Asp Ser Val			
	50	55	60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr			
	65	70	75
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys			
	85	90	95
Ala Val Pro Gly Pro Val Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe			
	100	105	110
Asp Asn Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser			
	115	120	125

<210> SEQ ID NO 149
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 149

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly			
1	5	10	15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn			
	20	25	30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile			
	35	40	45
Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly			
	50	55	60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser			
	65	70	75
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Phe Pro Pro			
	85	90	95
Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val			

-continued

100	105	110
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys		
115	120	125
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg		
130	135	140
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn		
145	150	155
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser		
165	170	175
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys		
180	185	190
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr		
195	200	205
Lys Ser Phe Asn Arg Gly Glu Cys		
210	215	

<210> SEQ ID NO 150
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 150

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly		
1	5	10
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn		
20	25	30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile		
35	40	45
Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly		
50	55	60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser		
65	70	75
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Phe Pro Pro		
85	90	95
Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys		
100	105	

<210> SEQ ID NO 151
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 151

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly		
1	5	10
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn		
20	25	30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile		
35	40	45
Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly		
50	55	60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser		

-continued

65	70	75	80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Tyr Pro Pro	85	90	95
Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val	100	105	110
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys	115	120	125
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg	130	135	140
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn	145	150	155
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser	165	170	175
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys	180	185	190
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr	195	200	205
Lys Ser Phe Asn Arg Gly Glu Cys	210	215	

<210> SEQ ID NO 152
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 152

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly	1	5	10	15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn	20	25	30	
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile	35	40	45	
Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly	50	55	60	
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser	65	70	75	80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Tyr Pro Pro	85	90	95	
Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys	100	105		

<210> SEQ ID NO 153
 <211> LENGTH: 450
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 153

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser	1	5	10	15
Ser Met Lys Val Ser Cys Lys Ala Ser Gly Ser Ile Phe Ser Asn Tyr	20	25	30	
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met				

	35					40					45				
Gly	Gly	Ile	Ile	Pro	Ile	Phe	Gly	Ala	Ala	Asn	Tyr	Ala	Gln	Lys	Phe
	50					55					60				
Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Glu	Ser	Thr	Ser	Thr	Val	Tyr
65					70					75					80
Met	Glu	Val	Arg	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Arg	Gln	Gln	Leu	Tyr	Lys	Gly	Tyr	Tyr	His	His	Trp	Gly	Gln
			100					105					110		
Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val
			115					120				125			
Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala
	130					135					140				
Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser
145					150					155					160
Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val
				165					170					175	
Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro
			180					185					190		
Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys
		195					200					205			
Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp
	210					215					220				
Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly
225					230					235					240
Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile
				245					250					255	
Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu
			260					265					270		
Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His
		275					280					285			
Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg
	290					295					300				
Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys
305					310					315					320
Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu
				325					330					335	
Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr
			340					345					350		
Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu
		355					360					365			
Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp
	370					375					380				
Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val
385					390					395					400
Leu	Asp														

-continued

<210> SEQ ID NO 154
 <211> LENGTH: 120
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 154

```

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1           5           10           15
Ser Met Lys Val Ser Cys Lys Ala Ser Gly Ser Ile Phe Ser Asn Tyr
          20           25           30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
          35           40           45
Gly Gly Ile Ile Pro Ile Phe Gly Ala Ala Asn Tyr Ala Gln Lys Phe
          50           55           60
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Tyr
          65           70           75           80
Met Glu Val Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
          85           90           95
Ala Arg Arg Gln Gln Leu Tyr Lys Gly Tyr Tyr His His Trp Gly Gln
          100          105          110
Gly Thr Leu Val Thr Val Ser Ser
          115          120

```

<210> SEQ ID NO 155
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 155

```

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1           5           10           15
Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Asn Asn
          20           25           30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile
          35           40           45
Tyr Gly Ala Ser Thr Arg Asp Thr Gly Ile Pro Ala Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
          65           70           75           80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
          85           90           95
Met Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val
          100          105          110
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
          115          120          125
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
          130          135          140
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
          145          150          155          160
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
          165          170          175

```

-continued

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
180 185 190

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
195 200 205

Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> SEQ ID NO 156

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 156

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Asn Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Thr Arg Asp Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95

Met Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> SEQ ID NO 157

<211> LENGTH: 450

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 157

Gln Val Gln Leu Val Gln Ser Gly Ala Gly Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Met Lys Val Ser Cys Lys Ala Ser Gly Ser Ile Phe Ser Asn Tyr
20 25 30

Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Gly Ile Ile Pro Ile Phe Gly Ala Ala Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Tyr
65 70 75 80

Met Glu Val Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Arg Gln Gln Leu Tyr Lys Gly Tyr Tyr His His Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140

-continued

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 145 150 155 160
 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 165 170 175
 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 180 185 190
 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205
 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
 210 215 220
 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
 225 230 235 240
 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 245 250 255
 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 260 265 270
 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 275 280 285
 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 290 295 300
 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 305 310 315 320
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
 325 330 335
 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 340 345 350
 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
 355 360 365
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 370 375 380
 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 385 390 395 400
 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 405 410 415
 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 420 425 430
 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 435 440 445
 Gly Lys
 450

<210> SEQ ID NO 158

<211> LENGTH: 120

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 158

Gln Val Gln Leu Val Gln Ser Gly Ala Gly Val Lys Lys Pro Gly Ser
 1 5 10 15
 Ser Met Lys Val Ser Cys Lys Ala Ser Gly Ser Ile Phe Ser Asn Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

-continued

35					40					45					
Gly	Gly	Ile	Ile	Pro	Ile	Phe	Gly	Ala	Ala	Asn	Tyr	Ala	Gln	Lys	Phe
50					55					60					
Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Glu	Ser	Thr	Ser	Thr	Val	Tyr
65					70					75					80
Met	Glu	Val	Arg	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Arg	Gln	Gln	Leu	Tyr	Lys	Gly	Tyr	Tyr	His	His	Trp	Gly	Gln
			100					105					110		
Gly	Thr	Leu	Val	Thr	Val	Ser	Ser								
		115					120								

<210> SEQ ID NO 159

<211> LENGTH: 455

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 159

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Leu	Lys	Arg	Pro	Gly	Ala
1			5						10					15	
Ser	Val	Lys	Val	Ser	Cys	Lys	Thr	Ser	Gly	Tyr	Ser	Phe	Asn	Asn	Tyr
		20						25				30			
Gly	Ile	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
	35					40						45			
Gly	Trp	Ile	Ser	Ala	Tyr	Thr	Gly	Asn	Thr	His	Tyr	Ala	Lys	Asn	Phe
	50					55					60				
Glu	Gly	Arg	Val	Thr	Leu	Thr	Thr	Asp	Thr	Ser	Thr	Ser	Thr	Ala	Tyr
65					70					75					80
Met	Glu	Val	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Ser	Ala	Val	Tyr	Phe	Cys
			85					90						95	
Ala	Arg	Ala	Met	Ile	Gln	Gly	Val	Val	Thr	Leu	Tyr	Leu	Arg	Pro	Gly
			100					105					110		
Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr
		115					120						125		
Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser
	130					135					140				
Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu
145					150					155					160
Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His
			165					170						175	
Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser
			180					185					190		
Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys
			195				200					205			
Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu
	210						215				220				
Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro
225					230					235					240
Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys
			245						250					255	
Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val
			260					265							270

-continued

Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
 275 280 285
 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
 290 295 300
 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
 305 310 315 320
 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
 325 330 335
 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
 340 345 350
 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys
 355 360 365
 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 370 375 380
 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
 385 390 395 400
 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 405 410 415
 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
 420 425 430
 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
 435 440 445
 Leu Ser Leu Ser Pro Gly Lys
 450 455

<210> SEQ ID NO 160
 <211> LENGTH: 125
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 160

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Leu Lys Arg Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Ser Phe Asn Asn Tyr
 20 25 30
 Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Thr Gly Asn Thr His Tyr Ala Lys Asn Phe
 50 55 60
 Glu Gly Arg Val Thr Leu Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Val Arg Ser Leu Arg Ser Asp Asp Ser Ala Val Tyr Phe Cys
 85 90 95
 Ala Arg Ala Met Ile Gln Gly Val Val Thr Leu Tyr Leu Arg Pro Gly
 100 105 110
 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> SEQ ID NO 161
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

-continued

<400> SEQUENCE: 161

```

Asp Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Asn Trp
20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35          40          45
Tyr Lys Val Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50          55          60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro
65          70          75          80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Arg Tyr Thr Ser Asn Ser Gln
85          90          95
Gly Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val
100         105         110
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
115         120         125
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
130         135         140
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
145         150         155         160
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
165         170         175
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
180         185         190
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
195         200         205
Lys Ser Phe Asn Arg Gly Glu Cys
210         215

```

<210> SEQ ID NO 162

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 162

```

Asp Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Asn Trp
20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35          40          45
Tyr Lys Val Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50          55          60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro
65          70          75          80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Arg Tyr Thr Ser Asn Ser Gln
85          90          95
Gly Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100         105

```

<210> SEQ ID NO 163

-continued

```

<211> LENGTH: 452
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      polypeptide

<400> SEQUENCE: 163

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Gln Pro Gly Ala
1          5          10          15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn Ala Tyr
      20          25          30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
      35          40          45

Gly Trp Ile Asn Pro Asn Phe Gly Gly Thr His Tyr Ala Arg Lys Phe
50          55          60

Gln Gly Arg Val Thr Met Thr Arg Asp Ala Ser Ile Asn Thr Ala Tyr
65          70          75          80

Met Glu Leu Asp Arg Leu Ile Ser Asp Asp Thr Ala Val Tyr Tyr Cys
      85          90          95

Val Arg Trp Arg Ala Ala Ala Val Ile Met Asp Gln Phe Tyr Lys Met
      100          105          110

Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
      115          120          125

Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser
130          135          140

Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145          150          155          160

Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
      165          170          175

Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
      180          185          190

Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys
      195          200          205

Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Arg Glu
210          215          220

Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu
225          230          235          240

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
      245          250          255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
      260          265          270

Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
      275          280          285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
290          295          300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
305          310          315          320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
      325          330          335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
      340          345          350

Val Tyr Thr Leu Pro Pro Ala Gln Glu Glu Met Thr Lys Asn Gln Val
      355          360          365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val

```

-continued

370	375	380
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro		
385	390	395 400
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr		
	405	410 415
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val		
	420	425 430
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu		
	435	440 445
Ser Leu Gly Lys		
450		

<210> SEQ ID NO 164
 <211> LENGTH: 125
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 164

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Gln Pro Gly Ala		
1	5	10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn Ala Tyr		
	20	25 30
Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met		
	35	40 45
Gly Trp Ile Asn Pro Asn Phe Gly Gly Thr His Tyr Ala Arg Lys Phe		
	50	55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Ala Ser Ile Asn Thr Ala Tyr		
	65	70 75 80
Met Glu Leu Asp Arg Leu Ile Ser Asp Asp Thr Ala Val Tyr Tyr Cys		
	85	90 95
Val Arg Trp Arg Ala Ala Val Ile Met Asp Gln Phe Tyr Lys Met		
	100	105 110
Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser		
	115	120 125

<210> SEQ ID NO 165
 <211> LENGTH: 219
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 165

Ser Ser Glu Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln		
1	5	10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Tyr Asn		
	20	25 30
Pro Val Ser Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu		
	35	40 45
Ile Tyr Ser Asn Thr Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser		
	50	55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln		
	65	70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Thr Leu		

-continued

85	90	95
----	----	----

Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln
 100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
 115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
 130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
 145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
 165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
 180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
 195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> SEQ ID NO 166
 <211> LENGTH: 110
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 166

Ser Ser Glu Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Tyr Asn
20 25 30
Pro Val Ser Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Thr Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Thr Leu
85 90 95
Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105 110

<210> SEQ ID NO 167
 <211> LENGTH: 447
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 167

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Leu Ile Gly Thr Gly
20 25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Thr Pro Gly Lys Gly Met Glu
35 40 45
Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr His Pro Ser

-continued

50					55					60					
Leu	Lys	Ser	Arg	Val	Thr	Ile	Ser	Asp	Asp	Thr	Ser	Lys	Asn	Gln	Leu
65					70					75					80
Phe	Leu	Lys	Leu	Arg	Ser	Val	Thr	Ala	Ala	Asp	Thr	Ala	Gln	Tyr	Tyr
			85						90					95	
Cys	Ala	Arg	Tyr	Asn	Trp	Gly	Ile	Arg	Tyr	Phe	Asp	Phe	Trp	Gly	Arg
			100					105					110		
Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val
		115					120					125			
Phe	Pro	Leu	Ala	Pro	Cys	Ser	Arg	Ser	Thr	Ser	Glu	Ser	Thr	Ala	Ala
	130					135					140				
Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser
145					150					155					160
Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val
			165					170						175	
Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro
			180					185					190		
Ser	Ser	Ser	Leu	Gly	Thr	Lys	Thr	Tyr	Thr	Cys	Asn	Val	Asp	His	Lys
	195					200					205				
Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Thr	Arg	Glu	Ser	Lys	Tyr	Gly	Pro
	210					215					220				
Pro	Cys	Pro	Ser	Cys	Pro	Ala	Pro	Glu	Phe	Leu	Gly	Gly	Pro	Ser	Val
225					230					235					240
Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr
			245					250						255	
Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	Gln	Glu	Asp	Pro	Glu
		260						265					270		
Val	Gln	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys
		275					280					285			
Thr	Lys	Pro	Arg	Glu	Glu	Gln	Phe	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser
	290					295					300				
Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys
305					310					315					320
Cys	Lys	Val	Ser	Asn	Lys	Gly	Leu	Pro	Ser	Ser	Ile	Glu	Lys	Thr	Ile
			325					330						335	
Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro
		340						345					350		
Pro	Ala	Gln	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu
	355						360					365			
Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn
	370					375					380				
Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser
385					390					395					400
Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Arg	Leu	Thr	Val	Asp	Lys	Ser	Arg
			405					410						415	
Trp	Gln	Glu	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu
			420					425					430		
His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Leu	Gly	Lys	
	435						440						445		

<210> SEQ ID NO 168

<211> LENGTH: 120

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 168

```

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1           5           10           15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Leu Ile Gly Thr Gly
          20           25           30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Thr Pro Gly Lys Gly Met Glu
          35           40           45

Trp Ile Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr His Pro Ser
50           55           60

Leu Lys Ser Arg Val Thr Ile Ser Asp Asp Thr Ser Lys Asn Gln Leu
65           70           75           80

Phe Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Gln Tyr Tyr
          85           90           95

Cys Ala Arg Tyr Asn Trp Gly Ile Arg Tyr Phe Asp Phe Trp Gly Arg
          100          105          110

Gly Thr Leu Val Thr Val Ser Ser
          115          120

```

<210> SEQ ID NO 169
 <211> LENGTH: 216
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 169

```

Asp Ile Gln Leu Thr Gln Ser Pro Leu Ser Pro Pro Val Thr Leu Gly
1           5           10           15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Thr
          20           25           30

Asp Gly Phe Thr Tyr Leu Ser Trp Tyr His Gln Arg Pro Gly Gln Ser
          35           40           45

Pro Arg Arg Leu Ile Tyr Lys Ile Ser Asn Arg Asp Ser Gly Val Pro
50           55           60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
          85           90           95

Thr His Trp Pro Leu Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys
          100          105          110

Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
          115          120          125

Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
          130          135          140

Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
          145          150          155          160

Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
          165          170          175

Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
          180          185          190

Lys Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
          195          200          205

```

-continued

Thr Val Ala Pro Thr Glu Cys Ser
210 215

<210> SEQ ID NO 170
<211> LENGTH: 112
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide

<400> SEQUENCE: 170

Asp Ile Gln Leu Thr Gln Ser Pro Leu Ser Pro Pro Val Thr Leu Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Thr
20 25 30

Asp Gly Phe Thr Tyr Leu Ser Trp Tyr His Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Arg Leu Ile Tyr Lys Ile Ser Asn Arg Asp Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95

Thr His Trp Pro Leu Thr Phe Gly Glu Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> SEQ ID NO 171
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 171

Ser Val Ser His
1

<210> SEQ ID NO 172
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 172

Ser Val Asp Ser
1

<210> SEQ ID NO 173
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 173

Ser Val Ser Ser
1

-continued

<210> SEQ ID NO 174
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 174

Ser Val Asp His
1

<210> SEQ ID NO 175
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 175

Asn Phe Pro Pro
1

<210> SEQ ID NO 176
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 176

Asn Tyr Pro Pro
1

<210> SEQ ID NO 177
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 177

Asn Trp Pro Pro
1

<210> SEQ ID NO 178
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 178

Gly Phe Ala Phe His Asn Arg Ala Met His
1 5 10

<210> SEQ ID NO 179
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 179

-continued

Ala Leu Ile Tyr Phe Asp Gly Ser Lys Gln Tyr Tyr Ala Asp Ser Val
1 5 10 15

Lys Gly

<210> SEQ ID NO 180
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 180

Ala Val Pro Gly Pro Ile Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
1 5 10 15

Asp His Trp

<210> SEQ ID NO 181
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 181

Ala Val Pro Gly Pro Ile Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
1 5 10 15

Asp His

<210> SEQ ID NO 182
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 182

Arg Ala Ser Gln Ser Val Asp Ser Asn Leu Ala
1 5 10

<210> SEQ ID NO 183
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 183

Arg Ala Ser Gln Ser Val Ser His Asn Leu Ala
1 5 10

<210> SEQ ID NO 184
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 184

Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala
1 5 10

-continued

<210> SEQ ID NO 185
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 185

Arg Ala Ser Gln Ser Val Asp His Asn Leu Ala
1 5 10

<210> SEQ ID NO 186
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 186

Arg Ala Ser Gln Ser Val Asp Ser Asn Leu Ala
1 5 10

<210> SEQ ID NO 187
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 187

Ser Ala Ser Thr Arg Ala Thr
1 5

<210> SEQ ID NO 188
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 188

Gln His Tyr Thr Asn Trp Pro Pro Arg Leu Thr
1 5 10

<210> SEQ ID NO 189
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 189

Gln His Tyr Thr Asn Tyr Pro Pro Arg Leu Thr
1 5 10

<210> SEQ ID NO 190
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

-continued

<400> SEQUENCE: 190

Gln His Tyr Thr Asn Phe Pro Pro Arg Leu Thr
1 5 10

<210> SEQ ID NO 191

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 191

Gly Leu Thr Phe Ser Ser Tyr Ala Val His
1 5 10

<210> SEQ ID NO 192

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 192

Gly Pro Thr Phe Ser Ser Tyr Ala Val His
1 5 10

<210> SEQ ID NO 193

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 193

Thr Leu Ile Ser Tyr Asp Gly Ala Asn Gln Tyr Tyr Ala Asp Ser Val
1 5 10 15

Lys Gly

<210> SEQ ID NO 194

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 194

Ala Val Pro Gly Pro Val Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
1 5 10 15

Asp Asn

<210> SEQ ID NO 195

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 195

Arg Ala Ser Gln Val Ile Ser His Asn Leu Ala
1 5 10

-continued

<210> SEQ ID NO 196
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 196

Gly Ala Ser Thr Arg Ala Ser
1 5

<210> SEQ ID NO 197
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 197

Gln His Tyr Ser Asn Trp Pro Pro Arg Leu Thr
1 5 10

<210> SEQ ID NO 198
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 198

Gln His Tyr Ser Asn Phe Pro Pro Arg Leu Thr
1 5 10

<210> SEQ ID NO 199
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 199

Gln His Tyr Ser Asn Tyr Pro Pro Arg Leu Thr
1 5 10

<210> SEQ ID NO 200
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 200

Gly Ser Ile Phe Ser Asn Tyr Gly Ile Ser
1 5 10

<210> SEQ ID NO 201
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

-continued

<400> SEQUENCE: 201

Gly Gly Ile Ile Pro Ile Phe Gly Ala Ala Asn Tyr Ala Gln Lys Phe
1 5 10 15

Gln Gly

<210> SEQ ID NO 202

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 202

Ala Arg Arg Gln Gln Leu Tyr Lys Gly Tyr Tyr His His
1 5 10

<210> SEQ ID NO 203

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 203

Arg Ala Ser Gln Ser Val Ala Asn Asn Leu Ala
1 5 10

<210> SEQ ID NO 204

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 204

Gly Ala Ser Thr Arg Asp Thr
1 5

<210> SEQ ID NO 205

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 205

Gln Gln Tyr Asn Asn Trp Pro Pro Met Tyr Thr
1 5 10

<210> SEQ ID NO 206

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 206

Gly Tyr Ser Phe Asn Asn Tyr Gly Ile Asn
1 5 10

-continued

<210> SEQ ID NO 207
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 207

Gly Trp Ile Ser Ala Tyr Thr Gly Asn Thr His Tyr Ala Lys Asn Phe
1 5 10 15

Glu Gly

<210> SEQ ID NO 208
<211> LENGTH: 19
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 208

Ala Arg Ala Met Ile Gln Gly Val Val Thr Leu Tyr Leu Arg Pro Gly
1 5 10 15

Asp Tyr Trp

<210> SEQ ID NO 209
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 209

Arg Ala Ser Gln Ser Ile Gly Asn Trp Leu Ala
1 5 10

<210> SEQ ID NO 210
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 210

Lys Val Ser Thr Leu Glu Ser
1 5

<210> SEQ ID NO 211
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide

<400> SEQUENCE: 211

Gln Arg Tyr Thr Ser Asn Ser Gln Gly Phe Thr
1 5 10

<210> SEQ ID NO 212
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 212

Gly Tyr Thr Phe Asn Ala Tyr Tyr Ile His
1 5 10

<210> SEQ ID NO 213

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 213

Gly Trp Ile Asn Pro Asn Phe Gly Gly Thr His Tyr Ala Arg Lys Phe
1 5 10 15

Gln Gly

<210> SEQ ID NO 214

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 214

Val Arg Trp Arg Ala Ala Ala Val Ile Met Asp Gln Phe Tyr Lys Met
1 5 10 15

Asp Val

<210> SEQ ID NO 215

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 215

Ser Gly Ser Thr Ser Asn Ile Gly Tyr Asn Pro Val Ser
1 5 10

<210> SEQ ID NO 216

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 216

Ser Asn Thr Glu Arg Pro Ser
1 5

<210> SEQ ID NO 217

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 217

-continued

Ala Ala Trp Asp Asp Thr Leu Asn Gly Pro Val
1 5 10

<210> SEQ ID NO 218
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 218

Gly Gly Leu Ile Gly Thr Gly Ser Tyr Trp Gly
1 5 10

<210> SEQ ID NO 219
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 219

Gly Ser Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr His Pro Ser Leu Lys
1 5 10 15

Ser

<210> SEQ ID NO 220
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 220

Ala Arg Tyr Asn Trp Gly Ile Arg Tyr Phe Asp Phe
1 5 10

<210> SEQ ID NO 221
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 221

Arg Ser Ser Gln Ser Leu Leu Tyr Thr Asp Gly Phe Thr Tyr Leu Ser
1 5 10 15

<210> SEQ ID NO 222
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 222

Lys Ile Ser Asn Arg Asp Ser
1 5

<210> SEQ ID NO 223
 <211> LENGTH: 9
 <212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 223

Met Gln Ala Thr His Trp Pro Leu Thr
 1 5

<210> SEQ ID NO 224
 <211> LENGTH: 566
 <212> TYPE: PRT
 <213> ORGANISM: Influenza A virus
 <220> FEATURE:
 <221> NAME/KEY: MOD_RES
 <222> LOCATION: (239)..(240)
 <223> OTHER INFORMATION: Any amino acid

<400> SEQUENCE: 224

Met Lys Ala Ile Leu Val Val Leu Leu Tyr Thr Phe Ala Thr Ala Asn
 1 5 10 15
 Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr
 20 25 30
 Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn
 35 40 45
 Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Arg Gly Val
 50 55 60
 Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly
 65 70 75 80
 Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Ser Ser Trp Ser Tyr Ile
 85 90 95
 Val Glu Thr Pro Ser Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe
 100 105 110
 Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe
 115 120 125
 Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Asp
 130 135 140
 Ser Asn Lys Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser
 145 150 155 160
 Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Asn Ser Tyr Pro
 165 170 175
 Lys Leu Ser Lys Ser Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val
 180 185 190
 Leu Trp Gly Ile His His Pro Ser Thr Ser Ala Asp Gln Gln Ser Leu
 195 200 205
 Tyr Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Ser Ser Arg Tyr Ser
 210 215 220
 Lys Lys Phe Lys Pro Glu Ile Ala Ile Arg Pro Lys Val Arg Xaa Xaa
 225 230 235 240
 Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu Pro Gly Asp Lys
 245 250 255
 Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Val Pro Arg Tyr Ala Phe
 260 265 270
 Ala Met Glu Arg Asn Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro
 275 280 285
 Val His Asp Cys Asn Thr Thr Cys Gln Thr Pro Lys Gly Ala Ile Asn
 290 295 300

-continued

Thr Ser Leu Pro Phe Gln Asn Ile His Pro Ile Thr Ile Gly Lys Cys
 305 310 315 320
 Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg
 325 330 335
 Asn Ile Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly
 340 345 350
 Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr Gly Tyr
 355 360 365
 His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Leu Lys Ser
 370 375 380
 Thr Gln Asn Ala Ile Asp Glu Ile Thr Asn Lys Val Asn Ser Val Ile
 385 390 395 400
 Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His
 405 410 415
 Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe
 420 425 430
 Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn
 435 440 445
 Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu
 450 455 460
 Lys Val Arg Ser Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly
 465 470 475 480
 Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys Met Glu Ser Val
 485 490 495
 Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Lys Leu
 500 505 510
 Asn Arg Glu Glu Ile Asp Gly Val Lys Leu Glu Ser Thr Arg Ile Tyr
 515 520 525
 Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Val
 530 535 540
 Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu
 545 550 555 560
 Gln Cys Arg Ile Cys Ile
 565

<210> SEQ ID NO 225

<211> LENGTH: 562

<212> TYPE: PRT

<213> ORGANISM: Influenza A virus

<400> SEQUENCE: 225

Met Ala Ile Ile Tyr Leu Ile Leu Leu Phe Thr Ala Val Arg Gly Asp
 1 5 10 15
 Gln Ile Cys Ile Gly Tyr His Ala Asn Ser Thr Glu Met Val Asp
 20 25 30
 Thr Ile Leu Glu Arg Asn Val Thr Val Thr His Ala Lys Asp Ile Leu
 35 40 45
 Glu Lys Thr His Asn Gly Lys Leu Cys Lys Leu Asn Gly Ile Pro Pro
 50 55 60
 Leu Glu Leu Gly Asp Cys Ser Ile Ala Gly Trp Leu Leu Gly Asn Pro
 65 70 75 80
 Glu Cys Asp Arg Leu Leu Ser Val Pro Glu Trp Ser Tyr Ile Met Glu
 85 90 95
 Lys Glu Asn Pro Arg Asp Gly Leu Cys Tyr Pro Gly Ser Phe Asn Asp
 100 105 110

-continued

Tyr Glu Glu Leu Lys His Leu Leu Ser Ser Val Lys His Phe Glu Lys
 115 120 125
 Val Lys Ile Leu Pro Lys Asp Arg Trp Thr Gln His Thr Thr Thr Gly
 130 135 140
 Gly Ser Arg Ala Cys Ala Val Ser Gly Asn Pro Ser Phe Phe Arg Asn
 145 150 155 160
 Met Val Trp Leu Thr Lys Lys Gly Ser Asp Tyr Pro Val Ala Lys Gly
 165 170 175
 Ser Tyr Asn Asn Thr Ser Gly Glu Gln Met Leu Ile Ile Trp Gly Val
 180 185 190
 His His Pro Asn Asp Glu Thr Glu Gln Arg Thr Leu Tyr Gln Asn Val
 195 200 205
 Gly Thr Tyr Val Ser Val Gly Thr Ser Thr Leu Asn Lys Arg Ser Thr
 210 215 220
 Pro Glu Ile Ala Thr Arg Leu Lys Val Asn Gly Gln Gly Gly Arg Met
 225 230 235 240
 Glu Phe Ser Trp Thr Leu Leu Asp Met Trp Asp Thr Ile Asn Phe Glu
 245 250 255
 Ser Thr Gly Asn Leu Ile Ala Pro Glu Tyr Gly Phe Lys Ile Ser Lys
 260 265 270
 Arg Gly Ser Ser Gly Ile Met Lys Thr Glu Gly Thr Leu Glu Asn Cys
 275 280 285
 Glu Thr Lys Cys Gln Thr Pro Leu Gly Ala Ile Asn Thr Thr Leu Pro
 290 295 300
 Phe His Asn Val His Pro Leu Thr Ile Gly Glu Cys Pro Lys Tyr Val
 305 310 315 320
 Lys Ser Glu Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Val Pro Gln
 325 330 335
 Ile Glu Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Gly
 340 345 350
 Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly Tyr His His Ser Asn
 355 360 365
 Asp Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu Ser Thr Gln Lys Ala
 370 375 380
 Phe Asp Gly Ile Thr Asn Lys Val Asn Ser Val Ile Glu Lys Met Asn
 385 390 395 400
 Thr Gln Phe Glu Ala Val Gly Lys Glu Phe Ser Asn Leu Glu Arg Arg
 405 410 415
 Leu Glu Asn Leu Asn Lys Lys Met Glu Asp Gly Phe Leu Asp Val Trp
 420 425 430
 Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg Thr Leu
 435 440 445
 Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp Lys Val Arg Met
 450 455 460
 Gln Leu Arg Asp Asn Val Lys Glu Leu Gly Asn Gly Cys Phe Glu Phe
 465 470 475 480
 Tyr His Lys Cys Asp Asp Glu Cys Met Asn Ser Val Lys Thr Gly Thr
 485 490 495
 Tyr Asp Tyr Pro Lys Tyr Glu Glu Glu Ser Lys Leu Asn Arg Asn Glu
 500 505 510
 Ile Lys Gly Val Lys Leu Ser Ser Met Gly Val Tyr Gln Ile Leu Ala
 515 520 525

-continued

Ile Tyr Ala Thr Val Ala Gly Ser Leu Ser Leu Ala Ile Met Met Ala
530 535 540

Gly Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu Gln Cys Arg Ile
545 550 555 560

Cys Ile

<210> SEQ ID NO 226

<211> LENGTH: 566

<212> TYPE: PRT

<213> ORGANISM: Influenza A virus

<400> SEQUENCE: 226

Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Val Phe Ala
1 5 10 15

Gln Lys Leu Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly
20 25 30

His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp
35 40 45

Gln Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Ser Ser Ser Thr
50 55 60

Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Lys Asn Cys
65 70 75 80

Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln
85 90 95

Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Ser Lys Ala Tyr Ser Asn
100 105 110

Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val
115 120 125

Ala Ser Ser Gly Thr Leu Glu Phe Asn Asn Glu Ser Phe Asn Trp Thr
130 135 140

Gly Val Thr Gln Asn Gly Thr Ser Ser Ala Cys Ile Arg Arg Ser Lys
145 150 155 160

Asn Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Phe Lys
165 170 175

Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Asn Glu Gln Phe Asp Lys
180 185 190

Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile
195 200 205

Phe Leu Tyr Ala Gln Ala Ser Gly Arg Ile Thr Val Ser Thr Lys Arg
210 215 220

Ser Gln Gln Thr Val Ser Pro Asn Ile Gly Ser Arg Pro Arg Val Arg
225 230 235 240

Asn Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly
245 250 255

Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly
260 265 270

Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala
275 280 285

Pro Ile Gly Lys Cys Asn Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile
290 295 300

Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala
305 310 315 320

Cys Pro Arg Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met
325 330 335

-continued

Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala
 340 345 350
 Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly
 355 360 365
 Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys
 370 375 380
 Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu
 385 390 395 400
 Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser
 405 410 415
 Glu Val Glu Gly Arg Ile Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr
 420 425 430
 Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu
 435 440 445
 Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe
 450 455 460
 Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn
 465 470 475 480
 Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser
 485 490 495
 Ile Arg Asn Gly Thr Tyr Asp His Asp Val Tyr Arg Asp Glu Ala Leu
 500 505 510
 Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys
 515 520 525
 Asp Trp Ile Leu Trp Ile Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys
 530 535 540
 Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile
 545 550 555 560
 Arg Cys Asn Ile Cys Ile
 565

<210> SEQ ID NO 227

<211> LENGTH: 568

<212> TYPE: PRT

<213> ORGANISM: Influenza A virus

<400> SEQUENCE: 227

Met Glu Lys Ile Val Leu Leu Phe Ala Ile Val Ser Leu Val Lys Ser
 1 5 10 15
 Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val
 20 25 30
 Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile
 35 40 45
 Leu Glu Lys Lys His Asn Gly Lys Leu Cys Asp Leu Asp Gly Val Lys
 50 55 60
 Pro Leu Ile Leu Arg Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn
 65 70 75 80
 Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val
 85 90 95
 Glu Lys Ala Asn Pro Val Asn Asp Leu Cys Tyr Pro Gly Asp Phe Asn
 100 105 110
 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu
 115 120 125
 Lys Ile Gln Ile Ile Pro Lys Ser Ser Trp Ser Ser His Glu Ala Ser
 130 135 140

-continued

Leu Gly Val Ser Ser Ala Cys Pro Tyr Gln Gly Lys Ser Ser Phe Phe															
145					150					155					160
Arg Asn Val Val Trp Leu Ile Lys Lys Asn Ser Thr Tyr Pro Thr Ile															
				165					170					175	
Lys Arg Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp															
			180					185					190		
Gly Ile His His Pro Asn Asp Ala Ala Glu Gln Thr Lys Leu Tyr Gln															
			195				200					205			
Asn Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg															
			210			215				220					
Leu Val Pro Arg Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly															
					230				235						240
Arg Met Glu Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn															
				245				250						255	
Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile															
			260				265						270		
Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Leu Glu Tyr Gly															
			275			280						285			
Asn Cys Asn Thr Lys Cys Gln Thr Pro Met Gly Ala Ile Asn Ser Ser															
			290			295				300					
Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys															
					310				315						320
Tyr Val Lys Ser Asn Arg Leu Val Leu Ala Thr Gly Leu Arg Asn Ser															
				325				330						335	
Pro Gln Arg Glu Arg Arg Arg Lys Lys Arg Gly Leu Phe Gly Ala Ile															
				340			345						350		
Ala Gly Phe Ile Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr															
			355			360				365					
Gly Tyr His His Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys															
			370			375				380					
Glu Ser Thr Gln Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser															
			385			390			395						400
Ile Ile Asp Lys Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe															
				405				410						415	
Asn Asn Leu Glu Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp															
				420			425						430		
Gly Phe Leu Asp Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met															
				435			440					445			
Glu Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu															
				450		455				460					
Tyr Asp Lys Val Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly															
				465		470			475						480
Asn Gly Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu															
				485			490							495	
Ser Val Arg Asn Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala															
				500			505						510		
Arg Leu Lys Arg Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly															
				515			520					525			
Ile Tyr Gln Ile Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Ala															
			530			535				540					
Leu Ala Ile Met Val Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly															
				545		550			555						560

-continued

Ser Leu Gln Cys Arg Ile Cys Ile
565

<210> SEQ ID NO 228

<211> LENGTH: 562

<212> TYPE: PRT

<213> ORGANISM: Influenza A virus

<400> SEQUENCE: 228

Met Asn Thr Arg Ile Leu Ile Leu Thr Leu Thr Ala Val Ile His Thr
1 5 10 15

Asn Ala Asp Lys Ile Cys Leu Gly His His Ala Val Ser Asn Gly Thr
20 25 30

Lys Val Asn Thr Leu Thr Glu Arg Gly Val Glu Val Val Asn Ala Thr
35 40 45

Glu Thr Val Glu Gln Met Asn Ile Pro Arg Ile Cys Thr Lys Gly Lys
50 55 60

Lys Ala Ile Asp Leu Gly Gln Cys Gly Leu Leu Gly Ile Val Thr Gly
65 70 75 80

Pro Pro Gln Cys Asp Gln Phe Leu Glu Phe Thr Ala Asp Leu Ile Ile
85 90 95

Glu Arg Arg Glu Gly Asn Asp Val Cys Tyr Pro Gly Lys Phe Val Asn
100 105 110

Glu Glu Ala Leu Arg Gln Ile Leu Arg Gly Ser Gly Gly Ile Asn Lys
115 120 125

Glu Thr Thr Gly Phe Thr Tyr Ser Gly Ile Arg Thr Asn Gly Val Thr
130 135 140

Ser Ala Cys Arg Arg Ser Glu Ser Ser Phe Tyr Ala Glu Met Lys Trp
145 150 155 160

Leu Leu Ser Asn Thr Asp Asn Ala Ala Phe Pro Gln Met Thr Lys Ser
165 170 175

Tyr Lys Asn Thr Arg Asn Glu Pro Ala Leu Ile Val Trp Gly Ile His
180 185 190

His Ser Gly Ser Thr Thr Glu Gln Thr Lys Leu Tyr Gly Ser Gly Ser
195 200 205

Lys Leu Ile Thr Val Gly Ser Ser Asn Tyr Gln Gln Ser Phe Val Pro
210 215 220

Ser Pro Gly Ala Arg Pro Gln Val Asn Gly Gln Ser Gly Arg Ile Asp
225 230 235 240

Phe His Trp Leu Ile Leu Asn Pro Asn Asp Thr Val Thr Phe Ser Phe
245 250 255

Asn Gly Ala Phe Val Ala Pro Asp Arg Val Ser Phe Phe Lys Gly Glu
260 265 270

Ser Thr Gly Ile Gln Ser Glu Val Pro Val Asp Ala Asn Cys Glu Gly
275 280 285

Glu Cys Tyr His Ser Gly Gly Thr Ile Thr Ser Asn Leu Pro Phe Gln
290 295 300

Asn Val Asn Ser Arg Ala Val Gly Lys Cys Pro Lys Tyr Val Lys Gln
305 310 315 320

Lys Ser Leu Leu Leu Ala Thr Gly Met Lys Asn Val Pro Glu Ile Pro
325 330 335

Arg Lys Arg Lys Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu
340 345 350

Asn Gly Trp Glu Gly Leu Val Asp Gly Trp Tyr Gly Phe Arg His Gln
355 360 365

-continued

```

Asn Ser Gln Gly Glu Gly Thr Ala Ala Asp Tyr Lys Ser Thr Gln Ser
370                               375                               380

Ala Ile Asp Gln Ile Thr Gly Lys Leu Asn Arg Leu Ile Glu Lys Thr
385                               390                               395                               400

Asn Gln Gln Phe Glu Leu Ile Asp Asn Glu Phe Asn Glu Val Glu Lys
405                               410                               415

Gln Ile Gly Asn Val Ile Asn Trp Thr Arg Asp Ser Ile Thr Glu Val
420                               425                               430

Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Met Glu Asn Gln His Thr
435                               440                               445

Ile Asp Leu Ala Asp Ser Glu Met Asn Lys Leu Tyr Glu Arg Val Arg
450                               455                               460

Arg Gln Leu Arg Glu Asn Ala Glu Glu Asp Gly Thr Gly Cys Phe Glu
465                               470                               475                               480

Ile Phe His Lys Cys Asp Asp Asp Cys Met Ala Ser Ile Arg Asn Asn
485                               490                               495

Thr Tyr Asp His Ser Thr Tyr Arg Glu Glu Ala Met Gln Asn Arg Leu
500                               505                               510

Lys Ile Asp Pro Val Lys Leu Ser Ser Gly Tyr Lys Asp Val Ile Leu
515                               520                               525

Trp Phe Ser Phe Gly Ala Ser Cys Phe Leu Leu Leu Ala Ile Ala Met
530                               535                               540

Gly Leu Gly Phe Ile Cys Val Lys Asn Gly Asn Met Arg Cys Thr Ile
545                               550                               555                               560

Cys Ile

```

```

<210> SEQ ID NO 229
<211> LENGTH: 566
<212> TYPE: PRT
<213> ORGANISM: Influenza A virus

```

```

<400> SEQUENCE: 229

```

```

Met Lys Ala Ile Leu Val Val Leu Leu Tyr Thr Phe Ala Thr Ala Asn
1      5      10      15

Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr
20     25     30

Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn
35     40     45

Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Arg Gly Val
50     55     60

Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly
65     70     75     80

Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Ser Ser Trp Ser Tyr Ile
85     90     95

Val Glu Thr Pro Ser Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe
100    105    110

Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe
115    120    125

Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Asp
130    135    140

Ser Asn Lys Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser
145    150    155    160

Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Asn Ser Tyr Pro
165    170    175

```

-continued

Lys Leu Ser Lys Ser Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val
 180 185 190
 Leu Trp Gly Ile His His Pro Ser Thr Ser Ala Asp Gln Gln Ser Leu
 195 200 205
 Tyr Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Ser Ser Arg Tyr Ser
 210 215 220
 Lys Lys Phe Lys Pro Glu Ile Ala Ile Arg Pro Lys Val Arg Asp Gln
 225 230 235 240
 Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu Pro Gly Asp Lys
 245 250 255
 Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Val Pro Arg Tyr Ala Phe
 260 265 270
 Ala Met Glu Arg Asn Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro
 275 280 285
 Val His Asp Cys Asn Thr Thr Cys Gln Thr Pro Lys Gly Ala Ile Asn
 290 295 300
 Thr Ser Leu Pro Phe Gln Asn Ile His Pro Ile Thr Ile Gly Lys Cys
 305 310 315 320
 Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg
 325 330 335
 Asn Ile Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly
 340 345 350
 Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr Gly Tyr
 355 360 365
 His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Leu Lys Ser
 370 375 380
 Thr Gln Asn Ala Ile Asp Glu Ile Thr Asn Lys Val Asn Ser Val Ile
 385 390 395 400
 Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His
 405 410 415
 Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe
 420 425 430
 Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn
 435 440 445
 Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu
 450 455 460
 Lys Val Arg Ser Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly
 465 470 475 480
 Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys Met Glu Ser Val
 485 490 495
 Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Lys Leu
 500 505 510
 Asn Arg Glu Glu Ile Asp Gly Val Lys Leu Glu Ser Thr Arg Ile Tyr
 515 520 525
 Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Val
 530 535 540
 Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu
 545 550 555 560
 Gln Cys Arg Ile Cys Ile
 565

<210> SEQ ID NO 230

<211> LENGTH: 565

-continued

<212> TYPE: PRT

<213> ORGANISM: Influenza A virus

<400> SEQUENCE: 230

```

Met Lys Ala Lys Leu Leu Val Leu Leu Tyr Ala Phe Val Ala Thr Asp
 1          5          10          15

Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr
 20          25          30

Val Asp Thr Ile Phe Glu Lys Asn Val Ala Val Thr His Ser Val Asn
 35          40          45

Leu Leu Glu Asp Arg His Asn Gly Lys Leu Cys Lys Leu Lys Gly Ile
 50          55          60

Ala Pro Leu Gln Leu Gly Lys Cys Asn Ile Thr Gly Trp Leu Leu Gly
 65          70          75          80

Asn Pro Glu Cys Asp Ser Leu Leu Pro Ala Arg Ser Trp Ser Tyr Ile
 85          90          95

Val Glu Thr Pro Asn Ser Glu Asn Gly Ala Cys Tyr Pro Gly Asp Phe
100          105          110

Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Leu
115          120          125

Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Asn His Thr
130          135          140

Phe Asn Gly Val Thr Val Ser Cys Ser His Arg Gly Lys Ser Ser Phe
145          150          155          160

Tyr Arg Asn Leu Leu Trp Leu Thr Lys Lys Gly Asp Ser Tyr Pro Lys
165          170          175

Leu Thr Asn Ser Tyr Val Asn Asn Lys Gly Lys Glu Val Leu Val Leu
180          185          190

Trp Gly Val His His Pro Ser Ser Ser Asp Glu Gln Gln Ser Leu Tyr
195          200          205

Ser Asn Gly Asn Ala Tyr Val Ser Val Ala Ser Ser Asn Tyr Asn Arg
210          215          220

Arg Phe Thr Pro Glu Ile Ala Ala Arg Pro Lys Val Lys Asp Gln His
225          230          235          240

Gly Arg Met Asn Tyr Tyr Trp Thr Leu Leu Glu Pro Gly Asp Thr Ile
245          250          255

Ile Phe Glu Ala Thr Gly Asn Leu Ile Ala Pro Trp Tyr Ala Phe Ala
260          265          270

Leu Ser Arg Gly Phe Glu Ser Gly Ile Ile Thr Ser Asn Ala Ser Met
275          280          285

His Glu Cys Asn Thr Lys Cys Gln Thr Pro Gln Gly Ser Ile Asn Ser
290          295          300

Asn Leu Pro Phe Gln Asn Ile His Pro Val Thr Ile Gly Glu Cys Pro
305          310          315          320

Lys Tyr Val Arg Ser Thr Lys Leu Arg Met Val Thr Gly Leu Arg Asn
325          330          335

Ile Pro Ser Ile Gln Tyr Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe
340          345          350

Ile Glu Gly Gly Trp Thr Gly Met Ile Asp Gly Trp Tyr Gly Tyr His
355          360          365

His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Gln Lys Ser Thr
370          375          380

Gln Asn Ala Ile Asn Gly Ile Thr Asn Lys Val Asn Ser Val Ile Glu
385          390          395          400

```

Met 1	Lys	Thr	Ile 5	Ile	Ala	Leu	Ser	Tyr	Ile 10	Phe	Cys	Leu	Ala	Leu 15	Gly
Gln	Asp	Leu	Pro 20	Gly	Asn	Asp	Asn	Ser 25	Thr	Ala	Thr	Leu	Cys 30	Leu	Gly
His	His 35	Ala	Val	Pro	Asn	Gly	Thr 40	Leu	Val	Lys	Thr	Ile 45	Thr	Asp	Asp
Gln	Ile 50	Glu	Val	Thr	Asn 55	Ala	Thr	Glu	Leu	Val	Gln 60	Ser	Ser	Ser	Thr
Gly 65	Lys	Ile	Cys	Asn 70	Asn	Pro	His	Arg	Ile	Leu 75	Asp	Gly	Ile	Asp	Cys 80
Thr	Leu	Ile	Asp	Ala 85	Leu	Leu	Gly	Asp 90	Pro	His	Cys	Asp	Val	Phe 95	Gln
Asn	Glu	Thr	Trp 100	Asp	Leu	Phe	Val	Glu 105	Arg	Ser	Lys	Ala	Phe 110	Ser	Asn
Cys	Tyr	Pro 115	Tyr	Asp	Val	Pro	Asp 120	Tyr	Ala	Ser	Leu	Arg 125	Ser	Leu	Val
Ala	Ser 130	Ser	Gly	Thr	Leu	Glu 135	Phe	Ile	Thr	Glu	Gly 140	Phe	Thr	Trp	Thr
Gly 145	Val	Thr	Gln	Asn 150	Gly	Gly	Ser	Asn	Ala	Cys 155	Lys	Arg	Gly	Pro	Gly 160
Asn	Gly	Phe	Phe 165	Ser	Arg	Leu	Asn	Trp 170	Leu	Thr	Lys	Ser	Gly	Ser 175	Thr
Tyr	Pro	Val 180	Leu	Asn	Val	Thr	Met 185	Pro	Asn	Asn	Asp	Asn	Phe 190	Asp	Lys
Leu	Tyr	Ile	Trp	Gly	Val	His	His	Pro	Ser	Thr	Asn	Gln	Glu	Gln	Thr

-continued

195					200					205					
Ser	Leu	Tyr	Val	Gln	Glu	Ser	Gly	Arg	Val	Thr	Val	Ser	Thr	Arg	Arg
210						215					220				
Ser	Gln	Gln	Ser	Ile	Ile	Pro	Asn	Ile	Gly	Ser	Arg	Pro	Trp	Val	Arg
225						230					235				240
Gly	Gln	Ser	Ser	Arg	Ile	Ser	Ile	Tyr	Trp	Thr	Ile	Val	Lys	Pro	Gly
						245					250				255
Asp	Val	Leu	Val	Ile	Asn	Ser	Asn	Gly	Asn	Leu	Ile	Ala	Pro	Arg	Gly
						260					265				270
Tyr	Phe	Lys	Met	Arg	Thr	Gly	Lys	Ser	Ser	Ile	Met	Ser	Ser	Asp	Ala
						275					280				285
Pro	Ile	Asp	Thr	Cys	Ile	Ser	Glu	Cys	Ile	Thr	Pro	Asn	Gly	Ser	Ile
						290					295				300
Pro	Asn	Asp	Lys	Pro	Phe	Gln	Asn	Val	Asn	Lys	Ile	Thr	Tyr	Gly	Ala
305						310					315				320
Cys	Pro	Lys	Tyr	Val	Lys	Gln	Asn	Thr	Leu	Lys	Leu	Ala	Thr	Gly	Met
						325					330				335
Arg	Asn	Val	Pro	Glu	Lys	Gln	Thr	Arg	Gly	Leu	Phe	Gly	Ala	Ile	Ala
						340					345				350
Gly	Phe	Ile	Glu	Asn	Gly	Trp	Glu	Gly	Met	Ile	Asp	Gly	Trp	Tyr	Gly
						355					360				365
Phe	Arg	His	Gln	Asn	Ser	Glu	Gly	Thr	Gly	Gln	Ala	Ala	Asp	Leu	Lys
						370					375				380
Ser	Thr	Gln	Ala	Ala	Ile	Asp	Gln	Ile	Asn	Gly	Lys	Leu	Asn	Arg	Val
385						390					395				400
Ile	Glu	Lys	Thr	Asn	Glu	Lys	Phe	His	Gln	Ile	Glu	Lys	Glu	Phe	Ser
						405					410				415
Glu	Val	Glu	Gly	Arg	Ile	Gln	Asp	Leu	Glu	Lys	Tyr	Val	Glu	Asp	Thr
						420					425				430
Lys	Ile	Asp	Leu	Trp	Ser	Tyr	Asn	Ala	Glu	Leu	Leu	Val	Ala	Leu	Glu
						435					440				445
Asn	Gln	His	Thr	Ile	Asp	Leu	Thr	Asp	Ser	Glu	Met	Asn	Lys	Leu	Phe
						450					455				460
Glu	Lys	Thr	Arg	Arg	Gln	Leu	Arg	Glu	Asn	Ala	Glu	Asp	Met	Gly	Asn
465						470					475				480
Gly	Cys	Phe	Lys	Ile	Tyr	His	Lys	Cys	Asp	Asn	Ala	Cys	Ile	Glu	Ser
						485					490				495
Ile	Arg	Asn	Gly	Thr	Tyr	Asp	His	Asp	Val	Tyr	Arg	Asp	Glu	Ala	Leu
						500					505				510
Asn	Asn	Arg	Phe	Gln	Ile	Lys	Gly	Val	Glu	Leu	Lys	Ser	Gly	Tyr	Lys
						515					520				525
Asp	Trp	Ile	Leu	Trp	Ile	Ser	Phe	Ala	Ile	Ser	Cys	Phe	Leu	Leu	Cys
						530					535				540
Val	Val	Leu	Leu	Gly	Phe	Ile	Met	Trp	Ala	Cys	Gln	Arg	Gly	Asn	Ile
545						550					555				560
Arg	Cys	Asn	Ile	Cys	Ile										
						565									

<210> SEQ ID NO 232

<211> LENGTH: 562

<212> TYPE: PRT

<213> ORGANISM: Influenza A virus

<400> SEQUENCE: 232

-continued

Met 1	Asn	Thr	Gln	Ile 5	Leu	Val	Phe	Ala	Leu 10	Val	Ala	Ser	Ile	Pro 15	Thr
Asn	Ala	Asp	Lys 20	Ile	Cys	Leu	Gly	His 25	His	Ala	Val	Ser	Asn 30	Gly	Thr
Lys	Val	Asn	Thr 35	Leu	Thr	Glu	Arg 40	Gly	Val	Glu	Val	Val 45	Asn	Ala	Thr
Glu	Thr 50	Val	Glu	Arg	Thr	Asn 55	Val	Pro	Arg	Ile	Cys 60	Ser	Lys	Gly	Lys
Arg 65	Thr	Val	Asp	Leu	Gly 70	Gln	Cys	Gly	Leu	Leu 75	Gly	Thr	Ile	Thr	Gly 80
Pro	Pro	Gln	Cys 85	Asp	Gln	Phe	Leu	Glu	Phe 90	Ser	Ala	Asp	Leu 95	Ile	Ile
Glu	Arg	Arg	Glu 100	Gly	Ser	Asp	Val	Cys 105	Tyr	Pro	Gly	Lys 110	Phe	Val	Asn
Glu	Glu	Ala	Leu 115	Arg	Gln	Ile	Leu 120	Arg	Glu	Ser	Gly	Gly 125	Ile	Asp	Lys
Glu	Thr 130	Met	Gly	Phe	Thr	Tyr 135	Ser	Gly	Ile	Arg	Thr 140	Asn	Gly	Thr	Thr
Ser 145	Ala	Cys	Arg	Arg	Ser 150	Gly	Ser	Ser	Phe	Tyr 155	Ala	Glu	Met	Lys	Trp 160
Leu	Leu	Ser	Asn 165	Thr	Asp	Asn	Ala	Ala	Phe 170	Pro	Gln	Met	Thr 175	Lys	Ser
Tyr	Lys	Asn	Thr 180	Arg	Lys	Asp	Pro	Ala 185	Leu	Ile	Ile	Trp 190	Gly	Ile	His
His	Ser	Gly 195	Ser	Thr	Thr	Glu	Gln 200	Thr	Lys	Leu	Tyr	Gly 205	Ser	Gly	Asn
Lys	Leu 210	Ile	Thr	Val	Gly	Ser 215	Ser	Asn	Tyr	Gln	Gln 220	Ser	Phe	Val	Pro
Ser 225	Pro	Gly	Ala	Arg	Pro 230	Gln	Val	Asn	Gly	Gln 235	Ser	Gly	Arg	Ile	Asp 240
Phe	His	Trp	Leu 245	Ile	Leu	Asn	Pro	Asn	Asp 250	Thr	Val	Thr	Phe 255	Ser	Phe
Asn	Gly	Ala	Phe 260	Ile	Ala	Pro	Asp	Arg 265	Ala	Ser	Phe	Leu 270	Arg	Gly	Lys
Ser	Met	Gly 275	Ile	Gln	Ser	Glu	Val 280	Gln	Val	Asp	Ala	Asn 285	Cys	Glu	Gly
Asp 290	Cys	Tyr	His	Ser	Gly	Gly 295	Thr	Ile	Ile	Ser	Asn 300	Leu	Pro	Phe	Gln
Asn 305	Ile	Asn	Ser	Arg	Ala 310	Val	Gly	Lys	Cys	Pro 315	Arg	Tyr	Val	Lys	Gln 320
Glu	Ser	Leu	Leu 325	Leu	Ala	Thr	Gly	Met	Lys 330	Asn	Val	Pro	Glu	Ile	Pro 335
Lys	Arg	Arg	Arg 340	Arg	Gly	Leu	Phe	Gly 345	Ala	Ile	Ala	Gly	Phe 350	Ile	Glu
Asn	Gly	Trp 355	Glu	Gly	Leu	Ile	Asp 360	Gly	Trp	Tyr	Gly	Phe 365	Arg	His	Gln
Asn 370	Ala	Gln	Gly	Glu	Gly	Thr 375	Ala	Ala	Asp	Tyr	Lys 380	Ser	Thr	Gln	Ser
Ala 385	Ile	Asp	Gln	Ile	Thr 390	Gly	Lys	Leu	Asn	Arg 395	Leu	Ile	Glu	Lys	Thr 400
Asn	Gln	Gln	Phe 405	Glu	Leu	Ile	Asp	Asn	Glu	Phe 410	Thr	Glu	Val	Glu	Arg 415
Gln	Ile	Gly	Asn	Val	Ile	Asn	Trp	Thr	Arg	Asp	Ser	Met	Thr	Glu	Val

```

      420              425              430
Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Met Glu Asn Gln His Thr
      435              440              445

Ile Asp Leu Ala Asp Ser Glu Met Asn Lys Leu Tyr Glu Arg Val Lys
      450              455              460

Arg Gln Leu Arg Glu Asn Ala Glu Glu Asp Gly Thr Gly Cys Phe Glu
465              470              475              480

Ile Phe His Lys Cys Asp Asp Asp Cys Met Ala Ser Ile Arg Asn Asn
      485              490              495

Thr Tyr Asp His Ser Lys Tyr Arg Glu Glu Ala Ile Gln Asn Arg Ile
      500              505              510

Gln Ile Asp Pro Val Lys Leu Ser Ser Gly Tyr Lys Asp Val Ile Leu
      515              520              525

Trp Phe Ser Phe Gly Ala Ser Cys Phe Ile Leu Leu Ala Ile Ala Met
      530              535              540

Gly Leu Val Phe Ile Cys Val Lys Asn Gly Asn Met Arg Cys Thr Ile
545              550              555              560

Cys Ile

<210> SEQ ID NO 233
<211> LENGTH: 566
<212> TYPE: PRT
<213> ORGANISM: Influenza A virus

<400> SEQUENCE: 233

Met Glu Ala Arg Leu Leu Val Leu Leu Cys Ala Phe Ala Ala Thr Asn
1              5              10              15

Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr
      20              25              30

Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn
      35              40              45

Leu Leu Glu Asp Ser His Asn Gly Lys Leu Cys Lys Leu Lys Gly Ile
      50              55              60

Ala Pro Leu Gln Leu Gly Lys Cys Asn Ile Ala Gly Trp Leu Leu Gly
65              70              75              80

Asn Pro Glu Cys Asp Leu Leu Leu Thr Ala Ser Ser Trp Ser Tyr Ile
      85              90              95

Val Glu Thr Ser Asn Ser Glu Asn Gly Thr Cys Tyr Pro Gly Asp Phe
      100              105              110

Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe
      115              120              125

Glu Lys Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Glu
      130              135              140

Thr Thr Lys Gly Val Thr Ala Ala Cys Ser Tyr Ala Gly Ala Ser Ser
145              150              155              160

Phe Tyr Arg Asn Leu Leu Trp Leu Thr Lys Lys Gly Ser Ser Tyr Pro
      165              170              175

Lys Leu Ser Lys Ser Tyr Val Asn Asn Lys Gly Lys Glu Val Leu Val
      180              185              190

Leu Trp Gly Val His His Pro Pro Thr Gly Thr Asp Gln Gln Ser Leu
      195              200              205

Tyr Gln Asn Ala Asp Ala Tyr Val Ser Val Gly Ser Ser Lys Tyr Asn
      210              215              220

Arg Arg Phe Thr Pro Glu Ile Ala Ala Arg Pro Lys Val Arg Asp Gln

```

-continued

225	230	235	240
Ala Gly Arg Met Asn Tyr Tyr Trp Thr Leu Leu Glu Pro Gly Asp Thr	245	250	255
Ile Thr Phe Glu Ala Thr Gly Asn Leu Ile Ala Pro Trp Tyr Ala Phe	260	265	270
Ala Leu Asn Arg Gly Ser Gly Ser Gly Ile Ile Thr Ser Asp Ala Pro	275	280	285
Val His Asp Cys Asn Thr Lys Cys Gln Thr Pro His Gly Ala Ile Asn	290	295	300
Ser Ser Leu Pro Phe Gln Asn Ile His Pro Val Thr Ile Gly Glu Cys	305	310	315
Pro Lys Tyr Val Arg Ser Thr Lys Leu Arg Met Ala Thr Gly Leu Arg	325	330	335
Asn Ile Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly	340	345	350
Phe Ile Glu Gly Gly Trp Thr Gly Met Ile Asp Gly Trp Tyr Gly Tyr	355	360	365
His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Gln Lys Ser	370	375	380
Thr Gln Asn Ala Ile Asp Gly Ile Thr Asn Lys Val Asn Ser Val Ile	385	390	395
Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn Asn	405	410	415
Leu Glu Arg Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe	420	425	430
Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn	435	440	445
Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Arg Asn Leu Tyr Glu	450	455	460
Lys Val Lys Ser Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly	465	470	475
Cys Phe Glu Phe Tyr His Lys Cys Asp Asp Ala Cys Met Glu Ser Val	485	490	495
Arg Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys Leu	500	505	510
Asn Arg Glu Glu Ile Asp Gly Val Lys Leu Glu Ser Met Gly Val Tyr	515	520	525
Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Leu	530	535	540
Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu	545	550	555
Gln Cys Arg Ile Cys Ile	565		

<210> SEQ ID NO 234

<211> LENGTH: 125

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 234

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys
1 5 10 15

-continued

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr
 20 25 30

Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Thr Leu Ile Ser Tyr Asp Gly Ala Asn Gln Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Val Pro Gly Pro Val Phe Gly Ile Phe Pro Pro Trp Ser Tyr Phe
 100 105 110

Asp Asn Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser
 115 120 125

<210> SEQ ID NO 235
 <211> LENGTH: 109
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 235

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ile Ser His Asn
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45

Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Thr Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ser Asn Trp Pro Pro
 85 90 95

Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 236
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 236

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45

Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
 65 70 75 80

-continued

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 237
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 237

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
 Ala Arg Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
100 105 110

<210> SEQ ID NO 238
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

<400> SEQUENCE: 238

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
 Ala Arg Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
100 105 110

<210> SEQ ID NO 239
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 polypeptide

-continued

<400> SEQUENCE: 239

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
           20           25           30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
           35           40           45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
           50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr
           85           90           95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
           100           105

```

<210> SEQ ID NO 240

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 240

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
           20           25           30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
           35           40           45
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
           50           55           60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65           70           75           80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
           85           90           95
Ala Arg Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
           100           105           110

```

<210> SEQ ID NO 241

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 241

```

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1           5           10           15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
           20           25           30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
           35           40           45
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
           50           55           60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln

```

-continued

65	70	75	80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu			
	85	90	95
Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu			
	100	105	110

<210> SEQ ID NO 242
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 242

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala			
1	5	10	15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr			
	20	25	30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met			
	35	40	45
Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe			
	50	55	60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr			
	65	70	75
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys			
	85	90	95
Ala Arg Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser			
	100	105	110

<210> SEQ ID NO 243
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 243

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly			
1	5	10	15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser			
	20	25	30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser			
	35	40	45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro			
	50	55	60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile			
	65	70	75
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly			
	85	90	95
Thr His Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys			
	100	105	110

<210> SEQ ID NO 244
 <211> LENGTH: 113
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

polypeptide

<400> SEQUENCE: 244

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
 20 25 30
 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
 35 40 45
 Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
 65 70 75 80
 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
 85 90 95
 Cys Ala Arg Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser
 100 105 110
 Ser

<210> SEQ ID NO 245

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 245

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 100 105 110

What is claimed is:

1. An isolated anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin, wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1, HVR-H2, and HVR-H3) and three light chain hypervariable regions (HVR-L1, HVR-L2, and HVR-L3), wherein:

- (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:178;
- (b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:179;
- (c) HVR-H3 comprises the amino acid sequence of SEQ ID NO: 181;
- (d) HVR-L1 comprises the amino acid sequence of SEQ ID NO: 183;
- (e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:187; and

(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO: 189.

2. The isolated anti-hemagglutinin antibody of claim 1, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 117.

3. The isolated anti-hemagglutinin antibody of claim 1, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 115.

4. The isolated anti-hemagglutinin antibody of claim 1, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 115, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 117.

5. The isolated anti-hemagglutinin antibody of claim 1, wherein the antibody comprises a light chain comprising the amino acid of SEQ ID NO: 116.

6. The isolated anti-hemagglutinin antibody of claim 1, wherein the antibody comprises a heavy chain comprising the amino acid of SEQ ID NO: 114.

7. The isolated anti-hemagglutinin antibody of claim 1, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 114, and the light chain comprises the amino acid sequence of SEQ ID NO: 116. 5

8. An isolated anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:115, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:117. 10 15

9. The isolated anti-hemagglutinin antibody of claim 8, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:114, and the light chain comprises the amino acid sequence of SEQ ID NO:116. 20

10. An isolated anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:114, and the light chain comprises the amino acid sequence of SEQ ID NO:116. 25

11. A composition comprising the antibody of claim 1, claim 8, or claim 10.

12. A pharmaceutical composition comprising the antibody of claim 1, claim 8, or claim 10 and a pharmaceutically acceptable carrier. 30

* * * * *